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I. Introduction
Although considerable improvement has occurred in the process
of care for patients with ST-elevation myocardial infarction
(STEMI), room for improvement exists (1–3). The purpose of
the present guideline is to focus on the numerous advances in the
diagnosis and management of patients with STEMI since 1999.
This is reflected in the changed name of the guideline: “ACC/
AHA Guidelines for the Management of Patients With ST-
Elevation Myocardial Infarction.” The final recommendations
for indications for a diagnostic procedure, a particular therapy, or
an intervention in patients with STEMI summarize both clinical
evidence and expert opinion (Table 1). To provide clinicians
with a set of recommendations that can easily be translated into
the practice of caring for patients with STEMI, this guideline is
organized around the chronology of the interface between the
patient and the clinician. The full guideline is available at
http://www.acc.org/clinical/guidelines/stemi/index.htm.
II. Pathology
A. Epidemiology
STEMI continues to be a significant public health problem in
industrialized countries and is becoming an increasingly
significant problem in developing countries (4). Although the
exact incidence is difficult to ascertain, using first-listed and
secondary hospital discharge data, there were 1 680 000
unique discharges for ACS in 2001 (5). Applying the conser-
vative estimate of 30% of the ACS patients who have STEMI
from the National Registry of Myocardial Infarction-4
[NRMI-4] (5a), we estimate 500 000 STEMI events per year
in the U.S. This writing committee strongly endorses several
public health campaigns that are likely to contribute to a
reduction in the incidence of and fatality from STEMI in the
future and additional research of new strategies for the
management of STEMI patients in the community (6–13).
III. Management Before STEMI
A. Identification of Patients at Risk of STEMI
Class I
1. Primary care providers should evaluate the presence and
status of control of major risk factors for coronary heart
disease (CHD) for all patients at regular intervals (ap-
proximately every 3 to 5 years). (Level of Evidence: C)
2. Ten-year risk (National Cholesterol Education Program
[NCEP] global risk) of developing symptomatic CHD
should be calculated for all patients who have 2 or more
major risk factors to assess the need for primary preven-
tion strategies (14) (Level of Evidence: B).
3. Patients with established CHD should be identified for
secondary prevention, and patients with a CHD risk
equivalent (eg, diabetes mellitus, chronic kidney disease,
or 10-year risk greater than 20% as calculated by Fra-
mingham equations) should receive equally intensive risk
factor intervention as those with clinically apparent CHD.
(Level of Evidence: A)
B. Patient Education for Early Recognition and
Response to STEMI
Class I
1. Patients with symptoms of STEMI (chest discomfort
with or without radiation to the arms[s], back, neck,
jaw, or epigastrium; shortness of breath; weakness;
diaphoresis; nausea; lightheadedness) should be trans-
ported to the hospital by ambulance rather than by
friends or relatives. (Level of Evidence: B)
2. Healthcare providers should actively address the fol-
lowing issues regarding STEMI with patients and their
families:
a. The patient’s heart attack risk (Level of
Evidence: C)
b. How to recognize symptoms of STEMI (Level of
Evidence: C)
c. The advisability of calling 9-1-1 if symptoms are
unimproved or worsening after 5 minutes, despite
feelings of uncertainty about the symptoms and
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fear of potential embarrassment (Level of Evi-
dence: C)
d. A plan for appropriate recognition and re-
sponse to a potential acute cardiac event that
includes the phone number to access emergency
medical services (EMS), generally 9-1-1 (15). (Level
of Evidence: C)
3. Healthcare providers should instruct patients for
whom nitroglycerin has been prescribed previously to
take ONE nitroglycerin dose sublingually in response
to chest discomfort/pain. If chest discomfort/pain is
unimproved or worsening 5 minutes after 1 sublingual
nitroglycerin dose has been taken, it is recommended
that the patient or family member/friend call 9-1-1
immediately to access EMS. (Level of Evidence: C)
Morbidity and mortality due to STEMI can be reduced
significantly if patients and bystanders recognize symp-
toms early, activate the EMS system, and thereby shorten
the time to definitive treatment. Patients with possible
symptoms of STEMI should be transported to the hospital
by ambulance rather than by friends or relatives because
there is a significant association between arrival at the
emergency department (ED) by ambulance and early
reperfusion therapy (16 –19). Although the traditional
recommendation is for patients to take 1 nitroglycerin dose
sublingually, 5 minutes apart, for up to 3 doses before
TABLE 1. Applying Classification of Recommendations and Level of Evidence
“Size of Treatment Effect”
Class I Class IIa Class IIb Class III
Benefit  Risk
Procedure/Treatment SHOULD be
performed/administered
Benefit  Risk
Additional studies with
focused objectives needed
IT IS REASONABLE to
perform
procedure/administer
treatment
Benefit  Risk
Additional studies with
broad objectives needed;
additional registry data
would be helpful
Procedure/Treatment
MAY BE CONSIDERED
Risk  Benefit
No additional studies needed
Procedure/Treatment should
NOT be
performed/administered SINCE
IT IS NOT HELPFUL AND MAY
BE HARMFUL
Level A
Multiple (3–5)
population risk strata
evaluated *
General consistency of
direction and magnitude
of effect
• Recommendation that
procedure or treatment is
useful/effective
• Sufficient evidence from
multiple randomized trials or
meta-analyses
• Recommendation in favor
of treatment or procedure
being useful/effective
• Some conflicting evidence
from multiple randomized
trials or meta-analyses
• Recommendation’s
usefulness/efficacy
less well established
• Greater conflicting
evidence from
multiple randomized
trials or meta-
analyses
• Recommendation that
procedure or treatment is
not useful/effective and
may be harmful
• Sufficient evidence from
multiple randomized trials
or meta-analyses
Level B
Limited (2–3) population
risk strata evaluated*
• Recommendation that
procedure or treatment is
useful/effective
• Limited evidence from single
randomized trial or
nonrandomized studies
• Recommendation in favor
of treatment or procedure
being useful/effective
• Some conflicting evidence
from single randomized
trial or nonrandomized
studies
• Recommendation’s
usefulness/efficacy
less well established
• Greater conflicting
evidence from single
randomized trial or
nonrandomized
studies
• Recommendation that
procedure or treatment is
not useful/effective and
may be harmful
• Limited evidence from
single randomized trial or
nonrandomized studies
Level C
Very limited (1–2)
population risk strata
evaluated *
• Recommendation that
procedure or treatment is
useful/effective
• Only expert opinion, case
studies, or standard-of-care
• Recommendation in favor
of treatment or procedure
being useful/effective
• Only diverging expert
opinion, case studies, or
standard-of-care
• Recommendation’s
usefulness/efficacy
less well established
• Only diverging expert
opinion, case studies,
or standard-of-care
• Recommendation that
procedure or treatment is
not useful/effective and
may be harmful
• Only expert opinion, case
studies, or standard-of-care
Suggested phrases for
writing
recommendations†
should
is recommended
is indicated
is useful/effective/beneficial
is reasonable
can be useful/effective/
beneficial
is probably recommended or
indicated
may/might be considered
may/might be reasonable
usefulness/effectiveness
is unknown/unclear
/uncertain or not
well established
is not recommended
is not indicated
should not
is not
useful/effective/beneficial
may be harmful
*Data available from clinical trials or registries about the usefulness/efficacy in different subpopulations, such as gender, age, history of diabetes, history of prior
MI, history of heart failure, and prior aspirin use.
†The ACC/AHA Task Force on Practice Guidelines recently provided a list of suggested phrases to use when writing recommendations. All recommendations in the
STEMI guideline have been written in full sentences that express a complete thought, such that a recommendation, even if separated and presented apart from the
rest of the document (including headings above sets of recommendations), would still convey the full intent of the recommendation. It is hoped that this will increase
readers’ comprehension of the guidelines and will allow queries at the individual recommendation level.
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calling for emergency evaluation, this recommendation has
been modified by the writing committee to encourage
earlier contacting of EMS by patients with symptoms
suggestive of STEMI (20,21).
IV. Onset of STEMI
A. Out-of-Hospital Cardiac Arrest
Class I
1. All communities should create and maintain a strong
“Chain of Survival” for out-of-hospital cardiac arrest
that includes early access (recognition of the problem
and activation of the EMS system by a bystander),
early cardiopulmonary resuscitation (CPR), early de-
fibrillation for patients who need it, and early ad-
vanced cardiac life support (ACLS). (Level of Evi-
dence: C)
2. Family members of patients experiencing STEMI
should be advised to take CPR training and familiarize
themselves with the use of an automated external
defibrillator (AED). In addition, they should be re-
ferred to a CPR training program that has a social
support component for family members of post-STEMI
patients. (Level of Evidence: B)
The links in the chain include early access (recognition of
the problem and activation of the EMS system by a by-
stander), early CPR, early defibrillation for patients who need
it, and early ACLS.
V. Prehospital Issues
A. Emergency Medical Services Systems
Class I
1. All EMS first responders who respond to patients with
chest pain and/or suspected cardiac arrest should be
trained and equipped to provide early defibrillation.
(Level of Evidence: A)
2. All public safety first responders who respond to patients
with chest pain and/or suspected cardiac arrest should be
trained and equipped to provide early defibrillation with
AEDs. (Provision of early defibrillation with AEDs by
nonpublic safety first responders is a promising new
strategy, but further study is needed to determine its
safety and efficacy.) (Level of Evidence: B)
3. Dispatchers staffing 9-1-1 center emergency medical
calls should have medical training, should use nation-
ally developed and maintained protocols, and should
have a quality-improvement system in place to ensure
compliance with protocols. (Level of Evidence: C)
Early access to EMS is promoted by a 9-1-1 system
currently available to more than 90% of the US population.
To minimize time to treatment, particularly for cardiopulmo-
nary arrest, many communities allow volunteer and/or paid
firefighters and other first-aid providers to function as first
responders, providing CPR and, increasingly, early defibril-
lation using automated external defibrillators (AEDs) until
emergency medical technicians and paramedics arrive. Most
cities and larger suburban areas provide EMS ambulance
services with providers from the fire department, a private
ambulance company, and/or volunteers.
B. Prehospital Chest Pain Evaluation
and Treatment
Class I
1. Prehospital EMS providers should administer 162 to 325
mg of aspirin (chewed) to chest pain patients suspected of
having STEMI unless contraindicated or already taken
by patient. Although some trials have used enteric-coated
aspirin for initial dosing, more rapid buccal absorption
occurs with non–enteric-coated formulations. (Level of
Evidence: C)
Class IIa
1. It is reasonable for all 9-1-1 dispatchers to advise
patients without a history of aspirin allergy who have
symptoms of STEMI to chew aspirin (162 to 325 mg)
while awaiting arrival of prehospital EMS providers.
Although some trials have used enteric-coated aspirin
for initial dosing, more rapid buccal absorption occurs
with non–enteric-coated formulations. (Level of Evi-
dence: C)
2. It is reasonable that all ACLS providers perform and
evaluate 12-lead electrocardiograms (ECGs) routinely
on chest pain patients suspected of STEMI. (Level of
Evidence: B)
3. If the ECG shows evidence of STEMI, it is reasonable
that prehospital ACLS providers review a reperfusion
“checklist” and relay the ECG and checklist findings to
a predetermined medical control facility and/or receiv-
ing hospital. (Level of Evidence: C)
It is reasonable for physicians to encourage the prehospital
administration of aspirin via EMS personnel (ie, EMS dis-
patchers and providers) in patients with symptoms suggestive
of STEMI unless its use is contraindicated (22). For patients
who have ECG evidence of STEMI, it is reasonable that
paramedics review a reperfusion checklist and relay the ECG
and checklist findings to a predetermined medical control
facility and/or receiving hospital.
C. Prehospital Fibrinolysis
Class IIa
1. Establishment of a prehospital fibrinolysis protocol is
reasonable in 1) settings in which physicians are present
in the ambulance or in 2) well-organized EMS systems
with full-time paramedics who have 12-lead ECGs in the
field with transmission capability, paramedic initial and
ongoing training in ECG interpretation and STEMI
treatment, online medical command, a medical director
with training/experience in STEMI management, and
an ongoing continuous quality-improvement program.
(Level of Evidence: B)
Randomized controlled trials of fibrinolytic therapy have
demonstrated the benefit of initiating fibrinolytic therapy as
early as possible after onset of ischemic-type chest discom-
fort (Figure 1) (23–25). It appears reasonable to expect that if
675JACC Vol. 44, No. 3, 2004 Antman et al.
August 4, 2004:671–719 Management of Patients With STEMI: Executive Summary
Figure 1. Options for transportation of STEMI patients and initial reperfusion treatment. Panel A, Patient transported by EMS after calling
9-1-1: Reperfusion in patients with STEMI can be accomplished by the pharmacological (fibrinolysis) or catheter-based (primary PCI)
approaches. Implementation of these strategies varies based on the mode of transportation of the patient and capabilities at the receiving
hospital. Transport time to the hospital is variable from case to case, but the goal is to keep total ischemic time within 120 minutes. There are
3 possibilities: (1) If EMS has fibrinolytic capability and the patient qualifies for therapy, prehospital fibrinolysis should be started within 30
minutes of EMS arrival on scene. (2) If EMS is not capable of administering prehospital fibrinolysis and the patient is transported to a non–
PCI-capable hospital, the hospital door-to-needle time should be within 30 minutes for patients in whom fibrinolysis is indicated. (3) If EMS is
not capable of administering prehospital fibrinolysis and the patient is transported to a PCI-capable hospital, the hospital door-to-balloon
time should be within 90 minutes. Interhospital transfer: It is also appropriate to consider emergency interhospital transfer of the patient to a
PCI-capable hospital for mechanical revascularization if (1) there is a contraindication to fibrinolysis; (2) PCI can be initiated promptly
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fibrinolytic therapy could be started at the time of prehospital
evaluation, a greater number of lives could be saved. Prehos-
pital fibrinolysis is reasonable in those settings in which
physicians are present in the ambulance or prehospital trans-
port times are more than 60 minutes in high-volume (more
than 25,000 runs per year) EMS systems (26). Other consid-
erations for implementing a prehospital fibrinolytic service
include the ability to transmit ECGs, paramedic initial and
ongoing training in ECG interpretation and myocardial in-
farction (MI) treatment, online medical command, a medical
director with training/experience in management of STEMI,
and full-time paramedics (27).
D. Prehospital Destination Protocols
Class I
1. Patients with STEMI who have cardiogenic shock and
are less than 75 years of age should be brought
immediately or secondarily transferred to facilities
capable of cardiac catheterization and rapid revascu-
larization (percutaneous coronary intervention [PCI]
or coronary artery bypass graft surgery [CABG]) if it
can be performed within 18 hours of onset of shock.
(Level of Evidence: A)
2. Patients with STEMI who have contraindications to
fibrinolytic therapy should be brought immediately or
secondarily transferred promptly (ie, primary-
receiving hospital door-to-departure time less than 30
minutes) to facilities capable of cardiac catheterization
and rapid revascularization (PCI or CABG). (Level of
Evidence: B)
3. Every community should have a written protocol that
guides EMS system personnel in determining where to
take patients with suspected or confirmed STEMI.
(Level of Evidence: C)
Class IIa
1. It is reasonable that patients with STEMI who have
cardiogenic shock and are 75 years of age or older be
considered for immediate or prompt secondary trans-
fer to facilities capable of cardiac catheterization and
rapid revascularization (PCI or CABG) if it can be
performed within 18 hours of onset of shock. (Level of
Evidence: B)
2. It is reasonable that patients with STEMI who are at
especially high risk of dying, including those with
severe congestive heart failure (CHF), be considered
for immediate or prompt secondary transfer (ie,
primary-receiving hospital door-to-departure time less
than 30 minutes) to facilities capable of cardiac cath-
eterization and rapid revascularization (PCI or
CABG). (Level of Evidence: B)
Every community should have a written protocol that
guides EMS system personnel in determining where to take
patients with suspected or confirmed STEMI. Active involve-
ment of local healthcare providers, particularly cardiologists
and emergency physicians, is needed to formulate local EMS
destination protocols for these patients. In general, patients
with suspected STEMI should be taken to the nearest appro-
priate hospital. However, patients with STEMI and shock are
an exception to this general rule. Whenever possible, STEMI
patients less than 75 years of age with shock should be
transferred to facilities capable of cardiac catheterization and
rapid revascularization (PCI or CABG). On the basis of
observations in the SHOCK Trial Registry and other regis-
tries, it is reasonable to extend such considerations of transfer
to invasive centers for elderly patients with shock (see
VII.F.5 and Section 7.6.5 of the full-text guidelines). Patients
with STEMI who have contraindications to fibrinolytic ther-
apy should be brought immediately or secondarily transferred
promptly (ie, primary-receiving hospital door-to-departure
time less than 30 minutes) to facilities capable of cardiac
catheterization and rapid revascularization (PCI or CABG).
VI. Initial Recognition and Management in
the Emergency Department
A. Optimal Strategies for Emergency
Department Triage
Class I
1. Hospitals should establish multidisciplinary teams (in-
cluding primary care physicians, emergency medicine
physicians, cardiologists, nurses, and laboratorians) to
develop guideline-based, institution-specific written
protocols for triaging and managing patients who are
seen in the prehospital setting or present to the ED
with symptoms suggestive of STEMI. (Level of Evi-
dence: B)
B. Initial Patient Evaluation
Class I
1. The delay from patient contact with the healthcare
system (typically, arrival at the ED or contact with
Figure 1 (continued). (within 90 minutes after the patient pre-
sented to the initial receiving hospital or within 60 minutes com-
pared to when fibrinolysis with a fibrin-specific agent could be
initiated at the initial receiving hospital); or (3) fibrinolysis is
administered and is unsuccessful (ie, “rescue PCI”). Secondary
nonemergency interhospital transfer can be considered for
recurrent ischemia. Patient self-transport: Patient self-
transportation is discouraged. If the patient arrives at a non–
PCI-capable hospital, the door-to-needle time should be within
30 minutes. If the patient arrives at a PCI-capable hospital, the
door-to-balloon time should be within 90 minutes. The treatment
options and time recommendations after first hospital arrival are
the same. Panel B, For patients who receive fibrinolysis, nonin-
vasive risk stratification is recommended to identify the need for
rescue PCI (failed fibrinolysis) or ischemia-driven PCI. See Sec-
tions 6.3.1.6.4.5. and 6.3.1.6.7. in the full-text guidelines.
Regardless of the initial method of reperfusion treatment, all
patients should receive late hospital care and secondary pre-
vention of STEMI. EMS indicates Emergency Medical System;
PCI, percutaneous coronary intervention; CABG, coronary artery
bypass graft surgery; Hosp, hospital; Noninv., Noninvasive. *
Golden hour  First 60 minutes;† The medical system goal is to
facilitate rapid recognition and treatment of patients with STEMI
such that door-to-needle (or medical contact–to-needle) time for
initiation of fibrinolytic therapy is within 30 minutes or that door-
to-balloon (or medical contact–to-balloon) time for PCI is within
90 minutes. These goals should not be understood as ideal
times but rather as the longest times that should be considered
acceptable for a given system. Systems that are able to achieve
even more rapid times for treatment of patients with STEMI
should be encouraged. Modified with permission from
Armstrong et al. Circulation. 2003;107:2533–7 (25).
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paramedics) to initiation of fibrinolytic therapy should
be less than 30 minutes. Alternatively, if PCI is chosen,
the delay from patient contact with the healthcare
system (typically, arrival at the ED or contact with
paramedics) to balloon inflation should be less than 90
minutes. (Level of Evidence: B)
2. The choice of initial STEMI treatment should be made
by the emergency medicine physician on duty based on
a predetermined, institution-specific, written protocol
that is a collaborative effort of cardiologists (both those
involved in coronary care unit management and inter-
ventionalists), emergency physicians, primary care
physicians, nurses, and other appropriate personnel.
For cases in which the initial diagnosis and treatment
plan is unclear to the emergency physician or is not
covered directly by the agreed-on protocol, immediate
cardiology consultation is advisable. (Level of Evi-
dence: C)
Regardless of the approach used, all patients presenting to
the ED with chest discomfort or other symptoms suggestive
of STEMI or unstable angina should be considered high-
priority triage cases and should be evaluated and treated
based on a predetermined, institution-specific chest pain
protocol. The goal for patients with STEMI should be to
achieve a door-to-needle time within 30 minutes and a
door-to-balloon time within 90 minutes (Figure 1) (25).
1. History
Class I
1. The targeted history of STEMI patients taken in the
ED should ascertain whether the patient has had prior
episodes of myocardial ischemia such as stable or
unstable angina, MI, CABG, or PCI. Evaluation of the
patient’s complaints should focus on chest discomfort,
associated symptoms, sex- and age-related differences
in presentation, hypertension, diabetes mellitus, possi-
bility of aortic dissection, risk of bleeding, and clinical
cerebrovascular disease (amaurosis fugax, face/limb
weakness or clumsiness, face/limb numbness or sen-
sory loss, ataxia, or vertigo). (Level of Evidence: C)
2. Physical Examination
Class I
1. A physical examination should be performed to aid
in the diagnosis and assessment of the extent, loca-
tion, and presence of complications of STEMI. (Level
of Evidence: C)
2. A brief, focused, and limited neurological examination
to look for evidence of prior stroke or cognitive deficits
should be performed on STEMI patients before admin-
istration of fibrinolytic therapy. (Level of Evidence: C)
A brief physical examination may promote rapid triage,
whereas a more detailed physical examination aids in the
differential diagnosis and is useful for assessing the extent,
location, and presence of complications of STEMI.
3. Electrocardiogram
Class I
1. A 12-lead ECG should be performed and shown to an
experienced emergency physician within 10 minutes of
ED arrival for all patients with chest discomfort (or
anginal equivalent) or other symptoms suggestive of
STEMI. (Level of Evidence: C)
2. If the initial ECG is not diagnostic of STEMI but the
patient remains symptomatic, and there is a high
clinical suspicion for STEMI, serial ECGs at 5- to
10-minute intervals or continuous 12-lead ST-segment
monitoring should be performed to detect the potential
development of ST elevation. (Level of Evidence: C)
3. In patients with inferior STEMI, right-sided ECG
leads should be obtained to screen for ST elevation
suggestive of right ventricular (RV) infarction. (See
Section 7.6.6 of the full-text guidelines and the ACC/
AHA/ASE 2003 Guideline Update for the Clinical Appli-
cation of Echocardiography.) (Level of Evidence: B)
The 12-lead ECG in the ED is at the center of the
therapeutic decision pathway because of the strong evidence
that ST-segment elevation identifies patients who benefit
from reperfusion therapy (28).
4. Laboratory Examinations
Class I
1. Laboratory examinations should be performed as part
of the management of STEMI patients but should not
delay the implementation of reperfusion therapy.
(Level of Evidence: C)
In addition to serum cardiac biomarkers for cardiac damage,
several routine evaluations have important implications for
management of patients with STEMI. Although these studies
should be ordered when the patient is first seen, therapeutic
decisions should not be delayed until results are obtained
because of the crucial role of time to therapy in STEMI.
5. Biomarkers of Cardiac Damage
Class I
1. Cardiac-specific troponins should be used as the opti-
mum biomarkers for the evaluation of patients with
STEMI who have coexistent skeletal muscle injury.
(Level of Evidence: C)
2. For patients with ST elevation on the 12-lead ECG and
symptoms of STEMI, reperfusion therapy should be
initiated as soon as possible and is not contingent on a
biomarker assay. (Level of Evidence: C)
Class IIa
1. Serial biomarker measurements can be useful to pro-
vide supportive noninvasive evidence of reperfusion of
the infarct artery after fibrinolytic therapy in patients
not undergoing angiography within the first 24 hours
after fibrinolytic therapy. (Level of Evidence: B)
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Class III
1. Serial biomarker measurements should not be relied
on to diagnose reinfarction within the first 18 hours
after the onset of STEMI. (Level of Evidence: C)
For patients with ST-segment elevation, the diagnosis of
STEMI is secure; initiation of reperfusion therapy should not be
delayed to wait for the results of a cardiac biomarker assay (29).
Quantitative analysis of cardiac biomarker measurements pro-
vides prognostic information and a noninvasive assessment of
the likelihood that the patient has undergone successful reperfu-
sion when fibrinolytic therapy is administered.
a. Bedside Testing for Serum Cardiac Biomarkers
Class I
1. Although handheld bedside (point-of-care) assays may be
used for a qualitative assessment of the presence of an
elevated level of a serum cardiac biomarker, subsequent
measurements of cardiac biomarker levels should be
performed with a quantitative test. (Level of Evidence: B)
2. For patients with ST elevation on the 12-lead ECG and
symptoms of STEMI, reperfusion therapy should be
initiated as soon as possible and is not contingent on a
bedside biomarker assay. (Level of Evidence: C)
A positive bedside test should be confirmed by a conven-
tional quantitative test. However, reperfusion therapy should
not be delayed to wait for the results of a quantitative assay.
6. Imaging
Class I
1. Patients with STEMI should have a portable chest X-ray,
but this should not delay implementation of reperfusion
therapy (unless a potential contraindication, such as
aortic dissection, is suspected). (Level of Evidence: C)
2. Imaging studies such as a high-quality portable chest
X-ray, transthoracic and/or transesophageal echocar-
diography, and a contrast chest computed tomo-
graphic scan or a MRI scan should be used to differ-
entiate STEMI from aortic dissection in patients for
whom this distinction is initially unclear. (Level of
Evidence: B)
Class IIa
1. Portable echocardiography is reasonable to clarify the
diagnosis of STEMI and allow risk stratification of pa-
tients with chest pain on arrival at the ED, especially if
the diagnosis of STEMI is confounded by left bundle-
branch block (LBBB) or pacing, or there is suspicion of
posterior STEMI with anterior ST depressions. (See
Section 7.6.7 Mechanical Causes of Heart Failure/Low
Output Syndrome of the full-text guidelines.) (Level of
Evidence: B)
Class III
1. Single-photon emission computed tomography
(SPECT) radionuclide imaging should not be per-
formed to diagnose STEMI in patients for whom the
diagnosis of STEMI is evident on the ECG. (Level of
Evidence: B)
C. Management
1. Routine Measures
a. Oxygen
Class I
1. Supplemental oxygen should be administered to pa-
tients with arterial oxygen desaturation (SaO2 less than
90%). (Level of Evidence: B)
Class IIa
1. It is reasonable to administer supplemental oxygen to
all patients with uncomplicated STEMI during the first
6 hours. (Level of Evidence: C)
b. Nitroglycerin
Class I
1. Patients with ongoing ischemic discomfort should re-
ceive sublingual nitroglycerin (0.4 mg) every 5 minutes
for a total of 3 doses, after which an assessment should
be made about the need for intravenous nitroglycerin.
(Level of Evidence: C)
2. Intravenous nitroglycerin is indicated for relief of
ongoing ischemic discomfort, control of hypertension,
or management of pulmonary congestion. (Level of
Evidence: C)
Class III
1. Nitrates should not be administered to patients with
systolic blood pressure less than 90 mm Hg or greater
than or equal to 30 mm Hg below baseline, severe
bradycardia (less than 50 bpm), tachycardia (more
than 100 bpm), or suspected RV infarction. (Level of
Evidence: C)
2. Nitrates should not be administered to patients who
have received a phosphodiesterase inhibitor for erectile
dysfunction within the last 24 hours (48 hours for
tadalafil). (Level of Evidence: B)
Nitroglycerin may be administered to relieve ischemic pain
and is clearly indicated as a vasodilator in patients with
STEMI associated with left ventricular (LV) failure. Nitrates
in all forms should be avoided in patients with initial systolic
blood pressures less than 90 mm Hg or greater than or equal
to 30 mm Hg below baseline, in patients with marked
bradycardia or tachycardia (30), and in patients with known
or suspected RV infarction. In view of their marginal treat-
ment benefits, nitrates should not be used if hypotension
limits the administration of beta-blockers, which have more
powerful salutary effects.
c. Analgesia
Class I
1. Morphine sulfate (2 to 4 mg IV with increments of 2 to
8 mg IV repeated at 5- to 15-minute intervals) is the
analgesic of choice for management of pain associated
with STEMI. (Level of Evidence: C)
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d. Aspirin
Class I
1. Aspirin should be chewed by patients who have not taken
aspirin before presentation with STEMI. The initial dose
should be 162 mg (Level of Evidence: A) to 325 mg (Level of
Evidence: C). Although some trials have used enteric-coated
aspirin for initial dosing, more rapid buccal absorption
occurs with non–enteric-coated aspirin formulations.
In a dose of 162 mg or more, aspirin produces a rapid clinical
antithrombotic effect caused by immediate and near-total inhi-
bition of thromboxane A2 production. Aspirin now forms part of
the early management of all patients with suspected STEMI and
should be given promptly, and certainly within the first 24 hours,
at a dose between 162 and 325 mg and continued indefinitely at
a daily dose of 75 to 162 mg (31). Although some trials have
used enteric-coated aspirin for initial dosing, more rapid buccal
absorption occurs with non–enteric-coated formulations (32).
e. Beta-Blockers
Class I
1. Oral beta-blocker therapy should be administered
promptly to those patients without a contraindication,
irrespective of concomitant fibrinolytic therapy or
performance of primary PCI. (Level of Evidence: A)
Class IIa
1. It is reasonable to administer IV beta-blockers
promptly to STEMI patients without contraindica-
tions, especially if a tachyarrhythmia or hypertension
is present. (Level of Evidence: B)
Immediate beta-blocker therapy appears to reduce the mag-
nitude of infarction and incidence of associated complications in
subjects not receiving concomitant fibrinolytic therapy, the rate
of reinfarction in patients receiving fibrinolytic therapy, and the
frequency of life-threatening ventricular tachyarrhythmias.
f. Reperfusion
GENERAL CONCEPTS.
Class I
1. All STEMI patients should undergo rapid evaluation
for reperfusion therapy and have a reperfusion strat-
egy implemented promptly after contact with the med-
ical system. (Level of Evidence: A)
Evidence exists that expeditious restoration of flow in the
obstructed infarct artery after the onset of symptoms in STEMI
patients is a key determinant of short- and long-term outcomes
regardless of whether reperfusion is accomplished by fibrinolysis or
PCI (33–35). As discussed previously (also see Section 4.1 of the
full- text guidelines), efforts should be made to shorten the time
from recognition of symptoms by the patient to contact with the
medical system. All healthcare providers caring for STEMI patients
from the point of entry into the medical system must recognize the
need for rapid triage and implementation of care in a fashion
analogous to the handling of trauma patients. When considering
recommendations for timely reperfusion of STEMI patients, the
Writing Committee reviewed data from clinical trials, focusing
particular attention on enrollment criteria for selection of patients for
randomization, actual times reported in the trial report rather than
simply the allowable window specified in the trial protocol, treat-
ment effect of the reperfusion strategy on individual components of
a composite primary end point (eg, mortality, recurrent nonfatal
infarction), ancillary therapies (eg, antithrombin and antiplatelet
agents), and the interface between fibrinolysis and referral for
angiography and revascularization. When available, data from
registries were also reviewed to assess the generalizability of
observations from clinical trials of reperfusion to routine practice.
Despite the wealth of reports on reperfusion for STEMI, it is not
possible to produce a simple algorithm, given the heterogeneity of
patient profiles and availability of resources in various clinical
settings at various times of day. This section introduces the recom-
mendations for an aggressive attempt to minimize the time from
entry into the medical system to implementation of a reperfusion
strategy using the concept of medical system goals. More detailed
discussion of these goals and the issues to be considered in selecting
the type of reperfusion therapy are discussed in the Selection of
Reperfusion Therapy section of VI.C.1.f (Section 6.3.1.6.2 of the
full-text guidelines), followed by a discussion of available resources.
The medical system goal is to facilitate rapid recognition and
treatment of patients with STEMI such that door-to-needle (or
medical contact–to-needle) time for initiation of fibrinolytic
therapy can be achieved within 30 minutes or that door-to-
balloon (or medical contact–to-balloon) time for PCI can be kept
under 90 minutes. These goals may not be relevant for the
patients with an appropriate reason for delay, such as uncertainty
about the diagnosis (particularly for the use of fibrinolytic
therapy), need for the evaluation and treatment of other life-
threatening conditions (eg, respiratory failure), or delays associ-
ated with the patient’s informed choice to have more time to
consider the decision. In the absence of such types of circum-
stances, the emphasis is on having a system in place such that
when a patient with STEMI presents for medical care, reperfu-
sion therapy is able to be provided as soon as possible within
these time periods. Because there is not considered to be a
threshold effect for the benefit of shorter times to reper-
fusion, these goals should not be understood as “ideal” times but
the longest times that should be considered acceptable. Systems that
are able to achieve even more rapid times for patients should be
encouraged. Also, this goal should not be perceived as an average
performance standard but a goal of an early treatment system that
every hospital should seek for every appropriate patient.
SELECTION OF REPERFUSION STRATEGY. Several issues should
be considered in selecting the type of reperfusion therapy:
● Time From Onset of Symptoms. Time from onset of
symptoms to fibrinolytic therapy is an important predictor
of MI size and patient outcome (36). The efficacy of
fibrinolytic agents in lysing thrombus diminishes with the
passage of time (37). Fibrinolytic therapy administered
within the first 2 hours (especially the first hour) can
occasionally abort MI and dramatically reduce mortality
(23,38).
In contrast, the ability to produce a patent infarct artery
is much less dependent on symptom duration in patients
undergoing PCI. Several reports claim no influence of time
delay on mortality rates when PCI is performed after 2 to
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3 hours of symptom duration (39,40). Importantly, after
adjustment for baseline characteristics, time from symptom
onset to balloon inflation is significantly correlated with
1-year mortality in patients undergoing primary PCI for
STEMI (41). The Task Force on the Management of Acute
Myocardial Infarction of the European Society of Cardiol-
ogy (42) and this Committee both recommend a target of
medical contact–to-balloon or door-to-balloon time within
90 minutes.
● Risk of STEMI. Several models have been developed that
assist clinicians in estimating the risk of mortality in
patients with STEMI (43–47). Although these models vary
somewhat in the factors loaded into the risk-prediction tool
and also vary with respect to statistical measures of their
discriminative power (eg, C statistic), all the models
provide clinicians with a means to assess the continuum of
risk from STEMI. When the estimated mortality with
fibrinolysis is extremely high, as is the case in patients with
cardiogenic shock, compelling evidence exists that favors a
PCI strategy.
● Risk of Bleeding. Choice of reperfusion therapy is also
affected by the patient’s risk of bleeding. When both types
of reperfusion are available, the higher the patient’s risk of
bleeding with fibrinolytic therapy, the more strongly the
decision should favor PCI. If PCI is unavailable, then the
benefit of pharmacological reperfusion therapy should be
balanced against the risk.
● Time Required for Transport to a Skilled PCI Laboratory.
The availability of interventional cardiology facilities is a
key determinant of whether PCI can be provided. For
facilities that can offer PCI, the literature suggests that this
approach is superior to pharmacological reperfusion (48).
The trials comparing pharmacological and PCI strategies,
however, were conducted before the advent of more recent
pharmacological and PCI strategies. When a composite end
point of death, nonfatal recurrent MI, or stroke is analyzed,
much of the superiority of a PCI strategy is driven by a
reduction in the rate of nonfatal recurrent MI (Figure 2)
(36). The rate of nonfatal recurrent MI can be influenced
Figure 2. PCI vs fibrinolysis for STEMI. Short-term (4 to 6 weeks; top left) and long-term (top right) outcomes for various end points shown
are plotted for STEMI patients randomized to PCI or fibrinolysis for reperfusion in 23 trials (n7739). Given the frequency of events for each
end point in the 2 treatment groups, the number needed to treat (NNT) or number needed to harm (NNH) is shown for the short-term (bottom
left) and long-term (bottom right) outcomes. The magnitude of treatment differences for death, nonfatal reinfarction, and stroke varies
depending on whether PCI is compared with streptokinase or a fibrin-specific lytic. For example, when primary PCI is compared with alte-
plase and the SHOCK trial is excluded, the mortality rate is 5.5% vs 6.7% (odds ratio 0.81, 95% confidence interval 0.64 to 1.03, P0.081)
(76a). See references 76 and 76a for additional discussion. Modified with permission from Elsevier (Keeley et al. The Lancet. 2003;361:13–20)
(76) ReMI indicates recurrent MI; Rec. Isch, recurrent ischemia; Hem. Stroke, hemorrhagic stroke; and CVA, cerebrovascular accident.
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both by the adjunctive therapy used and by the proportion
of patients who are referred for PCI when the initial attempt
at fibrinolysis fails or myocardial ischemia recurs after
initially successful pharmacological reperfusion.
The experience and location of the PCI laboratory also plays
a role in the choice of therapy. Not all laboratories can provide
prompt, high-quality primary PCI. Even centers with interven-
tional cardiology facilities may not be able to provide the
staffing required for 24-hour coverage of the catheterization
laboratory. Despite staffing availability, the volume of cases in
the laboratory may be insufficient for the team to acquire and
maintain skills required for rapid PCI reperfusion strategies.
A decision must be made when a STEMI patient presents to
a center without interventional cardiology facilities. Fibrinolytic
therapy can generally be provided sooner than primary PCI. As
the time delay for performing PCI increases, the mortality
benefit associated with expeditiously performed primary PCI
over fibrinolysis decreases (49). Compared with a fibrin-specific
lytic agent, a PCI strategy may not reduce mortality when a
delay greater than 60 minutes is anticipated versus immediate
administration of a lytic.
Given the current literature, it is not possible to say defini-
tively that a particular reperfusion approach is superior for all
patients, in all clinical settings, at all times of day (Danchin N;
oral presentation at American Heart Association Scientific Ses-
sions 2003, Orlando, FL, November 2003) (50–52). The main
point is that some type of reperfusion therapy should be selected
for all appropriate patients with suspected STEMI. The appro-
priate and timely use of some reperfusion therapy is likely more
important than the choice of therapy, given the current literature
and the expanding array of options. Clinical circumstances in
which fibrinolytic therapy is generally preferred or an invasive
strategy is generally preferred are shown in Figure 3.
Available Resources
Class I
1. STEMI patients presenting to a facility without the
capability for expert, prompt intervention with pri-
mary PCI within 90 minutes of first medical contact
should undergo fibrinolysis unless contraindicated.
(Level of Evidence: A)
PHARMACOLOGICAL REPERFUSION.
Indications for Fibrinolytic Therapy
Class I
1. In the absence of contraindications, fibrinolytic ther-
apy should be administered to STEMI patients with
symptom onset within the prior 12 hours and ST
elevation greater than 0.1 mV in at least 2 contiguous
precordial leads or at least 2 adjacent limb leads.
(Level of Evidence: A)
2. In the absence of contraindications, fibrinolytic ther-
apy should be administered to STEMI patients with
Figure 3. Assessment of reperfusion options for patients with STEMI. STEMI indicates ST-elevation myocardial infarction; PCI, percuta-
neous coronary intervention; ICH, intracranial hemorrhage. *Applies to fibrin-specific agents (see Figure 15 in the full-text STEMI guide-
lines). †Operator experience greater than a total of 75 primary PCI cases per year. ‡Team experience greater than a total of 36 primary
PCI cases per year. §This calculation implies that the estimated delay to the implementation of the invasive strategy is greater than 1
hour vs initiation of fibrinolytic therapy immediately with a fibrin-specific agent.
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symptom onset within the prior 12 hours and new or
presumably new LBBB. (Level of Evidence: A)
Class IIa
1. In the absence of contraindications, it is reasonable to
administer fibrinolytic therapy to STEMI patients with
symptom onset within the prior 12 hours and 12-lead ECG
findings consistent with a true posterior MI. (Level of
Evidence: C)
2. In the absence of contraindications, it is reasonable
to administer fibrinolytic therapy to patients with
symptoms of STEMI beginning within the prior 12
to 24 hours who have continuing ischemic symptoms
and ST elevation greater than 0.1 mV in at least 2
contiguous precordial leads or at least 2 adjacent limb
leads. (Level of Evidence: B)
Class III
1. Fibrinolytic therapy should not be administered to
asymptomatic patients whose initial symptoms of
STEMI began more than 24 hours earlier. (Level of
Evidence: C)
2. Fibrinolytic therapy should not be administered to pa-
tients whose 12-lead ECG shows only ST-segment depres-
sion except if a true posterior MI is suspected. (Level of
Evidence: A)
Because the benefit of fibrinolytic therapy is directly
related to the time from symptom onset, treatment benefit
is maximized by the earliest possible application of ther-
apy. The constellation of clinical features that must be
present (although not necessarily at the same time) to serve
as an indication for fibrinolysis includes symptoms of
myocardial ischemia and ST elevation greater than 0.1
mV, in at least 2 contiguous leads, or new or presumably
new LBBB on the presenting ECG (23,54).
Contraindications/Cautions
Class I
1. Healthcare providers should ascertain whether the pa-
tient has neurological contraindications to fibrinolytic
therapy, including any history of intracranial hemor-
rhage (ICH), significant closed head or facial trauma
within the past 3 months, uncontrolled hypertension, or
ischemic stroke within the past 3 months. (See Table 2 for
a comprehensive list.) (Level of Evidence: A)
2. STEMI patients at substantial (greater than or equal to
4%) risk of ICH should be treated with PCI rather than
with fibrinolytic therapy. (See Figure 3 for further man-
agement considerations.) (Level of Evidence: A)
A detailed list of contraindications and cautions for the use
of fibrinolytic therapy is shown in Table 2.
Complications of Fibrinolytic Therapy: Neurological and
Other
Class I
1. The occurrence of a change in neurological status
during or after reperfusion therapy, particularly
within the first 24 hours after initiation of treatment, is
considered to be due to ICH until proven otherwise.
Fibrinolytic, antiplatelet, and anticoagulant therapies
should be discontinued until brain imaging scan shows
no evidence of ICH. (Level of Evidence: A)
2. Neurology and/or neurosurgery or hematology consulta-
tions should be obtained for STEMI patients who have
ICH as dictated by clinical circumstances. (Level of
Evidence: C)
3. In patients with ICH, infusions of cryoprecipitate,
fresh frozen plasma, protamine, and platelets should
be given, as dictated by clinical circumstances.
(Level of Evidence: C)
Class IIa
1. In patients with ICH, it is reasonable to:
a. Optimize blood pressure and blood glucose levels.
(Level of Evidence: C)
b. Reduce intracranial pressure with an infusion of
mannitol, endotracheal intubation, and hyperven-
tilation. (Level of Evidence: C)
c. Consider neurosurgical evacuation of ICH. (Level
of Evidence: C)
TABLE 2. Contraindications and Cautions for Fibrinolysis Use
in ST-Elevation Myocardial Infarction*
Absolute contraindications
● Any prior ICH
● Known structural cerebral vascular lesion (eg, AVM)
● Known malignant intracranial neoplasm (primary or metastatic)
● Ischemic stroke within 3 months EXCEPT acute ischemic stroke within 3
hours
● Suspected aortic dissection
● Active bleeding or bleeding diathesis (excluding menses)
● Significant closed head or facial trauma within 3 months
Relative contraindications
● History of chronic severe, poorly controlled hypertension
● Severe uncontrolled hypertension on presentation (SBP greater than
180 mm Hg or DBP greater than 110 mm Hg)†
● History of prior ischemic stroke greater than 3 months, dementia, or
known intracranial pathology not covered in contraindications
● Traumatic or prolonged (greater than 10 minutes) CPR or major surgery
(less than 3 weeks)
● Recent (within 2 to 4 weeks) internal bleeding
● Noncompressible vascular punctures
● For streptokinase/anistreplase: prior exposure (more than 5 days ago) or
prior allergic reaction to these agents
● Pregnancy
● Active peptic ulcer
● Current use of anticoagulants: the higher the INR, the higher the risk of
bleeding
AVM indicates arteriovenous malformation; SBP, systolic blood pressure;
DBP, diastolic blood pressure; ICH, intracranial hemorrhage; CPR, cardiopul-
monary resuscitation.
*Viewed as advisory for clinical decision making and may not be all-inclusive
or definitive.
†Could be an absolute contraindication in low-risk patients with ST-elevation
myocardial infarction (see Section 6.3.1.6.3.2 of the full-text guidelines).
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Combination Therapy With Glycoprotein IIb/IIIa Inhibitors
Class IIb
1. Combination pharmacological reperfusion with abcix-
imab and half-dose reteplase or tenecteplase may be
considered for prevention of reinfarction (Level of Evi-
dence: A) and other complications of STEMI in selected
patients: anterior location of MI, age less than 75 years,
and no risk factors for bleeding. In two clinical trials of
combination reperfusion, the prevention of reinfarction
did not translate into a survival benefit at either 30 days
or 1 year (54a). (Level of Evidence: B)
2. Combination pharmacological reperfusion with abcix-
imab and half-dose reteplase or tenecteplase may be
considered for prevention of reinfarction and other
complications of STEMI in selected patients (anterior
location of MI, age less than 75 years, and no risk
factors for bleeding) in whom an early referral for
angiography and PCI (ie, facilitated PCI) is planned.
(Level of Evidence: C)
Class III
1. Combination pharmacological reperfusion with abcix-
imab and half-dose reteplase or tenecteplase should not
be given to patients aged greater than 75 years because
of an increased risk of ICH. (Level of Evidence: B)
PERCUTANEOUS CORONARY INTERVENTION
Coronary Angiography
Class I
1. Diagnostic coronary angiography should be
performed:
a. In candidates for primary or rescue PCI. (Level of
Evidence: A)
b. In patients with cardiogenic shock who are candi-
dates for revascularization. (Level of Evidence: A)
c. In candidates for surgical repair of ventricular
septal rupture or severe mitral regurgitation
(MR). (Level of Evidence: B)
d. In patients with persistent hemodynamic and/or
electrical instability. (Level of Evidence: C)
Class III
1. Coronary angiography should not be performed in
patients with extensive comorbidities in whom the risks
of revascularization are likely to outweigh the benefits.
(Level of Evidence: C)
Primary PCI
Class I
1. General considerations: If immediately available, pri-
mary PCI should be performed in patients with
STEMI (including true posterior MI) or MI with new
or presumably new LBBB who can undergo PCI of the
infarct artery within 12 hours of symptom onset, if
performed in a timely fashion (balloon inflation within
90 minutes of presentation) by persons skilled in the
procedure (individuals who perform more than 75 PCI
procedures per year). The procedure should be sup-
ported by experienced personnel in an appropriate
laboratory environment (performs more than 200 PCI
procedures per year, of which at least 36 are primary
PCI for STEMI, and has cardiac surgery capability).
(Level of Evidence: A)
2. Specific considerations:
a. Primary PCI should be performed as quickly as
possible, with a goal of a medical contact–to-
balloon or door-to-balloon time of within 90 min-
utes. (Level of Evidence: B)
b. If the symptom duration is within 3 hours and the
expected door-to-balloon time minus the expected
door-to-needle time is:
i) within 1 hour, primary PCI is generally pre-
ferred. (Level of Evidence: B)
ii) greater than 1 hour, fibrinolytic therapy
(fibrin-specific agents) is generally preferred.
(Level of Evidence: B)
c. If symptom duration is greater than 3 hours,
primary PCI is generally preferred and should be
performed with a medical contact–to-balloon or
door-to-balloon time as brief as possible, with a
goal of within 90 minutes. (Level of Evidence: B)
d. Primary PCI should be performed for patients
younger than 75 years old with ST elevation or
LBBB who develop shock within 36 hours of MI
and are suitable for revascularization that can be
performed within 18 hours of shock, unless fur-
ther support is futile because of the patient’s
wishes or contraindications/unsuitability for fur-
ther invasive care. (Level of Evidence: A)
e. Primary PCI should be performed in patients with
severe CHF and/or pulmonary edema (Killip class
3) and onset of symptoms within 12 hours. The
medical contact–to-balloon or door-to-balloon
time should be as short as possible (ie, goal within
90 min). (Level of Evidence: B)
Class IIa
1. Primary PCI is reasonable for selected patients 75 years
or older with ST elevation or LBBB or who develop shock
within 36 hours of MI and are suitable for revasculariza-
tion that can be performed within 18 hours of shock.
Patients with good prior functional status who are suit-
able for revascularization and agree to invasive care may
be selected for such an invasive strategy. (Level of Evi-
dence: B)
2. It is reasonable to perform primary PCI for patients with
onset of symptoms within the prior 12 to 24 hours and 1
or more of the following:
a. Severe CHF (Level of Evidence: C)
b. Hemodynamic or electrical instability (Level of
Evidence: C)
c. Persistent ischemic symptoms. (Level of Evidence: C)
Class IIb
1. The benefit of primary PCI for STEMI patients eligi-
ble for fibrinolysis is not well established when per-
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formed by an operator who performs fewer than 75
PCI procedures per year. (Level of Evidence: C)
Class III
1. PCI should not be performed in a noninfarct artery at
the time of primary PCI in patients without hemody-
namic compromise. (Level of Evidence: C)
2. Primary PCI should not be performed in asymptom-
atic patients more than 12 hours after onset of STEMI
if they are hemodynamically and electrically stable.
(Level of Evidence: C)
Primary PCI has been compared with fibrinolytic therapy
in 22 randomized clinical trials (50,52,55–74). An additional
trial, SHOCK (SHould we emergently revascularize Oc-
cluded Coronaries for cardiogenic shocK?) (75). that com-
pared medical stabilization with immediate revascularization
for cardiogenic shock was included along with the above 22
trials in an overview of primary PCI versus fibrinolysis (76).
These investigations demonstrate that PCI-treated patients
experience lower short-term mortality rates, less nonfatal
reinfarction, and less hemorrhagic stroke than those treated
by fibrinolysis but have an increased risk for major bleeding
(76). These results have been achieved in medical centers
with experienced providers and under circumstances in which
PCI can be performed promptly after patient presentation
(Figure 2) (76).
Additional considerations that affect the magnitude of the
difference between PCI- and fibrinolysis-treated patients
include the fact that unfractionated heparin (UFH) was used
as the antithrombin with fibrinolytics (as opposed to other
antithrombins such as enoxaparin [see Ancillary Therapy in
Section VI.C.1.f and also Section 6.3.1.6.8.1.1 of the full-text
guidelines] or bivalirudin [see Section 6.3.1.6.8.1.2 of the
full-text guidelines] that are associated with a reduction in the
rate of recurrent MI after fibrinolysis), a smaller but still
statistically significant advantage for PCI compared with a
fibrin-specific lytic versus streptokinase, and variation among
the PCI arms as to whether a stent was implanted or
glycoprotein (GP) IIb/IIIa antagonists were administered.
Figure 2 shows the short- and long-term outcomes of patients
with STEMI treated by fibrinolysis versus PCI and the
number of patients who need to be treated to prevent 1 event
or cause 1 harmful complication when selecting PCI instead
of fibrinolysis as the reperfusion strategy (Figure 2) (76). Of
note, when primary PCI is compared with tissue plasminogen
activator (tPA) and the SHOCK trial is excluded, the mortal-
ity rate is 5.5% versus 6.7% (odds ratio 0.81%, 95% confi-
dence interval [CI] 0.64 to 1.03, P equals 0.081 (76a).
There is serious and legitimate concern that a routine
policy of primary PCI for patients with STEMI will result in
unacceptable delays in achieving reperfusion in a substantial
number of cases and produce less than optimal outcomes if
performed by less-experienced operators. The mean time
delay for PCI instead of fibrinolysis in the randomized studies
was approximately 40 minutes (76). Strict performance cri-
teria must be mandated for primary PCI programs so that long
door-to-balloon times and performance by low-volume or poor-
outcome operators/laboratories do not occur. Interventional car-
diologists and centers should strive for outcomes to include (1)
medical contact–to-balloon or door-to-balloon times less than 90
minutes; (2) TIMI (Thrombolysis In Myocardial Infarction) 2/3
flow rates obtained in more than 90% of patients; (3) emergency
CABG rate less than 2% among all patients undergoing the
procedure; (4) actual performance of PCI in a high percentage of
patients (85%) brought to the laboratory; and (5) risk-adjusted
in-hospital mortality rate less than 7% in patients without
cardiogenic shock. This would result in a risk-adjusted mortality
rate with PCI comparable to that reported for fibrinolytic therapy
in fibrinolytic-eligible patients (76) and would be consistent with
previously reported registry experience (77–80). Otherwise, the
focus of treatment should be the early use of fibrinolytic therapy
(Figure 2) (76).
PCI appears to have its greatest mortality benefit in
high-risk patients. In patients with cardiogenic shock, an
absolute 9% reduction in 30-day mortality with coronary
revascularization instead of immediate medical stabilization
was reported in the SHOCK trial (75).
Time from symptom onset to reperfusion is an important
predictor of patient outcome. Two studies (81,82) have reported
increasing mortality rates with increasing door-to-balloon times.
Other studies have shown smaller infarct size, better LV func-
tion, and fewer complications when reperfusion occurs before
PCI (83–85). An analysis of the randomized controlled trials
comparing fibrinolysis with a fibrin-specific agent versus pri-
mary PCI suggests that the mortality benefit with PCI exists
when treatment is delayed by no more than 60 minutes.
Mortality increases significantly with each 15-minute delay in
the time between arrival and restoration of TIMI-3 flow (door-
to–TIMI-3 flow time), which further underscores the importance
of timely reperfusion in patients who undergo primary PCI (86).
Importantly, after adjustment for baseline characteristics, time
from symptom onset to balloon inflation is significantly corre-
lated with 1-year mortality in patients undergoing primary PCI
for STEMI (relative risk equals 1.08 for each 30-minute delay
from symptom onset to balloon inflation; P equals 0.04) (35,41).
Given that the medical contact–to-needle time goal within 30
minutes, this Writing Committee joins the Task Force on the
Management of Acute Myocardial Infarction of the European
Society of Cardiology in lowering the medical contact–to-
balloon or door-to-balloon time goal from within 120 minutes to
within 90 minutes in an attempt to maximize the benefits for
reperfusion by PCI (42).
If the expected door-to-balloon time exceeds the expected door-
to-needle time by more than 60 minutes, fibrinolytic treatment with
a fibrin-specific agent should be considered unless it is contraindi-
cated. This is particularly important when symptom duration is less
than 3 hours but is less important with longer symptom duration,
when less ischemic myocardium can be salvaged.
PRIMARY PCI IN FIBRINOLYTIC-INELIGIBLE PATIENTS
Class I
1. Primary PCI should be performed in fibrinolytic-
ineligible patients who present with STEMI within 12
hours of symptom onset. (Level of Evidence: C)
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Class IIa
1. It is reasonable to perform primary PCI for
fibrinolytic-ineligible patients with onset of symptoms
within the prior 12 to 24 hours and 1 or more of the
following:
a. Severe CHF (Level of Evidence: C)
b. Hemodynamic or electrical instability (Level of
Evidence: C)
c. Persistent ischemic symptoms. (Level of Evidence: C)
Randomized controlled trials evaluating the outcome of
PCI for patients who present with STEMI but who are
ineligible for fibrinolytic therapy have not been performed.
Few data are available to characterize the value of primary
PCI for this subset of STEMI patients; however, the recom-
mendations in Section IV.A (and Section 4.2 of the full-text
guidelines) are applicable to these patients. Nevertheless,
these patients are at increased risk for mortality (87), and
there is a general consensus that PCI is an appropriate means
for achieving reperfusion in those who cannot receive fibrino-
lytics because of increased risk of bleeding (88–91).
PRIMARY PCI WITHOUT ON-SITE CARDIAC SURGERY
Class IIb
1. Primary PCI might be considered in hospitals without
on-site cardiac surgery, provided that there exists a
proven plan for rapid transport to a cardiac surgery
operating room in a nearby hospital with appropriate
hemodynamic support capability for transfer. The
procedure should be limited to patients with STEMI or
MI with new, or presumably new, LBBB on ECG, and
should be done in a timely fashion (balloon inflation
within 90 minutes of presentation) by persons skilled in
the procedure (at least 75 PCIs per year) and at hospitals
that perform a minimum of 36 primary PCI procedures
per year. (Level of Evidence: B)
Class III
1. Primary PCI should not be performed in hospitals
without on-site cardiac surgery and without a proven
plan for rapid transport to a cardiac surgery operating
room in a nearby hospital or without appropriate
hemodynamic support capability for transfer. (Level of
Evidence: C)
From clinical data and expert consensus, the Committee
recommends that primary PCI for acute STEMI performed at
hospitals without established elective PCI programs should
be restricted to those institutions capable of performing a
requisite minimum number of primary PCI procedures (36
per year) with a proven plan for rapid and effective PCI and
rapid access to cardiac surgery in a nearby hospital. The
benefit of primary PCI is not well established for operators
who perform fewer than 75 PCIs per year or in a hospital that
performs fewer than 36 primary PCI procedures per year. In
addition, the benefit of timely reperfusion of the infarct artery
by primary PCI at sites without on-site surgery must be
weighed against the small but finite risk of harm to the patient
related to the time required to transfer the patient to a site with
CABG surgery capabilities (92,93).
INTERHOSPITAL TRANSFER FOR PRIMARY PCI
To achieve optimal results, time from the first hospital
door to the balloon inflation in the second hospital should
be as short as possible, with a goal of within 90 minutes.
Significant reductions in door-to-balloon times might be
achieved by directly transporting patients to PCI centers
rather than transporting them to the nearest hospital, if
interhospital transfer will subsequently be required to
obtain primary PCI.
Primary Stenting
Primary stenting has been compared with primary angio-
plasty in 9 studies (94–103). There were no differences in
mortality (3.0% versus 2.8%) or reinfarction (1.8% versus
2.1%) rates. However, major adverse cardiac events were
reduced, driven by the reduction in subsequent target-vessel
revascularization with stenting.
Preliminary reports suggest that compared with conven-
tional bare metal stents, drug-eluting stents are not associated
with increased risk when used for primary PCI in STEMI
patients (104). Postprocedure vessel patency, biomarker re-
lease, and the incidence of short-term adverse events were
similar in patients receiving sirolimus (n equals 186) or bare
metal (n equals 183) stents. Thirty-day event rates of death,
reinfarction, or revascularization were 7.5% versus 10.4%,
respectively (P equals 0.4) (104).
Facilitated PCI
Class IIb
1. Facilitated PCI might be performed as a reperfusion
strategy in higher-risk patients when PCI is not immedi-
ately available and bleeding risk is low. (Level of Evi-
dence: B)
Facilitated PCI refers to a strategy of planned immediate
PCI after an initial pharmacological regimen such as full-dose
fibrinolysis, half-dose fibrinolysis, a GP IIb/IIIa inhibitor, or
a combination of reduced-dose fibrinolytic therapy and a
platelet GP IIb/IIIa inhibitor. A strategy of facilitated PCI
holds promise in higher-risk patients when PCI is not imme-
diately available. Potential risks include increased bleeding
complications, especially in patients who are at least 75 years
of age (see Pharmacological Reperfusion in Section VI.C.1.f
and Section 6.3.1.6.3.8. of the full-text guidelines), and
potential limitations include added cost. Several randomized
trials of facilitated PCI with a variety of pharmacological
regimens are in progress.
Rescue PCI
Class I
1. Rescue PCI should be performed in patients less than
75 years old with ST elevation or LBBB who develop
shock within 36 hours of MI and are suitable for
revascularization that can be performed within 18
hours of shock, unless further support is futile because
686 Antman et al. JACC Vol. 44, No. 3, 2004
Management of Patients With STEMI: Executive Summary August 4, 2004:671–719
of the patient’s wishes or contraindications/unsuitabil-
ity for further invasive care. (Level of Evidence: B)
2. Rescue PCI should be performed in patients with
severe CHF and/or pulmonary edema (Killip class 3)
and onset of symptoms within 12 hours. (Level of
Evidence: B)
Class IIa
1. Rescue PCI is reasonable for selected patients 75 years or
older with ST elevation or LBBB or who develop shock
within 36 hours of MI and are suitable for revasculariza-
tion that can be performed within 18 hours of shock.
Patients with good prior functional status who are suit-
able for revascularization and agree to invasive care may
be selected for such an invasive strategy. (Level of Evi-
dence: B)
2. It is reasonable to perform rescue PCI for patients with
1 or more of the following:
a. Hemodynamic or electrical instability (Level of
Evidence: C)
b. Persistent ischemic symptoms. (Level of Evidence: C)
Rescue PCI refers to PCI within 12 hours after failed
fibrinolysis for patients with continuing or recurrent myocar-
dial ischemia.
A major problem in adopting a strategy of rescue PCI lies
in the limitation of accurate identification of patients for
whom fibrinolytic therapy has not restored antegrade coro-
nary flow. In a prior era in which the practice of PCI was less
mature, immediate catheterization of all patients after fibrino-
lytic therapy to identify those with an occluded infarct artery
was found to be impractical, costly, and often associated with
bleeding complications (105,106). This strategy is being re-
evaluated in clinical trials testing facilitated PCI in the
contemporary PCI setting.
There are no convincing data to support the routine use of
late adjuvant PCI days after failed fibrinolysis or for patients
who do not receive reperfusion therapy. Nevertheless, this is
being done in some STEMI patients as an extension of the
invasive strategy for non-STEMI patients. The Occluded
Artery Trial (OAT) is currently randomizing patients to test
whether routine PCI days to weeks after MI improves
long-term clinical outcomes in asymptomatic high-risk pa-
tients with an occluded infarct artery (107).
PCI for Cardiogenic Shock
Class I
1. Primary PCI is recommended for patients less than 75
years old with ST elevation or LBBB who develop
shock within 36 hours of MI and are suitable for
revascularization that can be performed within 18
hours of shock, unless further support is futile because
of the patient’s wishes or contraindications/unsuitabil-
ity for further invasive care. (Level of Evidence: A)
Class IIa
1. Primary PCI is reasonable for selected patients aged 75
years or older with ST elevation or LBBB who develop
shock within 36 hours of MI and who are suitable for
revascularization that can be performed within 18
hours of shock. Patients with good prior functional
status who are suitable for revascularization and agree
to invasive care may be selected for such an invasive
strategy. (Level of Evidence: B)
Observational studies support the value of PCI for patients
who develop cardiogenic shock in the early hours of STEMI. In
the SHOCK trial (75), the survival curves continued to progres-
sively diverge such that at 6 months and 1 year, there was a
significant mortality reduction with emergency revascularization
(53% versus 66%, P less than 0.03) (108). The prespecified
subgroup analysis of patients less than 75 years old showed an
absolute 15% reduction in 30-day mortality (P less than 0.02),
whereas there was no apparent benefit for the small cohort (n
equals 56) of patients more than 75 years old. These data
strongly support the approach that patients younger than 75
years with STEMI complicated by cardiogenic shock should
undergo emergency revascularization and support measures.
Three registries (109–111) have demonstrated a marked survival
benefit for elderly patients who are clinically selected for revascu-
larization (approximately 1 of 5 patients), so age alone should not
disqualify a patient from early revascularization. (See Section
VII.F.5 and also Section 7.6.5 of the full-text guidelines.)
Percutaneous Coronary Intervention
After Fibrinolysis
Class I
1. In patients whose anatomy is suitable, PCI should be
performed when there is objective evidence of recur-
rent MI. (Level of Evidence: C)
2. In patients whose anatomy is suitable, PCI should be
performed for moderate or severe spontaneous or
provocable myocardial ischemia during recovery from
STEMI. (Level of Evidence: B)
3. In patients whose anatomy is suitable, PCI should be
performed for cardiogenic shock or hemodynamic insta-
bility. (See section on PCI for Cardiogenic Shock in
Section VI.C.1.f.) (Level of Evidence: B)
Class IIa
1. It is reasonable to perform routine PCI in patients with
LV ejection fraction (LVEF) less than or equal to 0.40,
CHF, or serious ventricular arrhythmias. (Level of
Evidence: C)
2. It is reasonable to perform PCI when there is docu-
mented clinical heart failure during the acute episode,
even though subsequent evaluation shows preserved
LV function (LVEF greater than 0.40). (Level of Evi-
dence: C)
Class IIb
1. Routine PCI might be considered as part of an invasive
strategy after fibrinolytic therapy. (Level of Evidence: B)
Immediately After Successful Fibrinolysis. Randomized
prospective trials examined the efficacy and safety of imme-
diate PCI after fibrinolysis (105,106,112). These trials
showed no benefit of routine PCI of the stenotic infarct artery
immediately after fibrinolytic therapy. The strategy did not
appear to salvage myocardium, improve LVEF, or prevent
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reinfarction or death. Those subjected to this approach
appeared to have an increased incidence of adverse events,
including bleeding, recurrent ischemia, emergency CABG,
and death. These studies have not been repeated in the
modern interventional era with improved equipment, im-
proved antiplatelet and anticoagulant strategies, and coronary
stents, thus leaving the question of routine PCI early after
successful fibrinolysis unresolved in contemporary practice.
Studies of facilitated PCI are enrolling patients (113–116).
Hours to Days After Successful Fibrinolysis. Great
improvements in equipment, operator experience, and
adjunctive pharmacotherapy have increased PCI success
rates and decreased complications. More recently, the
invasive strategy for NSTEMI patients has been given a
Class I recommendation by the ACC/AHA Guidelines for
the Management of Patients With Unstable Angina/Non-
STEMI (117). STEMI patients are increasingly being
treated similarly as an extension of this approach. Al-
though 6 published reports (115,118 –121,123) and 1
preliminary report (122) support this strategy, randomized
studies similar to those in NSTEMI need to be performed.
ACUTE SURGICAL REPERFUSION
Class I
1. Emergency or urgent CABG in patients with STEMI
should be undertaken in the following circumstances:
a. Failed PCI with persistent pain or hemodynamic
instability in patients with coronary anatomy suit-
able for surgery. (Level of Evidence: B)
b. Persistent or recurrent ischemia refractory to
medical therapy in patients who have coronary
anatomy suitable for surgery, have a significant
area of myocardium at risk, and are not candi-
dates for PCI or fibrinolytic therapy. (Level of
Evidence: B)
c. At the time of surgical repair of postinfarction
ventricular septal rupture (VSR) or mitral valve
insufficiency. (Level of Evidence: B)
d. Cardiogenic shock in patients less than 75 years
old with ST elevation, LBBB, or posterior MI who
develop shock within 36 hours of STEMI, have
severe multivessel or left main disease, and are
suitable for revascularization that can be per-
formed within 18 hours of shock, unless further
support is futile because of the patient’s wishes or
contraindications/unsuitability for further inva-
sive care. (Level of Evidence: A)
e. Life-threatening ventricular arrhythmias in the
presence of greater than or equal to 50% left main
stenosis and/or triple-vessel disease. (Level of Ev-
idence: B)
Class IIa
1. Emergency CABG can be useful as the primary reper-
fusion strategy in patients who have suitable anatomy,
who are not candidates for fibrinolysis or PCI, and
who are in the early hours (6 to 12 hours) of an
evolving STEMI, especially if severe multivessel or left
main disease is present. (Level of Evidence: B)
2. Emergency CABG can be effective in selected patients
75 years or older with ST elevation, LBBB, or posterior
MI who develop shock within 36 hours of STEMI, have
severe triple-vessel or left main disease, and are suit-
able for revascularization that can be performed
within 18 hours of shock. Patients with good prior
functional status who are suitable for revascularization
and agree to invasive care may be selected for such an
invasive strategy. (Level of Evidence: B)
Class III
1. Emergency CABG should not be performed in pa-
tients with persistent angina and a small area of risk
if they are hemodynamically stable. (Level of Evi-
dence: C)
2. Emergency CABG should not be performed in pa-
tients with successful epicardial reperfusion but
unsuccessful microvascular reperfusion. (Level of
Evidence: C)
PATIENTS WITH STEMI NOT RECEIVING REPERFUSION
Guideline-based recommendations for nonreperfusion
treatments should not vary whether or not patients received
reperfusion therapy. The major difference is that patients
not receiving reperfusion therapy are considered to have a
higher risk for future adverse events (124).
ASSESSMENT OF REPERFUSION
Class IIa
1. It is reasonable to monitor the pattern of ST elevation,
cardiac rhythm, and clinical symptoms over the 60 to
180 minutes after initiation of fibrinolytic therapy.
Noninvasive findings suggestive of reperfusion include
relief of symptoms, maintenance or restoration of
hemodynamic and or electrical stability, and a reduc-
tion of at least 50% of the initial ST-segment elevation
injury pattern on a follow-up ECG 60 to 90 minutes
after initiation of therapy. (Level of Evidence: B)
Persistence of unrelenting ischemic chest pain, absence of
resolution of the qualifying ST-segment elevation, and hemo-
dynamic and/or electrical instability are generally indicators
of failed pharmacological reperfusion and the need to con-
sider rescue PCI. Aggressive medical support may be neces-
sary in the interim. (See Rescue PCI in Section in VI.C.I.f.)
ANCILLARY THERAPY
Antithrombins as Ancillary Therapy to Reperfusion
Therapy
UNFRACTIONATED HEPARIN AS ANCILLARY THERAPY TO
REPERFUSION THERAPY
Class I
1. Patients undergoing percutaneous or surgical revas-
cularization should be given UFH. (Level of Evi-
dence: C)
2. UFH should be given intravenously to patients under-
going reperfusion therapy with alteplase, reteplase, or
tenecteplase, with dosing as follows: bolus of 60 U/kg
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(maximum 4000 U) followed by an initial infusion of
12 U/kg per hour (maximum 1000 U/hr) adjusted to
maintain activated partial thromboplastin time (aPTT)
at 1.5 to 2.0 times control (approximately 50 to 70
seconds). (Level of Evidence: C)
3. UFH should be given intravenously to patients treated
with nonselective fibrinolytic agents (streptokinase,
anistreplase, or urokinase) who are at high risk for
systemic emboli (large or anterior MI, atrial fibrilla-
tion, previous embolus, or known LV thrombus).
(Level of Evidence: B)
4. Platelet counts should be monitored daily in patients
given UFH. (Level of Evidence: C)
Class IIb
1. It may be reasonable to administer UFH intravenously
to patients undergoing reperfusion therapy with strep-
tokinase. (Level of Evidence: B)
Because of the evidence that the measured effect of UFH
on the aPTT is important for patient outcome and that the
predominant variable mediating the effect of a given dose of
heparin is weight (125), it is important to administer the
initial doses of UFH as a weight-adjusted bolus (126). For
fibrin-specific (alteplase, reteplase, and tenecteplase)
fibrinolytic-treated patients, a 60 U/kg bolus followed by a
maintenance infusion of 12 U/kg per hour (with a maximum
of 4000 U bolus and 1000 U/h initial infusion for patients
weighing greater than 70 kg) is recommended. The recom-
mended weight-adjusted dose of UFH, when it is adminis-
tered without fibrinolytics, is 60 to 70 U/kg IV bolus and 12
to 15 U/kg per hour infusion (117).
LOW-MOLECULAR-WEIGHT HEPARIN AS ANCILLARY THERAPY TO
REPERFUSION THERAPY
Class IIb
1. LMWH might be considered an acceptable alternative
to UFH as ancillary therapy for patients less than 75
years of age who are receiving fibrinolytic therapy,
provided that significant renal dysfunction (serum
creatinine greater than 2.5 mg/dL in men or 2.0 mg/dL
in women) is not present. Enoxaparin (30 mg IV bolus
followed by 1.0 mg/kg subcutaneous injection every 12
hours until hospital discharge) used in combination
with full-dose tenecteplase is the most comprehensively
studied regimen in patients less than 75 years of age.
(Level of Evidence: B)
Class III
1. LMWH should not be used as an alternative to UFH as
ancillary therapy in patients over 75 years of age who are
receiving fibrinolytic therapy. (Level of Evidence: B)
2. LMWH should not be used as an alternative to UFH as
ancillary therapy in patients less than 75 years of age
who are receiving fibrinolytic therapy but have signif-
icant renal dysfunction (serum creatinine greater than
2.5 mg/dL in men or 2.0 mg/dL in women). (Level of
Evidence: B)
The available data suggest that the rate of early (60 to 90
minutes) reperfusion of the infarct artery, either assessed
angiographically or by noninvasive means, is not enhanced
by administration of an LMWH. However, a generally
consistent theme of a lower rate of reocclusion of the infarct
artery, reinfarction, or recurrent ischemic events emerges in
patients receiving LMWH regardless of whether the control
group was given placebo or UFH.
DIRECT ANTITHROMBINS AS ANCILLARY THERAPY TO
REPERFUSION THERAPY
Class IIa
1. In patients with known heparin-induced thrombocyto-
penia, it is reasonable to consider bivalirudin as a
useful alternative to heparin to be used in conjunction
with streptokinase. Dosing according to the HERO
(Hirulog and Early Reperfusion or Occlusion)-2 regi-
men (a bolus of 0.25 mg/kg followed by an intravenous
infusion of 0.5 mg/kg per hour for the first 12 hours and
0.25 mg/kg per hour for the subsequent 36 hours) (127) is
recommended but with a reduction in the infusion rate if
the PTT is above 75 seconds within the first 12 hours.
(Level of Evidence: B)
On the basis of the data in the HERO-2 trial, the Writing
Committee believed that bivalirudin could be considered an
acceptable alternative to UFH in those STEMI patients who
receive fibrinolysis with streptokinase, have heparin-induced
thrombocytopenia, and who, in the opinion of the treating
physician, would benefit from anticoagulation.
Antiplatelets
ASPIRIN
Class I
1. A daily dose of aspirin (initial dose of 162 to 325 mg
orally; maintenance dose of 75 to 162 mg) should be
given indefinitely after STEMI to all patients without a
true aspirin allergy. (Level of Evidence: A)
As discussed, aspirin should be given to the patient with
suspected STEMI as early as possible and should be contin-
ued indefinitely, regardless of the strategy for reperfusion and
regardless of whether additional antiplatelet agents are ad-
ministered. True aspirin allergy is the only exception to this
recommendation.
THIENOPYRIDINES
Class I
1. In patients who have undergone diagnostic cardiac cath-
eterization and for whom PCI is planned, clopidogrel
should be started and continued for at least 1 month after
bare metal stent implantation, for several months after
drug-eluting stent implantation (3 months for sirolimus, 6
months for paclitaxel), and for up to 12 months in
patients who are not at high risk for bleeding. (Level of
Evidence: B)
2. In patients taking clopidogrel in whom CABG is
planned, the drug should be withheld for at least 5
days, and preferably for 7, unless the urgency for
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revascularization outweighs the risks of excess bleed-
ing. (Level of Evidence: B)
Class IIa
1. Clopidogrel is probably indicated in patients receiving
fibrinolytic therapy who are unable to take aspirin
because of hypersensitivity or major gastrointestinal
intolerance. (Level of Evidence: C)
Clopidogrel combined with aspirin is recommended for
STEMI patients who undergo coronary stent implantation (128–
132).
There are no safety data available regarding the combina-
tion of fibrinolytic agents and clopidogrel, but ongoing trials
will provide this information in the future. However, in
patients in whom aspirin is contraindicated because of aspirin
sensitivity, clopidogrel is probably useful as a substitute for
aspirin to reduce the risk of occlusion (133). There are no
safety data comparing 300 and 600 mg as loading doses for
clopidogrel. We do not recommend routine administration
of clopidogrel as pretreatment in patients who have not yet
undergone diagnostic cardiac catheterization and in whom
CABG surgery would be performed within 5 to 7 days if
warranted (134).
GLYCOPROTEIN IIb/IIIa INHIBITORS
Class IIa
1. It is reasonable to start treatment with abciximab as early
as possible before primary PCI (with or without stenting)
in patients with STEMI. (Level of Evidence: B)
Class IIb
1. Treatment with tirofiban or eptifibatide may be con-
sidered before primary PCI (with or without stenting)
in patients with STEMI. (Level of Evidence: C)
The Writing Committee believes that it is reasonable to
start treatment with abciximab as early as possible in patients
undergoing primary PCI (with or without stenting) but, given
the size and limitations of the available data set, assigned a
Class IIa recommendation to this treatment. The data on
tirofiban and eptifibatide in primary PCI are far more limited
than for abciximab. However, given the common mode of
action of the agents, a modest amount of angiographic data
(135), and general clinical experience to date, tirofiban or
eptifibatide may be useful as antiplatelet therapy to support
primary PCI for STEMI (with or without stenting) (Class IIb
recommendation).
OTHER PHARMACOLOGICAL MEASURES
Inhibition of Renin-Angiotensin-
Aldosterone System
Class I
1. An angiotensin converting enzyme (ACE) inhibitor
should be administered orally within the first 24 hours
of STEMI to patients with anterior infarction, pulmo-
nary congestion, or LVEF less than 0.40, in the absence
of hypotension (systolic blood pressure less than
100 mm Hg or less than 30 mm Hg below baseline) or
known contraindications to that Class of medications.
(Level of Evidence: A)
2. An angiotensin receptor blocker (ARB) should be
administered to STEMI patients who are intolerant of
ACE inhibitors and who have either clinical or radio-
logical signs of heart failure or LVEF less than 0.40.
Valsartan and candesartan have established efficacy
for this recommendation. (Level of Evidence: C)
Class IIa
1. An ACE inhibitor administered orally within the first
24 hours of STEMI can be useful in patients without
anterior infarction, pulmonary congestion, or LVEF
less than 0.40 in the absence of hypotension (systolic
blood pressure less than 100 mm Hg or less than
30 mm Hg below baseline) or known contraindications
to that class of medications. The expected treatment
benefit in such patients is less (5 lives saved per 1000
patients treated) than for patients with LV dysfunc-
tion. (Level of Evidence: B)
Class III
1. An intravenous ACE inhibitor should not be given to
patients within the first 24 hours of STEMI because of the
risk of hypotension. (A possible exception may be patients
with refractory hypertension.) (Level of Evidence: B)
A number of large, randomized clinical trials have assessed
the role of ACE inhibitors early in the course of acute MI. All
trials with oral ACE inhibitors have shown benefit from their
early use, including those in which early entry criteria
included clinical suspicion of acute infarctions. Data from
these trials indicate that ACE inhibitors should generally be
started within the first 24 hours, ideally after fibrinolytic
therapy has been completed and blood pressure has stabilized.
ACE inhibitors should not be used if systolic blood pressure
is less than 100 mm Hg or less than 30 mm Hg below
baseline, if clinically relevant renal failure is present, if there
is a history of bilateral stenosis of the renal arteries, or if there
is known allergy to ACE inhibitors.
The use of ARBs has not been explored as thoroughly as
ACE inhibitors in STEMI patients. However, clinical
experience in the management of patients with heart
failure and data from clinical trials in STEMI patients (see
Sections 7.4.3 and 7.6.4 of the full-text guidelines) suggest
that ARBs may be useful in patients with depressed LV
function or clinical heart failure but who are intolerant of
an ACE inhibitor. Use of aldosterone antagonists in
STEMI patients is discussed in Sections 7.4.3 and 7.6.4 of
the full-text guidelines.
Metabolic Modulation of the
Glucose-Insulin Axis
STRICT GLUCOSE CONTROL DURING STEMI
Class I
1. An insulin infusion to normalize blood glucose is
recommended for patients with STEMI and compli-
cated courses. (Level of Evidence: B)
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Class IIa
1. During the acute phase (first 24 to 48 hours) of the
management of STEMI in patients with hyperglyce-
mia, it is reasonable to administer an insulin infusion
to normalize blood glucose, even in patients with an
uncomplicated course. (Level of Evidence: B)
2. After the acute phase of STEMI, it is reasonable to
individualize treatment of diabetics, selecting from a
combination of insulin, insulin analogs, and oral
hypoglycemic agents that achieve the best glycemic
control and are well tolerated. (Level of Evidence: C)
Compelling evidence for tight glucose control in patients in
the intensive care unit (a large proportion of whom were there
after cardiac surgery) supports the importance of intensive
insulin therapy to achieve a normal blood glucose level in
critically ill patients (136,136a).
Magnesium
Class IIa
1. It is reasonable that documented magnesium deficits
be corrected, especially in patients receiving diuret-
ics before the onset of STEMI. (Level of Evidence: C)
2. It is reasonable that episodes of torsade de pointes-type
ventricular tachycardia (VT) associated with a pro-
longed QT interval be treated with 1 to 2 g of magne-
sium administered as an intravenous bolus over 5
minutes. (Level of Evidence: C)
Class III
1. In the absence of documented electrolyte deficits or
torsade de pointes-type VT, routine intravenous mag-
nesium should not be administered to STEMI patients
at any level of risk. (Level of Evidence: A)
Calcium Channel Blockers
Class IIa
1. It is reasonable to give verapamil or diltiazem to
patients in whom beta-blockers are ineffective or con-
traindicated (eg, bronchospastic disease) for relief of
ongoing ischemia or control of a rapid ventricular
response with atrial fibrillation or flutter after STEMI
in the absence of CHF, LV dysfunction, or atrioven-
tricular (AV) block. (Level of Evidence: C)
Class III
1. Diltiazem and verapamil are contraindicated in pa-
tients with STEMI and associated systolic LV dysfunc-
tion and CHF. (Level of Evidence: A)
2. Nifedipine (immediate-release form) is contraindicated
in treatment of STEMI because of the reflex sympa-
thetic activation, tachycardia, and hypotension associ-
ated with its use. (Level of Evidence: B)
See the full-text guidelines for further explanation.
VII. Hospital Management
A. Location
1. Coronary Care Unit
Class I
1. STEMI patients should be admitted to a quiet and
comfortable environment that provides for continuous
monitoring of the ECG and pulse oximetry and has
ready access to facilities for hemodynamic monitoring
and defibrillation. (Level of Evidence: C)
2. The patient’s medication regimen should be reviewed
to confirm the administration of aspirin and beta-
blockers in an adequate dose to control heart rate and
to assess the need for intravenous nitroglycerin for
control of angina, hypertension, or heart failure. (Level
of Evidence: A)
3. The ongoing need for supplemental oxygen should be
assessed by monitoring arterial oxygen saturation.
When stable for 6 hours, the patient should be reas-
sessed for oxygen need (ie, O2 saturation of less than
90%), and discontinuation of supplemental oxygen
should be considered. (Level of Evidence: C)
4. Nursing care should be provided by individuals certi-
fied in critical care, with staffing based on the specific
needs of patients and provider competencies, as well as
organizational priorities. (Level of Evidence: C)
5. Care of STEMI patients in the critical care unit (CCU)
should be structured around protocols derived from
practice guidelines. (Level of Evidence: C)
6. Electrocardiographic monitoring leads should be
based on the location and rhythm to optimize detection
of ST deviation, axis shift, conduction defects, and
dysrhythmias. (Level of Evidence: B)
Class III
1. It is not an effective use of the CCU environment to
admit terminally ill, “do not resuscitate” patients with
STEMI, because clinical and comfort needs can be
provided outside of a critical care environment. (Level
of Evidence: C)
2. Stepdown Unit
Class I
1. It is a useful triage strategy to admit low-risk STEMI
patients who have undergone successful PCI directly to
the stepdown unit for post-PCI care rather than to the
CCU. (Level of Evidence: C)
2. STEMI patients originally admitted to the CCU who
demonstrate 12 to 24 hours of clinical stability (absence
of recurrent ischemia, heart failure, or hemodynam-
ically compromising dysrhythmias) should be trans-
ferred to the stepdown unit. (Level of Evidence: C)
Class IIa
1. It is reasonable for patients recovering from STEMI
who have clinically symptomatic heart failure to be
managed on the stepdown unit, provided that facilities
for continuous monitoring of pulse oximetry and ap-
propriately skilled nurses are available. (Level of Evi-
dence: C)
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2. It is reasonable for patients recovering from STEMI
who have arrhythmias that are hemodynamically well-
tolerated (eg, atrial fibrillation with a controlled ven-
tricular response; paroxysms of nonsustained VT last-
ing less than 30 seconds) to be managed on the
stepdown unit, provided that facilities for continuous
monitoring of the ECG, defibrillators, and appropri-
ately skilled nurses are available. (Level of Evidence: C)
Class IIb
1. Patients recovering from STEMI who have clinically
significant pulmonary disease requiring high-flow sup-
plemental oxygen or noninvasive mask ventilation/
bilevel positive airway pressure (BIPAP)/continuous
positive airway pressure (CPAP) may be considered
for care on a stepdown unit provided that facilities for
continuous monitoring of pulse oximetry and appro-
priately skilled nurses with a sufficient nurse:patient
ratio are available. (Level of Evidence: C)
B. Early, General Measures
1. Level of Activity
Class IIa
1. After 12 to 24 hours, it is reasonable to allow patients
with hemodynamic instability or continued ischemia to
have bedside commode privileges. (Level of Evidence: C)
Class III
1. Patients with STEMI who are free of recurrent ische-
mic discomfort, symptoms of heart failure, or serious
disturbances of heart rhythm should not be on bed rest
for more than 12 to 24 hours. (Level of Evidence: C)
2. Diet
Class I
1. Patients with STEMI should be prescribed the NCEP
Adult Treatment Panel III (ATP III) Therapeutic
Lifestyle Changes (TLC) diet, which focuses on re-
duced intake of fats and cholesterol, less than 7% of
total calories as saturated fats, less than 200 mg of
cholesterol per day, increased consumption of omega-3
fatty acids, and appropriate caloric intake for energy
needs. (Level of Evidence: C)
2. Diabetic patients with STEMI should have an appropri-
ate food group balance and caloric intake. (Level of
Evidence: B)
3. Sodium intake should be restricted in STEMI patients
with hypertension or heart failure. (Level of Evidence: B)
STEMI patients should receive a reduced saturated fat and
cholesterol diet per the ATP III TLC approach (137). (See
VII.L.2 and Section 7.12.2 of the full-text guidelines.)
3. Patient Education in the Hospital Setting
Class I
1. Patient counseling to maximize adherence to evidence-
based post-STEMI treatments (eg, compliance with
taking medication, exercise prescription, and smoking
cessation) should begin during the early phase of
hospitalization, occur intensively at discharge, and
continue at follow-up visits with providers and through
cardiac rehabilitation programs and community sup-
port groups, as appropriate. (Level of Evidence: C)
2. Critical pathways and protocols and other quality-
improvement tools (eg, the ACC “Guidelines Applied
in Practice” and the AHA’s “Get with the Guidelines”)
should be used to improve the application of evidence-
based treatments by patients with STEMI, caregivers,
and institutions. (Level of Evidence: C)
Patient education should be viewed as a continuous process
that should to be part of every patient encounter (ie, on
hospital arrival, inpatient admission, discharge, and at
follow-up visits).
4. Analgesia/Anxiolytics
Class IIa
1. It is reasonable to use anxiolytic medications in STEMI
patients to alleviate short-term anxiety or altered behav-
ior related to hospitalization for STEMI. (Level of Evi-
dence: C)
2. It is reasonable to routinely assess the patient’s anxiety
level and manage it with behavioral interventions and
referral for counseling. (Level of Evidence: C)
Anxiety and depression are prevalent in patients hospital-
ized for STEMI because patients are confronted with a
diagnosis that is major, both psychologically and physically
(138,139). Anxiety has been demonstrated to predict in-
hospital recurrent ischemia and arrhythmias (140) and cardiac
events during the first year after an MI (141).
C. Risk Stratification During Early
Hospital Course
Risk stratification is a continuous process and requires the
updating of initial assessments with data obtained during the
hospital stay. Indicators of failed reperfusion (eg, recurrence
of chest pain and persistence of ECG findings indicating
infarction) identify a patient who should undergo coronary
angiography. Similarly, findings consistent with mechanical
complications (eg, sudden onset of heart failure or presence
of a new murmur) herald increased risk and suggest the need
for rapid intervention. For patients who did not undergo
primary reperfusion, changes in clinical status (eg, develop-
ment of shock) may herald a worsening clinical status and are
an indication for coronary angiography. Patients with a low
risk of complications may be candidates for early discharge.
The lowest-risk patients are those who did not have STEMI
despite the initial suspicions. Clinicians should strive to
identify such patients within 8 to 12 hours of onset of
symptoms. Serial sampling of serum cardiac biomarkers and
use of 12-lead ECGs and their interpretation in the context of
the number of hours that have elapsed since onset of the
patient’s symptoms can determine the presence of STEMI
better than adherence to a rigid protocol that requires that a
specified number of samples be drawn in the hospital.
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D. Medication Assessment
1. Beta-Blockers
Class I
1. Patients receiving beta-blockers within the first 24
hours of STEMI without adverse effects should con-
tinue to receive them during the early convalescent
phase of STEMI. (Level of Evidence: A)
2. Patients without contraindications to beta-blockers
who did not receive them within the first 24 hours after
STEMI should have them started in the early conva-
lescent phase. (Level of Evidence: A)
3. Patients with early contraindications within the first 24
hours of STEMI should be reevaluated for candidacy
for beta-blocker therapy. (Level of Evidence: C)
There is overwhelming evidence for the benefits of early
beta-blockade in patients with STEMI and without contrain-
dications to their use (see Section 6.3.1.5 of the full-text
guidelines). Benefits have been demonstrated for patients
with and without concomitant fibrinolytic therapy, both early
and late after STEMI. Meta-analysis of trials from the
prefibrinolytic era involving more than 24 000 patients
receiving beta-blockers have shown a 14% relative risk
reduction in mortality through 7 days and a 23% reduction in
long-term mortality (142).
2. Nitroglycerin
Class I
1. Intravenous nitroglycerin is indicated in the first 48
hours after STEMI for treatment of persistent ische-
mia, CHF, or hypertension. The decision to administer
intravenous nitroglycerin and the dose used should not
preclude therapy with other proven mortality-
reducing interventions, such as beta-blockers or ACE
inhibitors. (Level of Evidence: B)
2. Intravenous, oral, or topical nitrates are useful beyond
the first 48 hours after STEMI for treatment of
recurrent angina or persistent CHF if their use does
not preclude therapy with beta-blockers or ACE inhib-
itors. (Level of Evidence: B)
Class IIb
1. The continued use of nitrate therapy beyond the first
24 to 48 hours in the absence of continued or recurrent
angina or CHF may be helpful, although the benefit is
likely to be small and is not well established in contem-
porary practice. (Level of Evidence: B)
Class III
1. Nitrates should not be administered to patients with
systolic pressure less than 90 mm Hg or greater than
or equal to 30 mm Hg below baseline, severe brady-
cardia (less than 50 bpm), tachycardia (more than 100
bpm) or RV infarction. (Level of Evidence: C)
3. Inhibition of the Renin-Angiotensin-
Aldosterone System
Class I
1. An ACE inhibitor should be administered orally dur-
ing convalescence from STEMI in patients who toler-
ate this class of medication, and it should be continued
over the long term. (Level of Evidence: A)
2. An ARB should be administered to STEMI patients
who are intolerant of ACE inhibitors and have either
clinical or radiological signs of heart failure or LVEF
less than 0.40. Valsartan and candesartan have dem-
onstrated efficacy for this recommendation. (Level of
Evidence: B)
3. Long-term aldosterone blockade should be pre-
scribed for post-STEMI patients without significant
renal dysfunction (creatinine should be less than or
equal to 2.5 mg/dL in men and less than or equal to
2.0 mg/dL in women) or hyperkalemia (potassium
should be less than or equal to 5.0 mEq/L) who are
already receiving therapeutic doses of an ACE in-
hibitor, have an LVEF less than or equal to 0.40, and
have either symptomatic heart failure or diabetes.
(Level of Evidence: A)
Class IIa
1. In STEMI patients who tolerate ACE inhibitors, an
ARB can be useful as an alternative to ACE inhibitors
provided there are either clinical or radiological signs
of heart failure or LVEF is less than 0.40. Valsartan
and candesartan have established efficacy for this
recommendation. (Level of Evidence: B)
The use of ACE inhibitors in the initial management of the
STEMI patient was reviewed previously. The proportional
benefit of ACE inhibitor therapy is largest in higher-risk
subgroups, including those with previous infarction, heart
failure, depressed LVEF, and tachycardia (143–145). Sur-
vival benefit for patients more than 75 years old and for a
low-risk subgroup without the features noted above is equiv-
ocal (144,145).
Aldosterone blockade is another means of inhibiting the
renin-angiotensin-aldosterone system that has been applied to
patients in the post-STEMI setting. RALES (Randomized
Aldactone Evaluation Study) and EPHESUS (Eplerenone
Post-Acute Myocardial Infarction Heart Failure Efficacy and
Survival Study) support the long-term use of an aldosterone
blocker in STEMI patients with heart failure, an ejection
fraction of 0.40 or less, or both, provided the serum creatinine
is less than or equal to 2.5 mg/dL in men and less than or
equal to 2.0 mg/dL in women and serum potassium concen-
tration is less than or equal to 5.0 mEq/L (146,147).
The use of ARBs after STEMI has not been explored as
thoroughly as ACE inhibitors in STEMI patients (148,149).
Given the extensive randomized trial and routine clinical
experience with ACE inhibitors, they remain the logical first
agent for inhibition of the renin-angiotensin-aldosterone sys-
tem in patients convalescing from STEMI (150). Valsartan
monotherapy (target dose 160 mg twice daily) should be
administered to STEMI patients who are intolerant of ACE
inhibitors and have evidence of LV dysfunction. Valsartan
monotherapy can be a useful alternative to ACE inhibitors;
the decision in individual patients may be influenced by
physician and patient preference, cost, and anticipated side-
effect profile.
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4. Antiplatelets
Class I
1. Aspirin 162 to 325 mg should be given on day 1 of
STEMI and in the absence of contraindications should
be continued indefinitely on a daily basis thereafter at
a dose of 75 to 162 mg. (Level of Evidence: A)
2. A thienopyridine (preferably clopidogrel) should be
administered to patients who are unable to take aspirin
because of hypersensitivity or major gastrointestinal
intolerance. (Level of Evidence: C)
3. For patients taking clopidogrel for whom CABG is
planned, if possible, the drug should be withheld for at
least 5 days, and preferably for 7, unless the urgency
for revascularization outweighs the risks of bleeding.
(Level of Evidence: B)
4. For patients who have undergone diagnostic cardiac
catheterization and for whom PCI is planned, clopi-
dogrel should be started and continued for at least 1
month after bare metal stent implantation and for
several months after drug-eluting stent implantation (3
months for sirolimus, 6 months for paclitaxel) and up
to 12 months in patients who are not at high risk for
bleeding. (Level of Evidence: B)
5. Antithrombotics
Class I
1. Intravenous UFH (bolus of 60 U/kg, maximum 4000 U
IV; initial infusion 12 U/kg per hour, maximum of 1000
U/h) or LMWH should be used in patients after
STEMI who are at high risk for systemic emboli (large
or anterior MI, atrial fibrillation, previous embolus,
known LV thrombus, or cardiogenic shock). (Level of
Evidence: C)
Class IIa
1. It is reasonable that STEMI patients not undergoing
reperfusion therapy who do not have a contraindica-
tion to anticoagulation be treated with intravenous or
subcutaneous UFH or with subcutaneous LMWH for
at least 48 hours. In patients whose clinical condition
necessitates prolonged bedrest and/or minimized activ-
ities, it is reasonable that treatment be continued until
the patient is ambulatory. (Level of Evidence: C)
Class IIb
1. Prophylaxis for deep venous thrombosis (DVT) with
subcutaneous LMWH (dosed appropriately for specific
agent) or with subcutaneous UFH, 7500 U to 12 500 U
twice per day until completely ambulatory, may be
useful, but the effectiveness of such a strategy is not well
established in the contemporary era of routine aspirin use
and early mobilization. (Level of Evidence: C)
6. Oxygen
Class I
1. Supplemental oxygen therapy should be continued
beyond the first 6 hours in STEMI patients with
arterial oxygen desaturation (SaO2 less than 90%) or
overt pulmonary congestion. (Level of Evidence: C)
E. Estimation of Infarct Size
Measurement of infarct size is an important element in the
overall care of patients with STEMI. There are 5 major
modalities that can be applied to sizing MI.
1. Electrocardiographic Techniques
Class I
1. All patients with STEMI should have follow-up ECGs
at 24 hours and at hospital discharge to assess the
success of reperfusion and/or the extent of infarction,
defined in part by the presence or absence of new Q
waves. (Level of Evidence: B)
2. Cardiac Biomarker Methods
The most widely accepted method for quantifying infarction
has been the use of serial creatine kinase and the creatine
kinase-MB isoenzyme.
3. Radionuclide Imaging
The most comprehensive assessment of STEMI with radio-
nuclide imaging was developed with the technetium sesta-
mibi SPECT approach (151). This approach is well delineated
in the ACC/AHA/ASNC Guidelines for the Clinical Use of
Cardiac Radionuclide Imaging (152).
4. Echocardiography
Global and regional LV function provides an assessment of
the functional consequences of STEMI and ischemia. Readers
are referred to the ACC/AHA/ASE 2003 Guideline Update
for the Clinical Application of Echocardiography (153) and to
Section 7.11.1.2 of the full-text STEMI guidelines.
5. Magnetic Resonance Imaging
Measurement of infarct size by MRI is a promising new
technique that affords enhanced spatial resolution, thereby
permitting more accurate assessment of both the transmural
and circumferential extent of infarction (154). However,
additional experience and comparison with other methods of
assessing infarct size are required before any clinical recom-
mendations can be provided.
F. Hemodynamic Disturbances
1. Hemodynamic Assessment
Class I
1. Pulmonary artery catheter monitoring should be per-
formed for the following:
a. Progressive hypotension, when unresponsive to
fluid administration or when fluid administration
may be contraindicated. (Level of Evidence: C)
b. Suspected mechanical complications of STEMI,
(ie, VSR, papillary muscle rupture, or free wall
rupture with pericardial tamponade) if an echo-
cardiogram has not been performed. (Level of
Evidence: C)
2. Intra-arterial pressure monitoring should be per-
formed for the following:
694 Antman et al. JACC Vol. 44, No. 3, 2004
Management of Patients With STEMI: Executive Summary August 4, 2004:671–719
a. Patients with severe hypotension (systolic arterial pres-
sure less than 80 mm Hg). (Level of Evidence: C)
b. Patients receiving vasopressor/inotropic agents.
(Level of Evidence: C)
c. Cardiogenic shock. (Level of Evidence: C)
Class IIa
1. Pulmonary artery catheter monitoring can be useful for
the following:
a. Hypotension in a patient without pulmonary con-
gestion who has not responded to an initial trial of
fluid administration. (Level of Evidence: C)
b. Cardiogenic shock. (Level of Evidence: C)
c. Severe or progressive CHF or pulmonary edema
that does not respond rapidly to therapy. (Level of
Evidence: C)
d. Persistent signs of hypoperfusion without hypoten-
sion or pulmonary congestion. (Level of Evidence: C)
e. Patients receiving vasopressor/inotropic agents.
(Level of Evidence: C)
2. Intra-arterial pressure monitoring can be useful for
patients receiving intravenous sodium nitroprusside or
other potent vasodilators. (Level of Evidence: C)
Class IIb
1. Intra-arterial pressure monitoring might be consid-
ered in patients receiving intravenous inotropic agents.
(Level of Evidence: C)
Class III
1. Pulmonary artery catheter monitoring is not recom-
mended in patients with STEMI without evidence of
hemodynamic instability or respiratory compromise.
(Level of Evidence: C)
2. Intra-arterial pressure monitoring is not recom-
mended for patients with STEMI who have no pulmo-
nary congestion and have adequate tissue perfusion
without use of circulatory support measures. (Level of
Evidence: C)
2. Hypotension
Class I
1. Rapid volume loading with an IV infusion should be
administered to patients without clinical evidence for
volume overload. (Level of Evidence: C)
2. Rhythm disturbances or conduction abnormalities
causing hypotension should be corrected. (Level of
Evidence: C)
3. Intra-aortic balloon counterpulsation should be per-
formed in patients who do not respond to other inter-
ventions, unless further support is futile because of the
patient’s wishes or contraindications/unsuitability for
further invasive care. (Level of Evidence: B)
4. Vasopressor support should be given for hypotension that
does not resolve after volume loading. (Level of Evidence: C)
5. Echocardiography should be used to evaluate mechan-
ical complications unless these are assessed by invasive
measures. (Level of Evidence: C)
3. Low-Output State
Class I
1. LV function and potential presence of a mechanical
complication should be assessed by echocardiography
if these have not been evaluated by invasive measures.
(Level of Evidence: C)
2. Recommended treatments for low-output states
include:
a. Inotropic support. (Level of Evidence: B)
b. Intra-aortic counterpulsation. (Level of Evidence: B)
c. Mechanical reperfusion with PCI or CABG.
(Level of Evidence: B)
d. Surgical correction of mechanical complications.
(Level of Evidence: B)
Class III
1. Beta-blockers or calcium channel antagonists should
not be administered to patients in a low-output state
due to pump failure. (Level of Evidence: B)
A preshock state of hypoperfusion with normal blood
pressure may develop before circulatory collapse and is
manifested by cold extremities, cyanosis, oliguria, or de-
creased mentation (155). Hospital mortality is high, so these
patients should be aggressively diagnosed and treated as
though they had cardiogenic shock. The initial pharmacolog-
ical intervention for low cardiac output is often a dobutamine
infusion. Intra-aortic counterpulsation therapy may be re-
quired to improve coronary artery perfusion pressure if
hypotension is present. If the blood pressure permits,
afterload-reducing agents should be added to decrease cardiac
work and pulmonary congestion. Coronary artery revascular-
ization of ischemic myocardium with either PCI or CABG
has been shown to decrease mortality in patients with
cardiogenic shock and is strongly recommended in suitable
candidates (75,108). Likewise, patients with VSR, papillary
muscle rupture, or free wall rupture with pericardial tampon-
ade may benefit from emergency surgical repair.
4. Pulmonary Congestion
Class I
1. Oxygen supplementation to arterial saturation greater
than 90% is recommended for patients with pulmo-
nary congestion. (Level of Evidence: C)
2. Morphine sulfate should be given to patients with
pulmonary congestion. (Level of Evidence: C)
3. ACE inhibitors, beginning with titration of a short-
acting ACE inhibitor with a low initial dose (eg, 1 to
6.25 mg of captopril) should be given to patients with
pulmonary edema unless the systolic blood pressure is
less than 100 mm Hg or more than 30 mm Hg below
baseline. Patients with pulmonary congestion and mar-
ginal or low blood pressure often need circulatory
support with inotropic and vasopressor agents and/or
intra-aortic balloon counterpulsation to relieve pulmo-
nary congestion and maintain adequate perfusion.
(Level of Evidence: A)
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4. Nitrates should be administered to patients with pul-
monary congestion unless the systolic blood pressure is
less than 100 mm Hg or more than 30 mm Hg below
baseline. Patients with pulmonary congestion and mar-
ginal or low blood pressure often need circulatory
support with inotropic and vasopressor agents and/or
intra-aortic balloon counterpulsation to relieve pulmo-
nary congestion and maintain adequate perfusion.
(Level of Evidence: C)
5. A diuretic (low- to intermediate-dose furosemide, or
torsemide or bumetanide) should be administered to
patients with pulmonary congestion if there is associ-
ated volume overload. Caution is advised for patients
who have not received volume expansion. (Level of
Evidence: C)
6. Beta-blockade should be initiated before discharge for
secondary prevention. For those who remain in heart
failure throughout the hospitalization, low doses
should be initiated, with gradual titration on an out-
patient basis. (Level of Evidence: B)
7. Long-term aldosterone blockade should be prescribed
for post-STEMI patients without significant renal
dysfunction (creatinine should be less than or equal
to 2.5 mg/dL in men and less than or equal to 2.0
mg/dL in women) or hyperkalemia (potassium
should be less than or equal to 5.0 mEq/L) who are
already receiving therapeutic doses of an ACE in-
hibitor, have an LVEF less than or equal to 0.40, and
have either symptomatic heart failure or diabetes.
(Level of Evidence: A)
8. Echocardiography should be performed urgently to
estimate LV and RV function and to exclude a mechan-
ical complication. (Level of Evidence: C)
Class IIb
1. It may be reasonable to insert an intra-aortic balloon
pump (IABP) for the management of patients with re-
fractory pulmonary congestion. (Level of Evidence: C)
Class III
1. Beta-blockers or calcium channel blockers should not
be administered acutely to STEMI patients with frank
cardiac failure evidenced by pulmonary congestion or
signs of a low-output state. (Level of Evidence: B)
The immediate management goals include adequate oxy-
genation and preload reduction to relieve pulmonary conges-
tion. Because of sympathetic stimulation, the blood pressure
should be elevated in the presence of pulmonary edema.
Patients with this appropriate response can typically tolerate
the required medications, all of which lower blood pressure.
However, iatrogenic cardiogenic shock may result from
aggressive simultaneous use of agents that cause hypotension,
initiating a cycle of hypoperfusion-ischemia. If acute pulmo-
nary edema is not associated with elevation of the systemic
blood pressure, impending cardiogenic shock must be sus-
pected. If pulmonary edema is associated with hypotension,
cardiogenic shock is diagnosed. Those patients often need
circulatory support with inotropic and vasopressor agents
and/or intra-aortic balloon counterpulsation to relieve pulmo-
nary congestion and maintain adequate perfusion (Figure 4)
(See Section VII.F.5, and see Section 7.6.5 of the full-text
guidelines).
5. Cardiogenic Shock
Class I
1. Intra-aortic balloon counterpulsation is recommended
for STEMI patients when cardiogenic shock is not
quickly reversed with pharmacological therapy. The
IABP is a stabilizing measure for angiography and
prompt revascularization. (Level of Evidence: B)
2. Intra-arterial monitoring is recommended for the
management of STEMI patients with cardiogenic
shock. (Level of Evidence: C)
3. Early revascularization, either PCI or CABG, is rec-
ommended for patients less than 75 years old with ST
elevation or LBBB who develop shock within 36 hours
of MI and are suitable for revascularization that can be
performed within 18 hours of shock, unless further
support is futile because of the patient’s wishes or
contraindications/unsuitability for further invasive
care. (Level of Evidence: A)
4. Fibrinolytic therapy should be administered to STEMI
patients with cardiogenic shock who are unsuitable for
further invasive care and do not have contraindica-
tions to fibrinolysis. (Level of Evidence: B)
5. Echocardiography should be used to evaluate mechan-
ical complications unless these are assessed by invasive
measures. (Level of Evidence: C)
Class IIa
1. Pulmonary artery catheter monitoring can be useful
for the management of STEMI patients with cardio-
genic shock. (Level of Evidence: C)
2. Early revascularization, either PCI or CABG, is rea-
sonable for selected patients 75 years or older with ST
elevation or LBBB who develop shock within 36 hours
of MI and are suitable for revascularization that can be
performed within 18 hours of shock. Patients with
good prior functional status who agree to invasive care
may be selected for such an invasive strategy. (Level of
Evidence: B)
Given the large overall treatment benefit of 13 lives saved
per 100 patients treated in the SHOCK trial, early revascu-
larization is recommended for those less than 75 years who
are suitable for revascularization (75,108,156). Two other
large registries reported a substantial survival benefit for
elderly patients who were selected clinically on the basis of
physician judgment.
Interventions should be performed as soon as possible. It is
recommended that patients who arrive at the hospital in
cardiogenic shock (15% of cases) or who develop it after
hospital arrival (85%) should be transferred to a regional
tertiary care center with revascularization facilities experi-
enced with these patients. When shock has resolved, ACE
inhibitors and beta-blockers, initiated in low doses with
progressive increases as recommended in the CHF guidelines,
should be administered before discharge (157). (See Section
7.6.7.6 of the full-text guidelines for discussion of mechanical
support for the failing heart.)
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6. Right Ventricular Infarction
Class I
1. Patients with inferior STEMI and hemodynamic com-
promise should be assessed with a right precordial V4R
lead to detect ST-segment elevation and an echocardio-
gram to screen for RV infarction. (See the ACC/AHA/
ASE 2003 Guideline Update for the Clinical Application
of Echocardiography.) (Level of Evidence: B)
2. The following principles apply to therapy of patients with
STEMI and RV infarction and ischemic dysfunction:
a. Early reperfusion should be achieved if possible.
(Level of Evidence: C)
b. AV synchrony should be achieved, and bradycar-
dia should be corrected. (Level of Evidence: C)
c. RV preload should be optimized, which usually re-
quires initial volume challenge in patients with hemo-
dynamic instability provided the jugular venous pres-
sure is normal or low. (Level of Evidence: C)
d. RV afterload should be optimized, which usually
requires therapy for concomitant LV dysfunction.
(Level of Evidence: C)
e. Inotropic support should be used for hemodynam-
ic instability not responsive to volume challenge.
(Level of Evidence: C)
Class IIa
1. After infarction that leads to clinically significant RV
dysfunction, it is reasonable to delay CABG surgery
for 4 weeks to allow recovery of contractile perfor-
mance. (Level of Evidence: C)
Treatment of RV ischemia/infarction includes early main-
tenance of RV preload, reduction of RV afterload, inotropic
support of the dysfunctional RV, early reperfusion (158), and
maintenance of AV synchrony.
7. Mechanical Causes of Heart
Failure/Low-Output Syndrome
a. Diagnosis
On physical examination, the presence of a new cardiac
murmur indicates the possibility of either a VSR or MR. A
precise diagnosis can usually be established with transthorac-
ic or transesophageal echocardiography.
b. Mitral Valve Regurgitation
Class I
1. Patients with acute papillary muscle rupture should be
considered for urgent cardiac surgical repair, unless
Figure 4. Emergency management of complicated ST-elevation myocardial infarction. The emergency management of patients with
cardiogenic shock, acute pulmonary edema, or both is outlined. SBP indicates systolic blood pressure; IV, intravenous; BP, blood pres-
sure; ACE, angiotensin converting enzyme; MI, myocardial infarction. *Furosemide less than 0.5 mg/kg for new-onset acute pulmonary
edema without hypovolemia; 1 mg/kg for acute or chronic volume overload, renal insufficiency. Nesiritide has not been studied ade-
quately in patients with STEMI. Combinations of medications, eg, dobutamine and dopamine, may be used. Modified with permission
from Guidelines 2000 for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care: Part 7: The Era of Reperfusion. Section
1: Acute Coronary Syndromes (Acute Myocardial Infarction). Circulation. 2000;102(suppl 1):I-172–I-216 (26).
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further support is considered futile because of the
patient’s wishes or contraindications/unsuitability for
further invasive care. (Level of Evidence: B)
2. CABG surgery should be undertaken at the same time
as mitral valve surgery. (Level of Evidence: B)
The patient should be stabilized with an IABP, inotropic
support, and afterload reduction (to reduce regurgitant vol-
ume and pulmonary congestion) while emergency surgery is
arranged.
c. Ventricular Septal Rupture After STEMI
Class I
1. Patients with STEMI complicated by the development
of a VSR should be considered for urgent cardiac
surgical repair, unless further support is considered
futile because of the patient’s wishes or contraindica-
tions/unsuitability for further invasive care. (Level of
Evidence: B)
2. CABG should be undertaken at the same time as
repair of the VSR. (Level of Evidence: B)
Insertion of an IABP and prompt surgical referral are
recommended for almost every patient with an acute VSR.
Invasive monitoring is recommended in all patients, together
with judicious use of inotropes and a vasodilator to maintain
optimal hemodynamics. Surgical repair usually involves ex-
cision of all necrotic tissue and patch repair of the VSR,
together with coronary artery grafting.
d. Left Ventricular Free-Wall Rupture
Class I
1. Patients with free-wall rupture should be considered
for urgent cardiac surgical repair, unless further sup-
port is considered futile because of the patient’s wishes
or contraindications/unsuitability for further invasive
care. (Level of Evidence: B)
2. CABG should be undertaken at the same time as
repair of free-wall rupture. (Level of Evidence: C)
Surgery includes repair of the ventricle by a direct suture
technique or patch to cover the ventricular perforation (159)
in addition to CABG as needed.
e. Left Ventricular Aneurysm
Class IIa
1. It is reasonable that patients with STEMI who develop
a ventricular aneurysm associated with intractable
ventricular tachyarrhythmias and/or pump failure unre-
sponsive to medical and catheter-based therapy be con-
sidered for LV aneurysmectomy and CABG surgery.
(Level of Evidence: B)
f. Mechanical Support of the Failing Heart
INTRA-AORTIC BALLOON COUNTERPULSATION
Class I
1. Intra-aortic balloon counterpulsation should be used in
STEMI patients with hypotension (systolic blood pres-
sure less than 90 mm Hg or 30 mm Hg below baseline
mean arterial pressure) who do not respond to other
interventions, unless further support is futile because
of the patient’s wishes or contraindications/unsuitability
for further invasive care. See Section 7.6.2 of the full-text
guidelines. (Level of Evidence: B)
2. Intra-aortic balloon counterpulsation is recommended
for STEMI patients with low-output state. See Section
7.6.3 of the full-text guidelines. (Level of Evidence: B)
3. Intra-aortic balloon counterpulsation is recommended
for STEMI patients when cardiogenic shock is not
quickly reversed with pharmacological therapy. IABP
is a stabilizing measure for angiography and prompt
revascularization. See Section 7.6.5 of the full-text
guidelines. (Level of Evidence: B)
4. Intra-aortic balloon counterpulsation should be used in
addition to medical therapy for STEMI patients with
recurrent ischemic-type chest discomfort and signs of
hemodynamic instability, poor LV function, or a large
area of myocardium at risk. Such patients should be
referred urgently for cardiac catheterization and should
undergo revascularization as needed. See Section 7.8.2 of
the full-text guidelines. (Level of Evidence: C)
Class IIa
1. It is reasonable to manage STEMI patients with re-
fractory polymorphic VT with intra-aortic balloon
counterpulsation to reduce myocardial ischemia. See
Section 7.7.1.2 of the full-text guidelines. (Level of
Evidence: B)
Class IIb
1. It may be reasonable to use intra-aortic balloon coun-
terpulsation in the management of STEMI patients
with refractory pulmonary congestion. See Section
7.6.4 of the full-text guidelines. (Level of Evidence: C)
Selected patients with cardiogenic shock after STEMI,
especially if not candidates for revascularization, may be
considered for either a short- or long-term mechanical sup-
port device to serve as a bridge to recovery or to subsequent
cardiac transplantation.
G. Arrhythmias After STEMI
1. Ventricular Arrhythmias
a. Ventricular Fibrillation
Class I
1. Ventricular fibrillation (VF) or pulseless VT should be
treated with an unsynchronized electric shock with an
initial monophasic shock energy of 200 J; if unsuccess-
ful, a second shock of 200 to 300 J should be given, and
then, if necessary, a third shock of 360 J. (Level of
Evidence: B)
Class IIa
1. It is reasonable that VF or pulseless VT that is
refractory to electrical shock be treated with amiod-
arone (300 mg or 5 mg/kg, IV bolus) followed by a
repeat unsynchronized electric shock. (Level of Evi-
dence: B)
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2. It is reasonable to correct electrolyte and acid-base
disturbances (potassium greater than 4.0 mEq/L and
magnesium greater than 2.0 mg/dL) to prevent recur-
rent episodes of VF once an initial episode of VF has
been treated. (Level of Evidence: C)
Class IIb
1. It may be reasonable to treat VT or shock-refractory
VF with boluses of intravenous procainamide. How-
ever, this has limited value owing to the length of time
required for administration. (Level of Evidence: C)
Class III
1. Prophylactic administration of antiarrhythmic therapy
is not recommended when using fibrinolytic agents.
(Level of Evidence: B)
There is no convincing evidence that the prophylactic use
of lidocaine reduces mortality, and the prior practice of
routine (prophylactic) administration of lidocaine to all pa-
tients with known or suspected STEMI has been largely
abandoned. VF should be treated with an unsynchronized
electric shock using an initial monophasic shock energy of
200 J. If this is unsuccessful, a second shock using 200 to 300
J and, if necessary, a third shock using 360 J are indicated
(160).
b. Ventricular Tachycardia
Class I
1. Sustained (more than 30 seconds or causing hemody-
namic collapse) polymorphic VT should be treated
with an unsynchronized electric shock with an initial
monophasic shock energy of 200 J; if unsuccessful, a
second shock of 200 to 300 J should be given, and, if
necessary, a third shock of 360 J. (Level of Evidence: B)
2. Episodes of sustained monomorphic VT associated
with angina, pulmonary edema, or hypotension (blood
pressure less than 90 mm Hg) should be treated with
a synchronized electric shock of 100 J initial
monophasic shock energy. Increasing energies may
be used if not initially successful. Brief anesthesia is
desirable if hemodynamically tolerable. (Level of
Evidence: B)
3. Sustained monomorphic VT not associated with
angina, pulmonary edema, or hypotension (blood
pressure less than 90 mm Hg) should be treated
with:
a. Amiodarone: 150 mg infused over 10 minutes
(alternative dose 5 mg/kg); repeat 150 mg every 10
to 15 minutes as needed. Alternative infusion: 360
mg over 6 hours (1 mg/min), then 540 mg over the
next 18 hours (0.5 mg/min). The total cumulative
dose, including additional doses given during car-
diac arrest, must not exceed 2.2 g over 24 hours.
(Level of Evidence: B)
b. Synchronized electrical cardioversion starting at
monophasic energies of 50 J (brief anesthesia is
necessary). (Level of Evidence: B)
Class IIa
1. It is reasonable to manage refractory polymorphic
VT by:
a. Aggressive attempts to reduce myocardial ische-
mia and adrenergic stimulation, including thera-
pies such as beta-adrenoceptor blockade, IABP
use, and consideration of emergency PCI/CABG
surgery. (Level of Evidence: B)
b. Aggressive normalization of serum potassium to
greater than 4.0 mEq/L and of magnesium to
greater than 2.0 mg/dL. (Level of Evidence: C)
c. If the patient has bradycardia to a rate less than
60 beats per minute or long QTc, temporary
pacing at a higher rate may be instituted. (Level of
Evidence: C)
Class IIb
1. It is may be useful to treat sustained monomorphic
VT not associated with angina, pulmonary edema, or
hypotension (blood pressure less than 90 mm Hg)
with a procainamide bolus and infusion. (Level of
Evidence: C)
Class III
1. The routine use of prophylactic antiarrhythmic drugs
(ie, lidocaine) is not indicated for suppression of iso-
lated ventricular premature beats, couplets, runs of
accelerated idioventricular rhythm, or nonsustained
VT. (Level of Evidence: B)
2. The routine use of prophylactic antiarrhythmic ther-
apy is not indicated when fibrinolytic agents are ad-
ministered. (Level of Evidence: B)
Management Strategies for VT. Cardioversion is always
indicated for episodes of sustained hemodynamically
compromising VT (161). Episodes of sustained VT that are
somewhat better tolerated hemodynamically may initially
be treated with drug regimens, including amiodarone or
procainamide.
c. Ventricular Premature Beats
Class III
1. Treatment of isolated ventricular premature beats,
couplets, and nonsustained VT is not recommended
unless they lead to hemodynamic compromise. (Level
of Evidence: A)
Before the present era of care of the STEMI patient with
antiplatelet therapy, beta-blockade, ACE inhibitors, and,
above all, reperfusion strategies, it was thought that ventric-
ular warning arrhythmias preceded VF. Careful monitoring
has refuted this concept, and treatment of these rhythm
disturbances is not recommended unless they lead to hemo-
dynamic compromise.
d. Accelerated Idioventricular Rhythms and Accelerated
Junctional Rhythms
Class III
1. Antiarrhythmic therapy is not indicated for acceler-
ated idioventricular rhythm. (Level of Evidence: C)
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2. Antiarrhythmic therapy is not indicated for acceler-
ated junctional rhythm. (Level of Evidence: C)
e. Implantable Cardioverter Defibrillator Implantation in
Patients After STEMI
Class I
1. An implantable cardioverter-defibrillator (ICD) is in-
dicated for patients with VF or hemodynamically
significant sustained VT more than 2 days after
STEMI, provided the arrhythmia is not judged to be
due to transient or reversible ischemia or reinfarction.
(Level of Evidence: A)
2. An ICD is indicated for patients without spontane-
ous VF or sustained VT more than 48 hours after
STEMI whose STEMI occurred at least 1 month
previously, who have an LVEF between 0.31 and
0.40, demonstrate additional evidence of electrical insta-
bility (eg, nonsustained VT), and have inducible VF or
sustained VT on electrophysiological testing. (Level of
Evidence: B)
Class IIa
1. If there is reduced LVEF (0.30 or less), at least 1 month
after STEMI and 3 months after coronary artery
revascularization, it is reasonable to implant an ICD in
post STEMI patients without spontaneous VF or sus-
tained VT more than 48 hours after STEMI. (Level of
Evidence: B)
Class IIb
1. The usefulness of an ICD is not well established in
STEMI patients without spontaneous VF or sustained
VT more than 48 hours after STEMI who have a
reduced LVEF (0.31 to 0.40) at least 1 month after
STEMI but who have no additional evidence of elec-
trical instability (eg, nonsustained VT). (Level of Evi-
dence: B)
2. The usefulness of an ICD is not well established in
STEMI patients without spontaneous VF or sustained
VT more than 48 hours after STEMI who have a
reduced LVEF (0.31 to 0.40) at least 1 month after
STEMI and additional evidence of electrical instability
(eg, nonsustained VT) but who do not have inducible
VF or sustained VT on electrophysiological testing.
(Level of Evidence: B)
Class III
1. An ICD is not indicated in STEMI patients who do not
experience spontaneous VF or sustained VT more than
48 hours after STEMI and in whom the LVEF is
greater than 0.40 at least 1 month after STEMI. (Level
of Evidence: C)
See the full-text guidelines for discussion.
2. Supraventricular Arrhythmias/Atrial Fibrillation
Class I
1. Sustained atrial fibrillation and atrial flutter in pa-
tients with hemodynamic compromise or ongoing is-
chemia should be treated with one or more of the
following:
a. Synchronized cardioversion with an initial
monophasic shock of 200 J for atrial fibrillation and
50 J for flutter, preceded by brief general anesthesia
or conscious sedation whenever possible. (Level of
Evidence: C)
b. For episodes of atrial fibrillation that do not
respond to electrical cardioversion or recur after
a brief period of sinus rhythm, the use of antiar-
rhythmic therapy aimed at slowing the ventricu-
lar response is indicated. One or more of these
pharmacological agents may be used:
i. Intravenous amiodarone (162). (Level of Evidence:
C)
ii. Intravenous digoxin for rate control principally
for patients with severe LV dysfunction and heart
failure. (Level of Evidence: C)
2. Sustained atrial fibrillation and atrial flutter in pa-
tients with ongoing ischemia but without hemodynamic
compromise should be treated with one or more of the
following:
a. Beta-adrenergic blockade is preferred, unless con-
traindicated. (Level of Evidence: C)
b. Intravenous diltiazem or verapamil. (Level of Ev-
idence: C)
c. Synchronized cardioversion with an initial
monophasic shock of 200 J for atrial fibrillation
and 50 J for flutter, preceded by brief general
anesthesia or conscious sedation whenever possi-
ble. (Level of Evidence: C)
3. For episodes of sustained atrial fibrillation or flutter
without hemodynamic compromise or ischemia, rate
control is indicated. In addition, patients with sus-
tained atrial fibrillation or flutter should be given
anticoagulant therapy. Consideration should be given
to cardioversion to sinus rhythm in patients with a
history of atrial fibrillation or flutter prior to STEMI.
(Level of Evidence: C)
4. Reentrant paroxysmal supraventricular tachycardia,
because of its rapid rate, should be treated with the
following in the sequence shown:
a. Carotid sinus massage. (Level of Evidence: C)
b. Intravenous adenosine (6 mg  1 over 1 to 2
seconds; if no response, 12 mg IV after 1 to 2
minutes may be given; repeat 12 mg dose if
needed. (Level of Evidence: C)
c. Intravenous beta-adrenergic blockade with meto-
prolol (2.5 to 5.0 mg every 2 to 5 minutes to a total
of 15 mg over 10 to 15 minutes) or atenolol (2.5 to
5.0 mg over 2 minutes to a total of 10 mg in 10 to 15
minutes). (Level of Evidence: C)
d. Intravenous diltiazem (20 mg [0.25 mg/kg]) over 2
minutes followed by an infusion of 10 mg/h).
(Level of Evidence: C)
e. Intravenous digoxin, recognizing that there may
be a delay of at least 1 hour before pharmacolog-
ical effects appear (8 to 15 mcg/kg [0.6 to 1.0 mg in
a person weighing 70 kg]). (Level of Evidence: C)
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Class III
1. Treatment of atrial premature beats is not indicated.
(Level of Evidence: C)
See the full-text guidelines for discussion.
3. Bradyarrhythmias
See Table 3 for recommendations.
a. Acute Treatment of Conduction Disturbances
and Bradyarrhythmias
VENTRICULAR ASYSTOLE
Class I
1. Prompt resuscitative measures, including chest com-
pressions, atropine, vasopressin, epinephrine, and tem-
porary pacing, should be administered to treat ventric-
ular asystole. (Level of Evidence: B)
b. Use of Permanent Pacemakers
PERMANENT PACING FOR BRADYCARDIA OR CONDUCTION
BLOCKS ASSOCIATED WITH STEMI
Class I
1. Permanent ventricular pacing is indicated for persis-
tent second-degree AV block in the His-Purkinje sys-
tem with bilateral bundle-branch block or third-degree
AV block within or below the His-Purkinje system
after STEMI. (Level of Evidence: B)
2. Permanent ventricular pacing is indicated for transient
advanced second- or third-degree infranodal AV block
and associated bundle-branch block. If the site of block
is uncertain, an electrophysiological study may be
necessary. (Level of Evidence: B)
3. Permanent ventricular pacing is indicated for persis-
tent and symptomatic second- or third-degree AV
block. (Level of Evidence: C)
Class IIb
1. Permanent ventricular pacing may be considered for
persistent second- or third-degree AV block at the AV
node level. (Level of Evidence: B)
Class III
1. Permanent ventricular pacing is not recommended for
transient AV block in the absence of intraventricular
conduction defects. (Level of Evidence: B)
2. Permanent ventricular pacing is not recommended for
transient AV block in the presence of isolated left
anterior fascicular block. (Level of Evidence: B)
3. Permanent ventricular pacing is not recommended for
acquired left anterior fascicular block in the absence of
AV block. (Level of Evidence: B)
4. Permanent ventricular pacing is not recommended for
persistent first-degree AV block in the presence of
bundle-branch block that is old or of indeterminate
age. (Level of Evidence: B)
Indications for permanent pacing after STEMI in patients
experiencing AV block are related in large measure to the
presence of intraventricular conduction defects (Table 3).
Unlike some other indications for permanent pacing, the
criteria for patients with STEMI and AV block do not
necessarily depend on the presence of symptoms. Further-
more, the requirement for temporary pacing in STEMI
does not by itself constitute an indication for permanent
pacing (163).
SINUS NODE DYSFUNCTION AFTER STEMI
Class I
1. Symptomatic sinus bradycardia, sinus pauses greater
than 3 seconds, or sinus bradycardia with a heart rate
less than 40 bpm and associated hypotension or signs of
systemic hemodynamic compromise should be treated
with an intravenous bolus of atropine 0.6 to 1.0 mg. If
bradycardia is persistent and maximal (2 mg) doses of
atropine have been used, transcutaneous or transvenous
(preferably atrial) temporary pacing should be instituted.
(Level of Evidence: C)
The published ACC/AHA Guidelines (164) for Implanta-
tion of Pacemakers should be used to guide therapy in STEMI
patients with persistent sinus node dysfunction.
PACING MODE SELECTION IN STEMI PATIENTS
Class I
1. All patients who have an indication for permanent
pacing after STEMI should be evaluated for ICD
indications. (Level of Evidence: C)
Class IIa
1. It is reasonable to implant a permanent dual-chamber
pacing system in STEMI patients who need permanent
pacing and are in sinus rhythm. It is reasonable that patients
in permanent atrial fibrillation or flutter receive a single-
chamber ventricular device. (Level of Evidence: C)
2. It is reasonable to evaluate all patients who have an
indication for permanent pacing after STEMI for
biventricular pacing (cardiac resynchronization ther-
apy). (Level of Evidence: C)
When a permanent pacemaker is being considered for a post-
STEMI patient, the clinician should address 2 additional questions
regarding the patient: is there an indication for biventricular pacing,
and is there an indication for ICD use? (165) The algorithm to
define whether an ICD is indicated is contained in Figure 5.
H. Recurrent Chest Pain After STEMI
1. Pericarditis
Class I
1. Aspirin is recommended for treatment of pericardi-
tis after STEMI. Doses as high as 650 mg orally
(enteric) every 4 to 6 hours may be needed. (Level of
Evidence: B)
2. Anticoagulation should be immediately discontinued if
pericardial effusion develops or increases. (Level of
Evidence: C)
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TABLE 3. Recommendations for Treatment of Atrioventricular and Intraventricular Conduction Disturbances During STEMI
Atrioventricular Conduction
Intraventricular
Conduction Normal
First-Degree AV Block Mobitz I Second-Degree AV Block Mobitz II Second-Degree AV Block
Anterior MI Nonanterior MI Anterior MI Nonanterior MI Anterior MI Nonanterior MI
Normal Action Class Action Class Action Class Action Class Action Class Action Class Action Class
Observe
A
TC
TV
I
III
III
III
Observe
A
TC
TV
I
III
IIb
III
Observe
A
TC
TV
I
III
IIb
III
Observe
A*
TC
TV
IIb
III
I
III
Observe
A
TC
TV
IIa
III
I
III
Observe
A
TC
TV
III
III
I
IIa
Observe
A
TC
TV
III
III
I
IIa
Old or new
fascicular block
(LAFB or LPFB)
Observe
A
TC
TV
I
III
IIb
III
Observe
A
TC
TV
IIb
III
I
III
Observe
A
TC
TV
IIb
III
IIa
III
Observe
A*
TC
TV
IIb
III
I
III
Observe
A
TC
TV
IIb
III
I
III
Observe
A
TC
TV
III
III
I
IIa
Observe
A
TC
TV
III
III
I
IIb
Old bundle-
branch block
Observe
A
TC
TV
I
III
IIb
III
Observe
A
TC
TV
III
III
I
IIb
Observe
A
TC
TV
III
III
I
IIb
Observe
A*
TC
TV
III
III
I
IIb
Observe
A
TC
TV
III
III
I
IIb
Observe
A
TC
TV
III
III
I
IIa
Observe
A
TC
TV
III
III
I
IIa
New bundle-
branch block
Observe
A
TC
TV
III
III
I
IIb
Observe
A
TC
TV
III
III
I
IIa
Observe
A
TC
TV
III
III
I
IIa
Observe
A*
TC
TV
III
III
I
IIa
Observe
A
TC
TV
III
III
I
IIa
Observe
A
TC
TV
III
III
IIb
I
Observe
A
TC
TV
III
III
IIb
I
Fascicular block
 RBBB
Observe
A
TC
TV
III
III
I
IIb
Observe
A
TC
TV
III
III
I
IIa
Observe
A
TC
TV
III
III
I
IIa
Observe
A*
TC
TV
III
III
I
IIa
Observe
A
TC
TV
III
III
I
IIa
Observe
A
TC
TV
III
III
IIb
I
Observe
A
TC
TV
III
III
IIb
I
Alternating left
and right
bundle-branch
block
Observe
A
TC
TV
III
III
IIb
I
Observe
A
TC
TV
III
III
IIb
I
Observe
A
TC
TV
III
III
IIb
I
Observe
A*
TC
TV
III
III
IIb
I
Observe
A
TC
TV
III
III
IIb
I
Observe
A
TC
TV
III
III
IIb
I
Observe
A
TC
TV
III
III
IIb
I
This table is designed to summarize the atrioventricular (column headings) and intraventricular (row headings) conduction disturbances that may occur during acute
anterior or nonanterior STEMI, the possible treatment options, and the indications for each possible therapeutic option.
LAFB indicates left anterior fascicular block; LPFB, left posterior fascicular block; RBBB, right bundle-branch block; A, atropine; TC, transcutaneous pacing; TV,
temporary transvenous pacing; STEMI, ST elevation myocardial infarction; AV, atrioventricular; and MI, myocardial infarction.
Action
There are 4 possible actions, or therapeutic options, listed and classified for each bradyarrhythmia or conduction problem:
1. Observe: continued ECG monitoring, no further action planned.
2. A, and A*: atropine administered at 0.6 to 1.0 mg IV every 5 minutes to up to 0.04 mg/kg. In general, because the increase in sinus rate with atropine is
unpredictable, this is to be avoided unless there is symptomatic bradycardia that will likely respond to a vagolytic agent, such as sinus bradycardia or Mobitz I, as
denoted by the asterisk, above.
3. TC: application of transcutaneous pads and standby transcutaneous pacing with no further progression to transvenous pacing imminently planned.
4. TV: temporary transvenous pacing. It is assumed, but not specified in the table, that at the discretion of the clinician, transcutaneous pads will be applied and
standby transcutaneous pacing will be in effect as the patient is transferred to the fluoroscopy unit for temporary transvenous pacing.
Class
Each possible therapeutic option is further classified according to ACC/AHA criteria as I, IIa, IIb, and III.
Level of Evidence
This table was developed from (1) published observational case reports and case series, (2) published summaries, not meta-analyses, of these data; and (3) expert
opinion, largely from the prereperfusion era. There are no published randomized trials comparing different strategies of managing conduction disturbances after STEMI.
Thus, the level of evidence for the recommendations in this table is C.
How to Use the Table
Example: 54-year-old man is admitted with an anterior STEMI and a narrow QRS on admission. On day 1, he develops a right bundle-branch block (RBBB), with
a PR interval of 0.28 seconds.
1. RBBB is an intraventricular conduction disturbance, so look at row New bundle-branch block.
2. Find the column for First-Degree AV Block.
3. Find the Action and Class cells at the convergence.
4. Note that “Observe” and “Atropine” are class III, not indicated; transcutaneous pacing (TC) is class I. Temporary transvenous pacing (TV) is class IIb.
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Class IIa
1. For episodes of pericarditis after STEMI that are not
adequately controlled with aspirin, it is reasonable to
administer 1 or more of the following:
a. Colchicine 0.6 mg every 12 hours orally. (Level of
Evidence: B)
b. Acetaminophen 500 mg orally every 6 hours.
(Level of Evidence: C)
Class IIb
1. Nonsteroidal anti-inflammatory drugs may be consid-
ered for pain relief; however, they should not be used
for extended periods because of their continuous effect
on platelet function, an increased risk of myocardial
scar thinning, and infarct expansion. (Level of Evi-
dence: B)
2. Corticosteroids might be considered only as a last
resort in patients with pericarditis refractory to aspirin
or nonsteroidal drugs. Although corticosteroids are
effective for pain relief, their use is associated with an
increased risk of scar thinning and myocardial rup-
ture. (Level of Evidence: C)
Class III
1. Ibuprofen should not be used for pain relief because it
blocks the antiplatelet effect of aspirin and can cause
myocardial scar thinning and infarct expansion. (Level of
Evidence: B)
2. Recurrent Ischemia/Infarction
Class I
1. Patients with recurrent ischemic-type chest discomfort after
initial reperfusion therapy for STEMI should undergo es-
calation of medical therapy with nitrates and beta-blockers
to decrease myocardial oxygen demand and reduce ische-
mia. Intravenous anticoagulation should be initiated if not
already accomplished. (Level of Evidence: B)
2. In addition to escalation of medical therapy, patients
with recurrent ischemic-type chest discomfort and
signs of hemodynamic instability, poor LV function, or
a large area of myocardium at risk should be referred
urgently for cardiac catheterization and undergo re-
vascularization as needed. Insertion of an IABP should
also be considered. (Level of Evidence: C)
3. Patients with recurrent ischemic-type chest discomfort who
are considered candidates for revascularization should un-
dergo coronary arteriography and PCI or CABG as dic-
tated by coronary anatomy. (Level of Evidence: B)
Class IIa
1. It is reasonable to (re)administer fibrinolytic therapy
to patients with recurrent ST elevation and ischemic-
type chest discomfort who are not considered candi-
Figure 5. Algorithm to aid in selection of ICD in patients with STEMI and diminished ejection fraction (EF). Appropriate management path is
selected based on LVEF measured at least 1 month after STEMI. These criteria, which are based on published data, form the basis for the
full-text guidelines in Section 7.7.1.5. All patients, whether an ICD is implanted or not, should receive medical therapy as outlined in the
guidelines. VF indicates ventricular fibrillation; VII, ventricular tachycardia; STEMI, ST-elevation myocardial infarction; NSVT, nonsustained VT;
LOE, level of evidence; EPS, electrophysiological studies; LVEF, left ventricular EF.
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dates for revascularization or for whom coronary
angiography and PCI cannot be rapidly (ideally within
60 minutes from the onset of recurrent discomfort)
implemented. (Level of Evidence: C)
Class III
1. Streptokinase should not be readministered to treat re-
current ischemia/infarction in patients who received a
non–fibrin-specific fibrinolytic agent more than 5 days
previously to treat the acute STEMI event. (Level of
Evidence: C)
Patients with recurrent ischemic-type chest discomfort
should undergo escalation of medical therapy that includes
beta-blockers (intravenously and then orally) and nitrates
(sublingually and then intravenously); consideration should
be given to initiation of intravenous anticoagulation if the
patient is not already therapeutically anticoagulated. Second-
ary causes of recurrent ischemia, such as poorly controlled
heart failure, anemia, and arrhythmias, should be corrected.
I. Other Complications
1. Ischemic Stroke
Class I
1. Neurological consultation should be obtained in
STEMI patients who have an acute ischemic stroke.
(Level of Evidence: C)
2. STEMI patients who have an acute ischemic stroke
should be evaluated with echocardiography, neuroim-
aging, and vascular imaging studies to determine the
cause of the stroke. (Level of Evidence: C)
3. STEMI patients with acute ischemic stroke and persis-
tent atrial fibrillation should receive lifelong moderate-
intensity (international normalized ratio [INR] 2 to 3)
warfarin therapy. (Level of Evidence: A)
4. STEMI patients with or without acute ischemic stroke
who have a cardiac source of embolism (atrial fibril-
lation, mural thrombus, or akinetic segment) should
receive moderate-intensity (INR 2 to 3) warfarin ther-
apy (in addition to aspirin). The duration of warfarin
therapy should be dictated by clinical circumstances
(eg, at least 3 months for patients with an LV mural
thrombus or akinetic segment and indefinitely in pa-
tients with persistent atrial fibrillation). The patient
should receive LMWH or UFH until adequately anti-
coagulated with warfarin. (Level of Evidence: B)
Class IIa
1. It is reasonable to assess the risk of ischemic stroke in
patients with STEMI. (Level of Evidence: A)
2. It is reasonable that STEMI patients with nonfatal
acute ischemic stroke receive supportive care to mini-
mize complications and maximize functional outcome.
(Level of Evidence: C)
Class IIb
1. Carotid angioplasty/stenting, 4 to 6 weeks after ische-
mic stroke, might be considered in STEMI patients
who have an acute ischemic stroke attributable to an
internal carotid artery–origin stenosis of at least 50%
and who have a high surgical risk of morbidity/
mortality early after STEMI. (Level of Evidence: C)
An algorithm for evaluation and antithrombotic therapy for
ischemic stroke is shown in Figure 35 of the full-text
guideline.
2. DVT and Pulmonary Embolism
Class I
1. DVT or pulmonary embolism after STEMI should be
treated with full-dose LMWH for a minimum of 5 days
and until the patient is adequately anticoagulated with
warfarin. Start warfarin concurrently with LMWH
and titrate to INR of 2 to 3. (Level of Evidence: A)
2. Patients with CHF after STEMI who are hospitalized
for prolonged periods, unable to ambulate, or consid-
ered at high risk for DVT and are not otherwise
anticoagulated should receive low-dose heparin pro-
phylaxis, preferably with LMWH. (Level of Evidence:
A)
J. CABG Surgery After STEMI
1. Timing of Surgery
Class IIa
1. In patients who have had a STEMI, CABG mortality is
elevated for the first 3 to 7 days after infarction, and
the benefit of revascularization must be balanced
against this increased risk. Patients who have been
stabilized (no ongoing ischemia, hemodynamic com-
promise, or life-threatening arrhythmia) after STEMI
and who have incurred a significant fall in LV function
should have their surgery delayed to allow myocardial
recovery to occur. If critical anatomy exists, revascular-
ization should be undertaken during the index hospital-
ization. (Level of Evidence: B)
The Writing Committee believes that if stable STEMI
patients with preserved LV function require surgical revas-
cularization, then CABG can be undertaken within several
days of the infarction without an increased risk.
2. Arterial Grafting
Class I
1. An internal mammary artery graft to a significantly
stenosed left anterior descending coronary artery
should be used whenever possible in patients undergo-
ing CABG after STEMI. (Level of Evidence: B)
3. CABG for Recurrent Ischemia After STEMI
Class I
1. Urgent CABG is indicated if the coronary angiogram
reveals anatomy that is unsuitable for PCI. (Level of
Evidence: B)
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4. Elective CABG Surgery After STEMI in Patients With
Angina
Class I
1. CABG is recommended for patients with stable angina
who have significant left main coronary artery steno-
sis. (Level of Evidence: A)
2. CABG is recommended for patients with stable angina
who have left main equivalent disease: significant (at
least 70%) stenosis of the proximal left anterior de-
scending coronary artery and proximal left circumflex
artery. (Level of Evidence: A)
3. CABG is recommended for patients with stable angina
who have 3-vessel disease (Survival benefit is greater
when LVEF is less than 0.50). (Level of Evidence: A)
4. CABG is beneficial for patients with stable angina who
have 1- or 2-vessel coronary disease without significant
proximal left anterior descending coronary artery ste-
nosis but with a large area of viable myocardium and
high-risk criteria on noninvasive testing. (Level of
Evidence: B)
5. CABG is recommended in patients with stable angina
who have 2-vessel disease with significant proximal left
anterior descending coronary artery stenosis and ei-
ther ejection fraction less than 0.50 or demonstrable
ischemia on noninvasive testing. (Level of Evidence: A)
The role of surgical revascularization has been reviewed
extensively in the ACC/AHA Guidelines for CABG Surgery
(166). Consideration for revascularization after STEMI in-
cludes PCI and CABG. Providers should individualize patient
management on the basis of clinical circumstances, available
revascularization options, and patient preference.
5. CABG Surgery After STEMI and Antiplatelet Agents
Class I
1. Aspirin should not be withheld before elective or
nonelective CABG after STEMI. (Level of Evidence: C)
2. Aspirin (75 to 325 mg daily) should be prescribed as
soon as possible (within 24 hours) after CABG unless
contraindicated. (Level of Evidence: B)
3. In patients taking clopidogrel in whom elective CABG
is planned, the drug should be withheld for 5 to 7 days.
(Level of Evidence: B)
STEMI patients undergoing revascularization frequently
receive 1 or more antiplatelet agents and heparin, all of which
may increase risk of serious bleeding during and after cardiac
surgery. Delaying surgery until platelet function has recov-
ered may not be feasible in many circumstances. In patients
treated with the small-molecule GP IIb/IIIa receptor antago-
nists, tirofiban and eptifibatide, platelet function returns
toward normal within 4 hours of stopping treatment. Platelet
aggregation does not return toward normal for more than 48
hours in patients treated with abciximab. Management strat-
egies, other than delaying surgery, include platelet transfu-
sions for patients who were recently treated with abciximab,
reduced heparin dosing during cardiopulmonary bypass, and
possible use of antifibrinolytic agents such as aprotinin or
tranexamic acid (167). Because clopidogrel, when added to
aspirin, increases the risk of bleeding during major surgery in
patients who are scheduled for elective CABG, clopidogrel
should be withheld for at least 5 days (168) and preferably for
7 days before surgery (169).
K. Convalescence, Discharge, and Post-MI Care
1. Risk Stratification at Hospital Discharge
The risk stratification approach for decision-making about
catheterization is described in Figure 6. The suggested
algorithm for electrophysiological testing and ICD placement
is shown in Figure 5.
a. Role of Exercise Testing
Class I
1. Exercise testing should be performed either in the
hospital or early after discharge in STEMI patients not
selected for cardiac catheterization and without high-
risk features to assess the presence and extent of
inducible ischemia. (Level of Evidence: B)
2. In patients with baseline abnormalities that compro-
mise ECG interpretation, echocardiography or myo-
cardial perfusion imaging should be added to standard
exercise testing. (Level of Evidence: B)
Class IIb
1. Exercise testing might be considered before discharge
of patients recovering from STEMI to guide the post-
discharge exercise prescription or to evaluate the func-
tional significance of a coronary lesion previously
identified at angiography. (Level of Evidence: C)
Class III
1. Exercise testing should not be performed within 2 to 3
days of STEMI in patients who have not undergone
successful reperfusion. (Level of Evidence: C)
2. Exercise testing should not be performed to evaluate
patients with STEMI who have unstable postinfarction
angina, decompensated CHF, life-threatening cardiac
arrhythmias, noncardiac conditions that severely limit
their ability to exercise, or other absolute contraindi-
cations to exercise testing (170). (Level of Evidence: C)
3. Exercise testing should not be used for risk stratification
in patients with STEMI who have already been selected
for cardiac catheterization. (Level of Evidence: C)
Exercise testing after STEMI may be performed to (1)
assess functional capacity and the patient’s ability to perform
tasks at home and at work; (2) establish exercise parameters
for cardiac rehabilitation; (3) evaluate the efficacy of the
patient’s current medical regimen; (4) risk-stratify the post-
STEMI patient according to the likelihood of a subsequent
cardiac event (171–175); (5) evaluate chest pain symptoms
after STEMI; and (6) provide reassurance to patients regard-
ing their functional capacity after STEMI as a guide to
returning to work.
b. Role of Echocardiography
Noninvasive imaging in patients recovering from STEMI
includes echocardiography and radionuclide imaging. This
section discusses the role of echocardiography. (See Sections
705JACC Vol. 44, No. 3, 2004 Antman et al.
August 4, 2004:671–719 Management of Patients With STEMI: Executive Summary
7.11.1.3, 7.11.1.4, and 7.11.1.5 of the full-text guidelines for
additional discussion on imaging considerations.)
Class I
1. Echocardiography should be used in patients with
STEMI not undergoing LV angiography to assess
baseline LV function, especially if the patient is hemo-
dynamically unstable. (Level of Evidence: C)
2. Echocardiography should be used to evaluate patients with
inferior STEMI, clinical instability, and clinical suspicion of
RV infarction. (See ACC/AHA Guidelines for Clinical Ap-
plication of Echocardiography (153).) (Level of Evidence: C)
3. Echocardiography should be used in patients with
STEMI to evaluate suspected complications, including
acute MR, cardiogenic shock, infarct expansion, VSR,
intracardiac thrombus, and pericardial effusion. (Level
of Evidence: C)
4. Stress echocardiography (or myocardial perfusion imag-
ing) should be used in patients with STEMI for in-
hospital or early postdischarge assessment for inducible
ischemia when baseline abnormalities are expected to
compromise ECG interpretation. (Level of Evidence: C)
Class IIa
1. Echocardiography is reasonable in patients with
STEMI to re-evaluate ventricular function during re-
covery when results are used to guide therapy. (Level
of Evidence: C)
2. Dobutamine echocardiography (or myocardial perfu-
sion imaging) is reasonable in hemodynamically and
electrically stable patients 4 or more days after STEMI
to assess myocardial viability when required to define
the potential efficacy of revascularization. (Level of
Evidence: C)
3. In STEMI patients who have not undergone contrast
ventriculography, echocardiography is reasonable to
assess ventricular function after revascularization.
(Level of Evidence: C)
Class III
1. Echocardiography should not be used for early routine
reevaluation in patients with STEMI in the absence of
any change in clinical status or revascularization pro-
cedure. Reassessment of LV function 30 to 90 days
later may be reasonable. (Level of Evidence: C)
Figure 6. Evidence-based approach to need for catheterization (cath) and revascularization after STEMI. This algorithm shows treat-
ment paths for patients who initially undergo a primary invasive strategy, receive fibrinolytic therapy, or do not undergo reperfusion
therapy for STEMI. Patients who have not undergone a primary invasive strategy and have no high-risk features should undergo func-
tional evaluation with one of the noninvasive tests shown. When clinically significant ischemia is detected, patients should undergo
catheterization and revascularization as indicated; if no clinically significant ischemia is detected, medical therapy is prescribed after
STEMI. *Please see Table 23 of the ACC/AHA Guidelines for the Management of Patients With Chronic Stable Angina for further defini-
tion. †Please see Table 3, Section 6.3.1.6.2., and Section 7.3. in the full-text STEMI guidelines for further discussion. STEMI indicates
ST-elevation myocardial infarction; EF, ejection fraction; ECG, electrocardiography.
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The use of echocardiography in STEMI is discussed in
detail in the ACC/AHA/ASE 2003 Guideline Update for the
Clinical Application of Echocardiography (153).
c. Exercise Myocardial Perfusion Imaging
Noninvasive imaging in patients recovering from STEMI
includes echocardiography and radionuclide imaging. This
section discusses the role of exercise myocardial perfusion
imaging. (See Sections 7.11.1.2, 7.11.1.4, and 7.11.1.5 of the
full-text guidelines for additional discussion on imaging
considerations.)
Class I
1. Dipyridamole or adenosine stress perfusion nuclear
scintigraphy or dobutamine echocardiography before
or early after discharge should be used in patients with
STEMI who are not undergoing cardiac catheteriza-
tion to look for inducible ischemia in patients judged to
be unable to exercise. (Level of Evidence: B)
Class IIa
1. Myocardial perfusion imaging or dobutamine echocar-
diography is reasonable in hemodynamically and elec-
trically stable patients 4 to 10 days after STEMI to
assess myocardial viability when required to define the
potential efficacy of revascularization. (Level of Evi-
dence: C)
Recommended strategies for exercise test evaluations after
STEMI are presented in Figure 6. These strategies and the
data on which they are based are reviewed in more detail in
the ACC/AHA 2002 Guideline Update for Exercise Testing
(170).
d. LV Function
Noninvasive imaging in patients recovering from STEMI
includes echocardiography and radionuclide imaging. This
section discusses the importance of measurement of LV
function. Either of the above imaging techniques can provide
clinically useful information.
Class I
1. LVEF should be measured in all STEMI patients.
(Level of Evidence: B)
Assessment of LV function after STEMI has been shown
to be one of the most accurate predictors of future cardiac
events in both the prereperfusion (176) and the reperfusion
eras (177,178). Multiple techniques for assessing LV
function of patients after STEMI have important prognos-
tic value. Because of the dynamic nature of LV function
recovery after STEMI, clinicians should consider the
timing of the imaging study relative to the index event
when assessing LV function. (See Table 6 of the ACC/
AHA/ASE 2003 Guideline Update on the Clinical Appli-
cation of Echocardiography for further discussion of the
impact of timing on assessment of LV function and
inducible ischemia.) (153).
e. Invasive Evaluation
Class I
1. Coronary arteriography should be performed in pa-
tients with spontaneous episodes of myocardial ische-
mia or episodes of myocardial ischemia provoked by
minimal exertion during recovery from STEMI. (Level of
Evidence: A)
2. Coronary arteriography should be performed for
intermediate- or high-risk findings on noninvasive
testing after STEMI (see Table 23 of the ACC/AHA
2002 Guideline Update for the Management of Pa-
tients With Chronic Stable Angina) (179). (Level of
Evidence: B)
3. Coronary arteriography should be performed if the
patient is sufficiently stable before definitive therapy of
a mechanical complication of STEMI, such as acute
MR, VSR, pseudoaneurysm, or LV aneurysm. (Level of
Evidence: B)
4. Coronary arteriography should be performed in pa-
tients with persistent hemodynamic instability. (Level
of Evidence: B)
5. Coronary arteriography should be performed in sur-
vivors of STEMI who had clinical heart failure during
the acute episode but subsequently demonstrated well-
preserved LV function. (Level of Evidence: C)
Class IIa
1. It is reasonable to perform coronary arteriography
when STEMI is suspected to have occurred by a
mechanism other than thrombotic occlusion of an
atherosclerotic plaque. This would include coronary
embolism, certain metabolic or hematological diseases,
or coronary artery spasm. (Level of Evidence: C)
2. Coronary arteriography is reasonable in STEMI pa-
tients with any of the following: diabetes mellitus,
LVEF less than 0.40, CHF, prior revascularization, or
life-threatening ventricular arrhythmias. (Level of Ev-
idence: C)
Class IIb
1. Catheterization and revascularization may be consid-
ered as part of a strategy of routine coronary arteriog-
raphy for risk assessment after fibrinolytic therapy
(See Section 6.3.1.6.4.7 of the full-text guidelines).
(Level of Evidence: B)
Class III
1. Coronary arteriography should not be performed in
survivors of STEMI who are thought not to be candi-
dates for coronary revascularization. (Level of Evi-
dence: A)
The Writing Committee encourages contemporary research
into the benefit of routine catheterization versus watchful
waiting after fibrinolytic therapy in the contemporary era
(180). (See Section 6.3.1.6.4.7 of the full-text guidelines)
f. Assessment of Ventricular Arrhythmias
Class IIb
1. Noninvasive assessment of the risk of ventricular ar-
rhythmias may be considered (including signal-
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averaged ECG, 24-hour ambulatory monitoring, heart
rate variability, micro T-wave alternans, and T-wave
variability) in patients recovering from STEMI. (Level
of Evidence: B)
The clinical applicability of these tests to the post-STEMI
patient is in a state of evolution. Until these issues are
resolved, use these tests are used only to support routine
management and risk assessment.
L. Secondary Prevention
Class I
1. Patients who survive the acute phase of STEMI should
have plans initiated for secondary prevention thera-
pies. (Level of Evidence: A)
Secondary prevention therapies, unless contraindicated, are
an essential part of the management of all patients with
STEMI (Table 4) (181); regardless of sex (182,183). Inas-
much as atherosclerotic vascular disease is frequently found
in multiple vascular beds, the physician should search for
symptoms or signs of peripheral vascular disease or cerebro-
vascular disease in patients presenting with STEMI.
1. Patient Education Before Discharge
Class I
1. Before hospital discharge, all STEMI patients should
be educated about and actively involved in planning
for adherence to the lifestyle changes and drug thera-
pies that are important for the secondary prevention of
cardiovascular disease. (Level of Evidence: B)
2. Post-STEMI patients and their family members
should receive discharge instructions about recog-
nizing acute cardiac symptoms and appropriate ac-
tions to take in response (ie, calling 9-1-1 if symp-
toms are unimproved or worsening 5 minutes after
onset, or if symptoms are unimproved or worsening
5 minutes after 1 sublingual nitroglycerin dose) to
ensure early evaluation and treatment should symp-
toms recur. (Level of Evidence: C)
3. Family members of STEMI patients should be advised
to learn about AEDs and CPR and be referred to a
CPR training program. Ideally, such training programs
would have a social support component targeting family
members of high-risk patients. (Level of Evidence: C)
2. Lipid Management
Class I
1. Dietary therapy that is low in saturated fat and cho-
lesterol (less than 7% of total calories as saturated fat
and less than 200 mg/d cholesterol) should be started
on discharge after recovery from STEMI. Increased
consumption of the following should be encouraged:
omega–3 fatty acids, fruits, vegetables, soluble (vis-
cous) fiber, and whole grains. Calorie intake should be
balanced with energy output to achieve and maintain a
healthy weight. (Level of Evidence: A)
2. A lipid profile should be obtained from past records,
but if not available, it should be performed in all
patients with STEMI, preferably after they have fasted
and within 24 hours of admission. (Level of Evidence: C)
3. The target LDL-C level after STEMI should be sub-
stantially less than 100 mg/dL. (Level of Evidence: A)
a. Patients with LDL-C 100 mg/dl or above should be
prescribed drug therapy on hospital discharge, with
preference given to statins. (Level of Evidence: A)
b. Patients with LDL-C less than 100 mg/dL or unknown
LDL-C levels should be prescribed statin therapy on
hospital discharge. (Level of Evidence: B)
4. Patients with non–high-density lipoprotein cholesterol
(non HDL-C) levels less than 130 mg/dL who have an
HDL-C level less than 40 mg/dL should receive special
emphasis on nonpharmacological therapy (eg, exercise,
weight loss, and smoking cessation) to increase HDL-C.
(Level of Evidence: B)
Class IIa
1. It is reasonable to prescribe drug therapy at discharge to
patients with non–HDL-C greater than or equal to 130
mg/dL, with a goal of reducing non–HDL-C to substan-
tially less than 130 mg/dL. (Level of Evidence: B)
2. It is reasonable to prescribe drug therapy such as
niacin or fibrate therapy to raise HDL-C levels in
patients with LDL-C less than 100 mg/dL and non–
HDL-C less than 130 mg/dL but HDL-C less than 40
mg/dL despite dietary and other nonpharmacological
therapy. (Level of Evidence: B) Dietary-supplement
niacin must not be used as a substitute for prescription
niacin, and over-the-counter niacin should be used
only if approved and monitored by a physician.
3. It is reasonable to add drug therapy with either niacin
or a fibrate to diet regardless of LDL-C and HDL-C
levels when triglyceride levels are greater than 500
mg/dL. In this setting, non–HDL-C (goal substantially
less than 130 mg/dL) should be the cholesterol target
rather than LDL-C. (Level of Evidence: B) Dietary-
supplement niacin must not be used as a substitute for
prescription niacin, and over-the-counter niacin
should be used only if approved and monitored by a
physician.
Early secondary prevention trials conducted before the
use of statin therapy, which used then-available drugs and
diet to lower cholesterol, demonstrated significant reduc-
tions of 25% in nonfatal MIs and 14% in fatal MIs (14).
Subsequently, a growing body of evidence, mainly from
large randomized clinical trials of statin therapy, has
firmly established the desirability of lowering atherogenic
serum lipids in patients who have recovered from a
STEMI. See Table 4 for additional discussion of
recommendations.
3. Weight Management
Class I
1. Measurement of waist circumference and calculation
of body mass index are recommended. Desirable body
mass index range is 18.5 to 24.9 kg/m2. A waist
circumference greater than 40 inches in men and 35
inches in women would result in evaluation for meta-
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TABLE 4. Secondary Prevention for STEMI Patients
Goals Intervention Recommendations
Smoking: Goal complete cessation Assess tobacco use. Strongly encourage patient and family to stop smoking and to avoid secondhand smoke.
Provide counseling, pharmacological therapy (including nicotine replacement and bupropion), and formal smoking
cessation programs as appropriate.
Blood pressure control: Goal Less than
140/90 mm Hg or Less than 130/80 mm Hg if
chronic kidney disease or diabetes
If blood pressure is 120/80 mm Hg or greater:
• Initiate lifestyle modification (weight control, physical activity, alcohol moderation, moderate sodium
restriction, and emphasis on fruits, vegetables, and low-fat dairy products) in all patients.
If blood pressure is 140/90 mm Hg or greater or 130/80 mm Hg or greater for individuals with
chronic kidney disease or diabetes:
• Add blood pressure medications, emphasizing the use of beta-blockers and inhibition of the
renin-angiotensin-aldosterone system.
Lipid management: (TG less than 200 mg/dL)
Primary goal LDL-C substantially less than 100
mg/dL
Start dietary therapy in all patients (less than 7% of total calories as saturated fat and less than 200
mg/d cholesterol). Promote physical activity and weight management. Encourage increased
consumption of omega-3 fatty acids.
Assess fasting lipid profile in all patients, preferably within 24 hours of STEMI.
Add drug therapy according to the following guide:
LDL-C substantially less than 100 mg/dL (baseline or on-treatment):
• Statins should be used to lower LDL-C.
LDL-C greater than or equal to 100 mg/dL (baseline or on-treatment):
• Intensify LDL-C–lowering therapy with drug treatment, giving preference to statins.
Lipid management: (TG 200 mg/dL or greater)
Primary goal Non–HDL-C* substantially less than
130 mg/dL
If TG is greater than or equal to 150 mg/dL or HDL-C is less than 40 mg/dL:
• Emphasize weight management and physical activity. Advise smoking cessation.
If TG is 200 to 499 mg/dL:
• After LDL-C–lowering therapy,† consider adding fibrate or niacin.‡
If TG is greater than or equal to 500 mg/dL:
• Consider fibrate or niacin‡ before LDL-C–lowering therapy.†
• Consider omega-3 fatty acids as adjunct for high TG.
Physical activity: Minimum goal 30 minutes 3
to 4 days per week; Optimal daily
Assess risk, preferably with exercise test, to guide prescription.
Encourage minimum of 30 to 60 minutes of activity, preferably daily, or at least 3 or 4 times weekly
(walking, jogging, cycling, or other aerobic activity) supplemented by an increase in daily lifestyle
activities (eg, walking breaks at work, gardening, household work). Cardiac rehabilitation/secondary
prevention programs, when available, are recommended for patients with STEMI, particularly those
with multiple modifiable risk factors and/or those moderate- to high-risk patients in whom
supervised exercise training is warranted.
Weight management: Goal BMI 18.5–24.9 kg/m2
Waist circumference: Women: Less than 35 inches
Men: Less than 40 inches
Calculate BMI and measure waist circumference as part of evaluation. Monitor response of BMI and
waist circumference to therapy.
Start weight management and physical activity as appropriate. Desirable BMI range is 18.5 to 24.9 kg/m2.
If waist circumference is greater than or equal to 35 inches in women or greater than or equal to 40
inches in men, initiate lifestyle changes and treatment strategies for metabolic syndrome.
Diabetes management: Goal HbA1c less than 7% Appropriate hypoglycemic therapy to achieve near-normal fasting plasma glucose, as indicated by HbA1c.
Treatment of other risks (eg, physical activity, weight management, blood pressure, and cholesterol
management).
Antiplatelet agents/anticoagulants: Start and continue indefinitely aspirin 75 to 162 mg/d if not contraindicated. Consider clopidogrel 75
mg/d or warfarin if aspirin is contraindicated. Manage warfarin to INR of 2.5 to 3.5 in post-STEMI
patients when clinically indicated or for those not able to take aspirin or clopidogrel (Figure 7).
Renin-Angiotensin-Aldosterone System
Blockers:
ACE inhibitors in all patients indefinitely; start, early in stable high-risk patients (anterior MI, previous
MI, Killip class greater than or equal to II S3 gallop, rales, radiographic CHF, LVEF less than 0.40).
ARBs in patients who are intolerant of ACE inhibitors and who have either clinical or radiological
signs of heart failure or LVEF less than 0.40.
Aldosterone blockade in patients without significant renal dysfunction§ or hyperkalemia who are
already receiving therapeutic doses of an ACE inhibitor, have an LVEF less than or equal to 0.40, and
have either diabetes or heart failure.
Beta-Blockers: Start in all patients. Continue indefinitely. Observe usual contraindications.
BMI indicates body mass index; in, inches; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; BMI, body mass index; INR,
international normalization ratio; ACE, angiotensin converting enzyme; CHF, congestive heart failure; LVEF, left ventricular ejection fraction; ARB, angiotensin receptor
blocker and TG, triglycerides.
*Non–HDL cholesterol equals total cholesterol minus HDL cholesterol.
†Treat to a goal of non–HDL-C substantially less than 130 mg/dL.
‡Dietary-supplement niacin must not be used as a substitute for prescription niacin, and over-the-counter niacin should be used only if approved and monitored by a physician.
§Creatinine should be less than or equal to 2.5 mg/dL in men or less than or equal to 2.0 mg/dL in women.
Potassium should be less than or equal to 5.0 mEq/L.
Modified with permission from Smith et al. Circulation. 2004;109:672–93 (181).
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bolic syndrome and implementation of weight-
reduction strategies. (Level of Evidence: B)
2. Patients should be advised about appropriate strate-
gies for weight management and physical activity
(usually accomplished in conjunction with cardiac
rehabilitation). (Level of Evidence: B)
3. A plan should be established to monitor the response of
body mass index and waist circumference to therapy
(usually accomplished in conjunction with cardiac
rehabilitation). (Level of Evidence: B)
4. Smoking Cessation
Class I
1. Patients recovering from STEMI who have a history
of cigarette smoking should be strongly encouraged
to stop smoking and to avoid secondhand smoke.
Counseling should be provided to the patient and
family, along with pharmacological therapy (includ-
ing nicotine replacement and bupropion) and formal
smoking-cessation programs as appropriate. (Level
of Evidence: B)
2. All STEMI patients should be assessed for a history of
cigarette smoking. (Level of Evidence: A)
5. Antiplatelet Therapy
Class I
1. A daily dose of aspirin 75 to 162 mg orally should be
given indefinitely to patients recovering from STEMI.
(Level of Evidence: A)
2. If true aspirin allergy is present, preferably clopidogrel
(75 mg orally per day) or, alternatively, ticlopidine
(250 mg orally twice daily) should be substituted.
(Level of Evidence: C)
3. If true aspirin allergy is present, warfarin therapy with
a target INR of 2.5 to 3.5 is a useful alternative to
clopidogrel in patients less than 75 years of age who are
at low risk for bleeding and who can be monitored
adequately for dose adjustment to maintain a target
INR range. (Level of Evidence: C)
Class III
1. Ibuprofen should not be used because it blocks the
antiplatelet effects of aspirin. (Level of Evidence: C)
On the basis of 12 randomized trials in 18 788 patients
with prior infarction, the Antiplatelet Trialists’ Collaboration
reported a 25% reduction in the risk of recurrent infarction,
stroke, or vascular death in patients receiving prolonged
antiplatelet therapy (36 fewer events for every 1000 patients
treated) (31). No antiplatelet therapy has proved superior to
aspirin in this population, and daily doses of aspirin between
80 and 325 mg appear to be effective (184). The CAPRIE
(Clopidogrel versus Aspirin in Patients at Risk of Ischemic
Events) trial, which compared aspirin with clopidogrel in
19 185 patients at high risk for vascular events, demonstrated
a modest but significant (8.6%, P equals 0.043) reduction in
serious vascular events with clopidogrel compared with
aspirin (185). These data suggest clopidogrel as the best
alternative to aspirin in patients with true aspirin allergy.
The use of warfarin therapy for secondary prevention of
vascular events in patients after STEMI is discussed in
Section 7.12.11 of the full-text guidelines. Large randomized
trials have demonstrated that oral anticoagulants, when given
in adequate doses, reduce the rates of adverse outcomes, at
the cost of a small increase in hemorrhagic events (186–188).
In the Warfarin, Aspirin, Reinfarction Study (WARIS II),
warfarin without aspirin in a dose intended to achieve an INR
of 2.8 to 4.2 resulted in a significant reduction in a composite
end point (death, nonfatal reinfarction, or thromboembolic
stroke) compared with therapy with aspirin alone (16.7%
versus 20.0%) (186). Warfarin therapy resulted in a small but
significant increase in major, nonfatal bleeding compared
with therapy with aspirin alone (0.62% versus 0.17% per
year). Chronic therapy with warfarin after STEMI presents an
alternative to clopidogrel in patients with aspirin allergy.
6. Inhibition of Renin-Angiotensin-
Aldosterone-System
Class I
1. An ACE inhibitor should be prescribed at discharge
for all patients without contraindications after STEMI.
(Level of Evidence: A)
2. Long-term aldosterone blockade should be prescribed
for post-STEMI patients without significant renal dys-
function (creatinine should be less than or equal to 2.5
mg/dL in men and less than or equal to 2.0 mg/dL in
women) or hyperkalemia (potassium should be less
than or equal to 5.0 mEq/L) who are already receiving
therapeutic doses of an ACE inhibitor, have an LVEF
less than or equal to 0.40, and have either symptomatic
heart failure or diabetes. (Level of Evidence: A)
3. An ARB should be prescribed at discharge in those
STEMI patients who are intolerant of an ACE inhibi-
tor and have either clinical or radiological signs of
heart failure and LVEF less than 0.40. Valsartan and
candesartan have established efficacy for this recom-
mendation. (Level of Evidence: B)
Class IIa
1. In STEMI patients who tolerate ACE inhibitors, an
ARB can be useful as an alternative to ACE inhibitors
in the long-term management of STEMI patients,
provided there are either clinical or radiological signs
of heart failure or LVEF less than 0.40. Valsartan and
candesartan have established efficacy for this recom-
mendation. (Level of Evidence: B)
Class IIb
1. The combination of an ACE inhibitor and an ARB may
be considered in the long-term management of STEMI
patients with persistent symptomatic heart failure and
LVEF less than 0.40. (Level of Evidence: B)
The use of ACE inhibitors early in the acute phase of
STEMI and in the hospital management phase has been
described earlier.
Compelling evidence now supports the broad long-term
use of ACE inhibitors after STEMI (189,190). The results of
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the VALIANT study (Valsartan in Acute Myocardial Infarc-
tion Trial) evaluating valsartan are discussed in Section 7.4.3
of the full-text guidelines. The series of CHARM studies
(Candesartan in Heart Failure Assessment in Reduction of
Mortality), although focusing on the evaluation of candesar-
tan in patients with chronic heart failure, provides informa-
tion that can be extrapolated to the long-term management of
the STEMI patient, because 50% to 60% of the patients
studied had ischemic heart disease as the cause of heart
failure (191–193).
Given the extensive randomized trial and routine clinical
experience with ACE inhibitors, they remain the logical first
agent for inhibition of the renin-angiotensin-aldosterone sys-
tem in the long-term management of patients with STEMI
(150,194). The ARBs valsartan and candesartan should be
administered over the long term to STEMI patients with
symptomatic heart failure who are intolerant of ACE inhibi-
tors. As described in Section 7.4.3 of the full-text guidelines,
the choice between an ACE inhibitor and an ARB over the
long term in patients who are tolerant of ACE inhibitors will
vary with individual physician and patient preference, as well
as cost and anticipated side-effect profile (150,194).
The results of the most relevant clinical trials that tested
combinations of ACE inhibitors and ARBs have been subtly
different, but clinically relevant. Whereas the CHARM-
Added (192) trial demonstrated a reduction in the combined
end point of heart failure hospitalization and death over ACE
inhibition alone, the VALIANT study (149) reported that the
combination of captopril and valsartan was equivalent to
either alone, but with a greater number of adverse effects.
Thus, when combination ACE inhibition and angiotensin
receptor blockade is considered necessary, the preferred ARB
is candesartan. Although there is evidence that the combina-
tion of an ACE inhibitor and an aldosterone inhibitor is
effective at reducing mortality and is well tolerated in patients
with a serum creatinine level of 2.5 mg/dL or less and a serum
potassium concentration of 5.0 mEq/L or less (see Section
7.4.3 of the full-text guidelines), much less experience exists
with the combination of an ARB and aldosterone inhibitor
(24% of 2028 patients in the CHARM-Alternative trial) (191)
and the triple combination of an ACE inhibitor, ARB, and an
aldosterone antagonist (17% of 2548 patients in the CHARM-
Added trial) (192).
The combination of an ACE inhibitor and an ARB
(valsartan 20 mg/d orally initially; titrated up to 160 mg orally
twice per day, or candesartan 4 to 8 mg/d orally initially; titrated
up to 32 mg/d orally) or an ACE inhibitor and an aldosterone
inhibitor may be considered for the long-term management of
STEMI patients with symptomatic heart failure and LVEF less
than 0.40, provided the serum creatinine level is less than or
equal to 2.5 mg/dL in men and less than or equal to 2.0 mg/dL
in women and the serum potassium concentration is less than or
equal to 5.0 mEq/L (See Sections 7.4.3 and 7.6.4 of the full-text
guidelines.)
7. Beta-Blockers
Class I
1. All patients after STEMI except those at low risk
(normal or near-normal ventricular function, success-
ful reperfusion, and absence of significant ventricular
arrhythmias) and those with contraindications should
receive beta-blocker therapy. Treatment should begin
within a few days of the event, if not initiated acutely,
and continue indefinitely. (Level of Evidence: A)
2. Patients with moderate or severe LV failure should
receive beta-blocker therapy with a gradual titration
scheme. (Level of Evidence: B)
Class IIa
1. It is reasonable to prescribe beta-blockers to low-risk
patients after STEMI who have no contraindications to
that class of medications. (Level of Evidence: A)
The use of beta-blockers in the early phase of STEMI and
in hospital management is reviewed in Sections 6.3.1.6 and
7.4.1 of the full-text guidelines. The benefits of beta-blocker
therapy in patients without contraindications have been dem-
onstrated with or without reperfusion, initiated early or later
in the clinical course, and for all age groups. The benefits of
beta-blocker therapy for secondary prevention are well estab-
lished (142,196). In patients with moderate or severe LV
failure, beta-blocker therapy should be administered with a
gradual titration scheme (197). Long-term beta-blocker ther-
apy should be administered to survivors of STEMI who have
subsequently undergone revascularization, because there is
evidence of a mortality benefit from their use despite revas-
cularization with either CABG surgery or PCI (198).
8. Blood Pressure Control
Class I
1. Blood pressure should be treated with drug therapy to
a target level of less than 140/90 mm Hg and to less
than 130/80 mm Hg for patients with diabetes or
chronic kidney disease. (Level of Evidence: B)
2. Lifestyle modification (weight control, dietary changes,
physical activity, and sodium restriction) should be
initiated in all patients with blood pressure greater
than or equal to 120/80 mm Hg. (Level of Evidence: B)
Class IIb
1. A target blood pressure goal of 120/80 mm Hg for
post-STEMI patients may be reasonable. (Level of
Evidence: C)
Class III
1. Short-acting dihydropyridine calcium channel block-
ing agents should not be used for the treatment of
hypertension. (Level of Evidence: B)
The Seventh Report of the Joint National Committee on
Prevention, Detection, Evaluation, and Treatment of High
Blood Pressure (JNC-7) (199) recommends that patients be
treated after MI with ACE inhibitors, beta-blockers, and, if
necessary, aldosterone antagonists to a target blood pressure
of less than 140/90 mm Hg, or less than 130/80 mm Hg for
those with chronic kidney disease or diabetes (199). Most
patients will require 2 or more drugs to reach this goal, and
when the blood pressure is greater than 20/10 mm Hg above
goal, 2 drugs should usually be used from the outset.
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JNC-7 emphasizes the importance of lifestyle modifica-
tions for all patients with blood pressure of 120/80 mm Hg or
greater (199). These modifications include weight reduction
if overweight or obese, consumption of a diet rich in fruits
and vegetables and low in total fat and saturated fat, and
reduction of sodium to no more than 2.4 g/d (199).
9. Diabetes Management
Class I
1. Hypoglycemic therapy should be initiated to achieve
HbA1c less than 7%. (Level of Evidence: B)
Class III
1. Thiazolidinediones should not be used in patients
recovering from STEMI who have New York Heart
Association class III or IV heart failure. (Level of
Evidence: B)
10. Hormone Therapy
Class III
1. Hormone therapy with estrogen plus progestin should
not be given de novo to postmenopausal women after
STEMI for secondary prevention of coronary events.
(Level of Evidence: A)
2. Postmenopausal women who are already taking estro-
gen plus progestin at the time of a STEMI should not
continue hormone therapy. However, women who are
beyond 1 to 2 years after initiation of hormone therapy
who wish to continue hormone therapy for another
compelling indication should weigh the risks and ben-
efits, recognizing a greater risk of cardiovascular
events. However, hormone therapy should not be con-
tinued while patients are on bedrest in the hospital.
(Level of Evidence: B)
On the basis of the Heart and Estrogen/progestin Replace-
ment Study (HERS) (200), the Heart and Estrogen/progestin
Replacement Study Follow-up (HERS-2) (201), and the
Women’s Health Initiative (202), postmenopausal women
should not receive combination estrogen and progestin ther-
apy for primary or secondary prevention of CHD. It is
recommended that the use of hormone therapy be discontin-
ued in women who have STEMI (200–202).
11. Warfarin Therapy
Class I
1. Warfarin should be given to aspirin-allergic post-
STEMI patients with indications for anticoagulation as
follows:
a. Without stent implanted (INR 2.5 to 3.5). (Level of
Evidence: B)
b. With stent implanted and clopidogrel 75 mg/d
administered concurrently (INR 2.0 to 3.0). (Level
of Evidence: C)
2. Warfarin (INR 2.5 to 3.5) is a useful alternative to
clopidogrel in aspirin-allergic patients after STEMI
who do not have a stent implanted. (Level of Evidence:
B)
3. Warfarin (INR 2.0 to 3.0) should be prescribed for
post-STEMI patients with either persistent or parox-
ysmal atrial fibrillation. (Level of Evidence: A)
4. In post-STEMI patients with LV thrombus noted on an
imaging study, warfarin should be prescribed for at least 3
months (Level of Evidence: B) and indefinitely in patients
without an increased risk of bleeding (Level of Evidence: C).
5. Warfarin alone (INR 2.5 to 3.5) or warfarin (INR 2.0 to 3.0)
in combination with aspirin (75 to 162 mg) should be
prescribed in post-STEMI patients who have no stent im-
planted and who have indications for anticoagulation. (Level
of Evidence: B)
Class IIa
1. In post-STEMI patients less than 75 years of age
without specific indications for anticoagulation who
can have their level of anticoagulation monitored reli-
ably, warfarin alone (INR 2.5 to 3.5) or warfarin (INR
2.0 to 3.0) in combination with aspirin (75 to 162 mg)
can be useful for secondary prevention. (Level of
Evidence: B)
2. It is reasonable to prescribe warfarin to post-STEMI
patients with LV dysfunction and extensive regional
wall-motion abnormalities. (Level of Evidence: A)
Class IIb
1. Warfarin may be considered in patients with severe
LV dysfunction, with or without CHF. (Level of Evi-
dence: C)
The indications for long-term anticoagulation after STEMI
remain controversial and are evolving. Although the use of
warfarin has been demonstrated to be cost-effective com-
pared with standard therapy without aspirin, the superior
safety, efficacy and cost-effectiveness of aspirin has made it
the antithrombotic agent of choice for secondary prevention
(203) (Figure 7).
12. Physical Activity
Class I
1. On the basis of assessment of risk, ideally with an
exercise test to guide the prescription, all patients
recovering from STEMI should be encouraged to
exercise for a minimum of 30 minutes, preferably daily
but at least 3 or 4 times per week (walking, jogging,
cycling, or other aerobic activity), supplemented by an
increase in daily lifestyle activities (eg, walking breaks
at work, gardening, and household work). (Level of
Evidence: B)
2. Cardiac rehabilitation/secondary prevention pro-
grams, when available, are recommended for patients
with STEMI, particularly those with multiple modifi-
able risk factors and/or those moderate- to high-risk
patients in whom supervised exercise training is war-
ranted. (Level of Evidence: C)
13. Antioxidants
Class III
1. Antioxidant vitamins such as vitamin E and/or vitamin
C supplements should not be prescribed to patients
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recovering from STEMI to prevent cardiovascular
disease. (Level of Evidence: A)
There is no convincing evidence to support lipid- or
water-soluble antioxidant supplementation in patients after
STEMI or patients with or without established coronary
disease.
VIII. Long-Term Management
A. Psychosocial Impact of STEMI
Class I
1. The psychosocial status of the patient should be evalu-
ated, including inquiries regarding symptoms of de-
pression, anxiety, or sleep disorders and the social
support environment. (Level of Evidence: C)
Class IIa
1. Treatment with cognitive-behavioral therapy and se-
lective serotonin reuptake inhibitors can be useful for
STEMI patients with depression that occurs in the year
after hospital discharge. (Level of Evidence: A)
Treatment of depression with combined cognitive-
behavioral therapy and selective serotonin reuptake inhibitors
improves outcome in terms of depression symptoms and
social function (204–206). It appears prudent to assess
STEMI patients for depression during hospitalization and
during the first month after STEMI and to intervene and
reassess yearly in the first 5 years, as appropriate. There is
evidence that the STEMI experience, with its sudden and
unexpected onset, dramatic changes in lifestyle, and the
additive effort of comorbid life events, is a relatively trau-
matic event and may produce impaired coping during subse-
quent ischemic events (207).
B. Cardiac Rehabilitation
Class IIa
1. Cardiac rehabilitation/secondary prevention pro-
grams, when available, are recommended for patients
with STEMI, particularly those with multiple modifi-
able risk factors and/or those moderate- to high-risk
patients in whom supervised exercise training is war-
ranted. (Level of Evidence: C)
C. Follow-Up Visit With Medical Provider
Class I
1. A follow-up visit should delineate the presence or
absence of cardiovascular symptoms and functional
class. (Level of Evidence: C)
Figure 7. Long-term antithrombotic therapy at hospital discharge after STEMI. ASA indicates aspirin; LOE, level of evidence LV, left
ventricular; and INR, international normalized ratio. *Clopidogrel is preferred over warfarin because of increased risk of bleeding and
low patient compliance in warfarin trials. †For 12 months. ‡Discontinue clopidogrel 1 month after implantation of a bare metal stent or
several months after implantation of a drug-eluting stent (3 months after sirolimus and 6 months after paclitaxel) because of the poten-
tial increased risk of bleeding with warfarin and 2 antiplatelet agents. Continue aspirin and warfarin long term if warfarin is indicated for
other reasons such as atrial fibrillation, LV thrombus, cerebral emboli, or extensive regional wall-motion abnormality. §An INR of 2.0 to
3.0 is acceptable with tight control, but the lower end of this range is preferable. The combination of antiplatelet therapy and warfarin
may be considered in patients aged less than 75 years with low bleeding risk who can be monitored reliably.
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2. The patient’s list of current medications should be
reevaluated in a follow-up visit, and appropriate titra-
tion of ACE inhibitors, beta-blockers, and statins
should be undertaken. (Level of Evidence: C)
3. The predischarge risk assessment and planned workup
should be reviewed and continued (Figure 6). This should
include a check of LV function and possibly Holter moni-
toring for those patients whose early post-STEMI ejection
fraction was 0.31 to 0.40 or lower, in consideration of
possible ICD use (Figure 5). (Level of Evidence: C)
4. The healthcare provider should review and empha-
size the principles of secondary prevention with the
patient and family members (Table 4) (181). (Level
of Evidence: C)
5. The psychosocial status of the patient should be eval-
uated in follow-up, including inquiries regarding
symptoms of depression, anxiety, or sleep disorders
and the social support environment. (Level of Evi-
dence: C)
6. In a follow-up visit, the healthcare provider should
discuss in detail issues of physical activity, return to
work, resumption of sexual activity, and travel,
including driving and flying. The metabolic equiva-
lent values for various activities are provided as a
resource in Table 34 of the full-text guideline. (Level
of Evidence: C)
7. Patients and their families should be asked if they are
interested in CPR training after the patient is dis-
charged from the hospital. (Level of Evidence: C)
8. Providers should actively review the following issues
with patients and their families:
a. The patient’s heart attack risk. (Level of Evidence: C)
b. How to recognize symptoms of STEMI. (Level of
Evidence: C)
c. The advisability of calling 9-1-1 if symptoms are
unimproved or worsening after 5 minutes, despite
feelings of uncertainty about the symptoms and fear
of potential embarrassment. (Level of Evidence: C)
d. A plan for appropriate recognition and response to a
potential acute cardiac event, including the phone
number to access EMS, generally 9-1-1 (15). (Level
of Evidence: C)
9. Cardiac rehabilitation/secondary prevention pro-
grams, when available, are recommended for patients
with STEMI, particularly those with multiple modifi-
able risk factors and/or those moderate- to high-risk
patients in whom supervised exercise training is war-
ranted. (Level of Evidence: C)
References
1. Mehta RH, Montoye CK, Gallogly M, et al., for the GAP Steering
Committee of the American College of Cardiology. Improving quality of
care for acute myocardial infarction: The Guidelines Applied in Practice
(GAP) Initiative. JAMA 2002;287:1269–76.
2. Jencks SF, Huff ED, Cuerdon T. Change in the quality of care delivered
to medicare beneficiaries, 1998–1999 to 2000–2001. JAMA 2003;289:
305–12.
3. Schneider EC, Zaslavsky AM, Epstein AM. Racial disparities in the
quality of care for enrollees in medicare managed care. JAMA 2002;
287:1288–94.
4. Rogers WJ, Canto JG, Lambrew CT, et al. Temporal trends in the
treatment of over 1.5 million patients with myocardial infarction in the
US from 1990 through 1999: the National Registry of Myocardial
Infarction 1, 2 and 3. J Am Coll Cardiol 2000;36:2056–63.
5. American Heart Association. Heart Disease and Stroke Statistics—2004
Update. Dallas, TX: American Heart Association, 2003.
5a. Wiviott SD, Morrow DA, Giugliano RP, et al. Performance of the
thrombolysis in myocardial infarction risk index for early acute coro-
nary syndrome in the National Registry of Myocardial Infarction: a
simple risk index predicts mortality in both ST and non-ST elevation
myocardial infarction. J Am Coll Cardiol 2003;41:365A–6A.
6. Expert Panel on Detection, Evaluation, and Treatment of High Blood
Cholesterol in Adults. Executive Summary of the Third Report of the
National Cholesterol Education Program (NCEP) Expert Panel on
Detection, Evaluation, and Treatment of High Blood Cholesterol in
Adults (Adult Treatment Panel III). JAMA 2001;285:2486–97.
7. Levey AS, Coresh J, Balk E, et al. National Kidney Foundation practice
guidelines for chronic kidney disease: evaluation, classification, and
stratification. Ann Intern Med 2003;139:137–47.
8. National, Heart, Lung, and Blood Institute. Act in Time to Heart Attack.
Available at: http://:www.nhlbi.nih.gov/actintime, 2003. Accessed May
15, 2003.
9. American College of Cardiology. Guidelines Applied in Practice.
Available at: http://www.acc.org/gap/gap.htm. Accessed May 15, 2003.
10. American Heart Association. Get With the Guidelines. Available at
http://www.americanheart.org/presenter.jhtml?identifier1165.
Accessed May 15, 2003.
11. Topol EJ, Kereiakes DJ. Regionalization of care for acute ischemic heart
disease: a call for specialized centers. Circulation 2003;107:1463–6.
12. Califf RM, Faxon DP. Need for centers to care for patients with acute
coronary syndromes. Circulation 2003;107:1467–70.
13. Willerson JT. Editor’s commentary: centers of excellence. Circulation
2003;107:1471–2.
14. National Cholesterol Education Program. Third Report of the Expert Panel
on Detection, Evaluation, and Treatment of High Blood Cholesterol in
Adults (Adult Treatment Panel III). NIH publication No. 02–5125.
Bethesda, Md: National Heart, Lung, and Blood Institute, 2002. Guidelines,
Related Tools, and Patient Information. Available at: http://www.nhlbi.ni-
h.gov/guidelines/cholesterol/index.htm. Accessed April 12, 2003.
15. Dracup K, Alonzo AA, Atkins JM, et al. The physician’s role in
minimizing prehospital delay in patients at high risk for acute myo-
cardial infarction: recommendations from the National Heart Attack
Alert Program. Working Group on Educational Strategies to Prevent
Prehospital Delay in Patients at High Risk for Acute Myocardial
Infarction. Ann Intern Med 1997;126:645–51.
16. Hedges JR, Feldman HA, Bittner V, et al., for the REACT Study Group.
Impact of community intervention to reduce patient delay time on use of
reperfusion therapy for acute myocardial infarction: Rapid Early Action
for Coronary Treatment (REACT) trial. Acad Emerg Med 2000;7:
862–72.
17. Canto JG, Zalenski RJ, Ornato JP, et al., for the National Registry of
Myocardial Infarction 2 Investigators. Use of emergency medical
services in acute myocardial infarction and subsequent quality of care:
observations from the National Registry of Myocardial Infarction 2.
Circulation 2002;106:3018–23.
18. Goldberg R, Goff D, Cooper L, et al. Age and sex differences in
presentation of symptoms among patients with acute coronary disease:
the Trial: Rapid Early Action for Coronary Treatment (REACT). Coron
Artery Dis 2000;11:399–407.
19. Hutchings CB, Mann NC, Daya M, et al., for the Rapid Early Action for
Coronary Treatment Study. Patients with chest pain calling 9-1-1 or
self-transporting to reach definitive care: which mode is quicker? Am
Heart J 2004;147:35–41.
20. Faxon D, Lenfant C. Timing is everything: motivating patients to call
9–1–1 at onset of acute myocardial infarction. Circulation 2001;104:
1210–1.
21. U.S. Department of Health and Human Services, Public Health Service,
National Institutes of Health, National Heart, Lung, and Blood Institute.
NIH publication No. 01–3313. September 2001. Available at: http://
www.nhlbi.nih.gov/health/prof/heart/mi/provider.pdf. Accessed
December 16, 2002.
22. Eisenberg MJ, Topol EJ. Prehospital administration of aspirin in patients
with unstable angina and acute myocardial infarction. Arch Intern Med
1996;156:1506–10.
23. Fibrinolytic Therapy Trialists’ (FTT) Collaborative Group. Indications for
fibrinolytic therapy in suspected acute myocardial infarction: collaborative
overview of early mortality and major morbidity results from all ran-
domised trials of more than 1000 patients. Lancet 1994;343:311–22.
24. Gruppo Italiano per lo Studio della Streptochinasi nell’Infarto Mio-
cardico (GISSI). Effectiveness of intravenous thrombolytic treatment in
acute myocardial infarction. Lancet 1986;1:397–402.
714 Antman et al. JACC Vol. 44, No. 3, 2004
Management of Patients With STEMI: Executive Summary August 4, 2004:671–719
25. Armstrong PW, Collen D, Antman E. Fibrinolysis for acute myocardial
infarction: the future is here and now. Circulation 2003;107:2533–7.
26. The American Heart Association in collaboration with the International
Liaison Committee on Resuscitation. Guidelines 2000 for Cardiopulmo-
nary Resuscitation and Emergency Cardiovascular Care: Part 7: the era
of reperfusion: section 1: acute coronary syndromes (acute myocardial
infarction). Circulation 2000;102 Suppl I:I172–203.
27. Pedley DK, Bissett K, Connolly EM, et al. Prospective observational
cohort study of time saved by prehospital thrombolysis for ST elevation
myocardial infarction delivered by paramedics. BMJ 2003;327:22–6.
28. Menown IB, Mackenzie G, Adgey AA. Optimizing the initial 12-lead
electrocardiographic diagnosis of acute myocardial infarction. Eur
Heart J 2000;21:275–83.
29. Case definitions for acute coronary heart disease in epidemiology and
clinical research studies: a statement from the AHA Council on Epide-
miology and Prevention; AHA Statistics Committee; World Heart Fed-
eration Council on Epidemiology and Prevention; the European Society
of Cardiology Working Group on Epidemiology and Prevention;
Centers for Disease Control and Prevention; and the National Heart,
Lung, and Blood Institute. Circulation 2003;108:2543–9.
30. Come PC, Pitt B. Nitroglycerin-induced severe hypotension and brady-
cardia in patients with acute myocardial infarction. Circulation 1976;54:
624–8.
31. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of ran-
domised trials of antiplatelet therapy for prevention of death, myocardial
infarction, and stroke in high risk patients. BMJ 2002;324:71–86.
32. Sagar KA, Smyth MR. A comparative bioavailability study of different
aspirin formulations using on-line multidimensional chromatography.
J Pharm Biomed Anal 1999;21:383–92.
33. De Luca G, Suryapranata H, Zijlstra F, et al., for the ZWOLLE Myo-
cardial Infarction Study Group. Symptom-onset-to-balloon time and
mortality in patients with acute myocardial infarction treated by primary
angioplasty. J Am Coll Cardiol 2003;42:991–7.
34. Boersma E, Mercado N, Poldermans D, et al. Acute myocardial
infarction. Lancet 2003;361:847–58.
35. De Luca G, Suryapranata H, Ottervanger JP, et al. Time delay to
treatment and mortality in primary angioplasty for acute myocardial
infarction: every minute of delay counts. Circulation 2004;109:1223–5.
36. Boersma E, Maas AC, Deckers JW, et al. Early thrombolytic treatment
in acute myocardial infarction: reappraisal of the golden hour. Lancet
1996;348:771–5.
37. Zeymer U, Tebbe U, Essen R, et al., for the ALKK-Study Group.
Influence of time to treatment on early infarct-related artery patency
after different thrombolytic regimens. Am Heart J 1999;137:34–8.
38. Weaver WD, Cerqueira M, Hallstrom AP, et al. Prehospital-initiated vs
hospital-initiated thrombolytic therapy: the Myocardial Infarction Triage
and Intervention Trial. JAMA 1993;270:1211–6.
39. Brodie BR, Stuckey TD, Wall TC, et al. Importance of time to reper-
fusion for 30-day and late survival and recovery of left ventricular
function after primary angioplasty for acute myocardial infarction. J Am
Coll Cardiol 1998;32:1312–9.
40. Brodie BR, Stuckey TD, Wall TC, et al. Importance of time to reper-
fusion on outcomes with primary coronary angioplasty for acute myo-
cardial infarction (results from the Stent Primary Angioplasty in Myo-
cardial Infarction Trial). Am J Cardiol 2001;88:1085–90.
41. Williams DO. Treatment delayed is treatment denied. Circulation 2004;
109:1806-8.
42. The Task Force on the Management of Acute Myocardial Infarction of
the European Society of Cardiology. Management of acute myocardial
infarction in patients presenting with ST-segment elevation. Eur Heart J
2003;24:28–66.
43. Morrow DA, Antman EM, Charlesworth A, et al. TIMI risk score for
ST-elevation myocardial infarction: a convenient, bedside, clinical score
for risk assessment at presentation: an intravenous nPA for treatment of
infarcting myocardium early II trial substudy. Circulation 2000;102:
2031–7.
44. Lee KL, Woodlief LH, Topol EJ, et al., for the GUSTO-I Investigators.
Predictors of 30-day mortality in the era of reperfusion for acute myo-
cardial infarction: results from an international trial of 41,021 patients.
Circulation 1995;91:1659–68.
45. Morrow DA, Antman EM, Giugliano RP, et al. A simple risk index for
rapid initial triage of patients with ST-elevation myocardial infarction:
an InTIME II substudy. Lancet 2001;358:1571–5.
46. Krumholz HM, Chen J, Wang Y, et al. Comparing AMI mortality
among hospitals in patients 65 years of age and older: evaluating
methods of risk adjustment. Circulation 1999;99:2986–92.
47. Granger CB, Goldberg RJ, Dabbous O, et al., for the Global Registry of
Acute Coronary Events Investigators. Predictors of hospital mortality in
the Global Registry of Acute Coronary Events. Arch Intern Med 2003;
163:2345–53.
48. Magid DJ, Calonge BN, Rumsfeld JS, et al., for the National Registry of
Myocardial Infarction 2 and 3 Investigators. Relation between hospital
primary angioplasty volume and mortality for patients with acute MI
treated with primary angioplasty vs thrombolytic therapy. JAMA 2000;
284:3131–8.
49. Nallamothu BK, Bates ER. Percutaneous coronary intervention versus
fibrinolytic therapy in acute myocardial infarction: is timing (almost)
everything? Am J Cardiol 2003;92:824–6.
50. Bonnefoy E, Lapostolle F, Leizorovicz A, et al., for the Comparison of
Angioplasty and Prehospital Thrombolysis in Acute Myocardial
Infarction study group. Primary angioplasty versus prehospital fibrino-
lysis in acute myocardial infarction: a randomised study. Lancet 2002;
360:825–9.
51. Steg PG, Bonnefoy E, Chabaud S, et al. Impact of time to treatment on
mortality after prehospital fibrinolysis or primary angioplasty: data from the
CAPTIM randomized clinical trial. Circulation 2003;108:2851–6.
52. Widimsky P, Budesinsky T, Vorac D, et al. Long distance transport for
primary angioplasty vs immediate thrombolysis in acute myocardial
infarction: final results of the randomized national multicentre trial:
PRAGUE-2. Eur Heart J 2003;24:94–104.
53. Deleted in press.
54. Antman EM. General hospital management. In: Julian DG, Braunwald
E, eds. Management of Acute Myocardial Infarction. London, England:
WB Saunders, 1994;42–4.
54a. Lincoff AM, Califf RM, Van de Werf F, et al., for the Global Use of
Strategies To Open Coronary Arteries (GUSTO) Investigators. Mor-
tality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition
and reduced-dose fibrinolytic therapy vs conventional fibrinolytic
therapy for acute myocardial infarction: GUSTO V randomized trial.
JAMA 2002;288:2130-5.
55. Zijlstra F, Beukema WP, van’t Hof AW, et al. Randomized comparison of
primary coronary angioplasty with thrombolytic therapy in low risk patients
with acute myocardial infarction. J Am Coll Cardiol 1997;29:908–12.
56. Ribeiro EE, Silva LA, Carneiro R, et al. Randomized trial of direct
coronary angioplasty versus intravenous streptokinase in acute myo-
cardial infarction. J Am Coll Cardiol 1993;22:376–80.
57. Grinfield L, Berrocal D, Bellardi J, et al. Fibrinolytics versus primary
angioplasty in acute myocardial infarction (FAP): a randomized trial in
a community hospital in Argentina (abstr). J Am Coll Cardiol 1996;
27:A222.
58. Zijlstra F, de Boer MJ, Hoorntje JC, et al. A comparison of immediate
coronary angioplasty with intravenous streptokinase in acute myocardial
infarction. N Engl J Med 1993;328:680–4.
59. Widimsky P, Groch L, Zelízko M, et al. Multicentre randomized trial
comparing transport to primary angioplasty vs immediate thrombolysis
vs combined strategy for patients with acute myocardial infarction
presenting to a community hospital without a catheterization laboratory:
the PRAGUE study. Eur Heart J 2000;21:823–31.
60. de Boer MJ, Ottervanger JP, van’t Hof AW, et al., for the Zwolle
Myocardial Infarction Study Group. Reperfusion therapy in elderly
patients with acute myocardial infarction: a randomized comparison of
primary angioplasty and thrombolytic therapy. J Am Coll Cardiol 2002;
39:1723–8.
61. Akhras F, Ousa AA, Swann G, et al. Primary coronary angioplasty or
intravenous thrombolysis for patients with acute myocardial infarction?
Acute and late follow-up results in a new cardiac unit (abstr). J Am Coll
Cardiol 1997;29:A235–6.
62. Deleted in press.
63. Grines CL, Browne KF, Marco J, et al., for the Primary Angioplasty in
Myocardial Infarction Study Group. A comparison of immediate angio-
plasty with thrombolytic therapy for acute myocardial infarction. N Engl
J Med 1993;328:673–9.
64. Gibbons RJ, Holmes DR, Reeder GS, et al, for the Mayo Coronary Care
Unit and Catheterization Laboratory Groups. Immediate angioplasty
compared with the administration of a thrombolytic agent followed by
conservative treatment for myocardial infarction. N Engl J Med 1993;
328:685–91.
715JACC Vol. 44, No. 3, 2004 Antman et al.
August 4, 2004:671–719 Management of Patients With STEMI: Executive Summary
65. Ribichini F, Steffenino G, Dellavalle A, et al. Comparison of
thrombolytic therapy and primary coronary angioplasty with liberal
stenting for inferior myocardial infarction with precordial ST-segment
depression: immediate and long-term results of a randomized study.
J Am Coll Cardiol 1998;32:1687–94.
66. García E, Elízaga J, Pérez-Castellano N, et al. Primary angioplasty
versus systemic thrombolysis in anterior myocardial infarction. J Am
Coll Cardiol 1999;33:605–11.
67. The Global Use of Strategies to Open Occluded Coronary Arteries in
Acute Coronary Syndromes (GUSTO IIb) Angioplasty Substudy Inves-
tigators. A clinical trial comparing primary coronary angioplasty with
tissue plasminogen activator for acute myocardial infarction. N Engl
J Med 1997;336:1621–8.
68. Le May MR, Labinaz M, Davies RF, et al. Stenting versus thrombolysis
in acute myocardial infarction trial (STAT). J Am Coll Cardiol 2001;
37:985–91.
69. Schömig A, Kastrati A, Dirschinger J, et al., for the Stent versus
Thrombolysis for Occluded Coronary Arteries in Patients with Acute
Myocardial Infarction Study Investigators. Coronary stenting plus plate-
let glycoprotein IIb/IIIa blockade compared with tissue plasminogen
activator in acute myocardial infarction. N Engl J Med 2000;343:
385–91.
70. Vermeer F, Oude Ophuis AJ, vd Berg EJ, et al. Prospective randomised
comparison between thrombolysis, rescue PTCA, and primary PTCA in
patients with extensive myocardial infarction admitted to a hospital
without PTCA facilities: a safety and feasibility study. Heart 1999;82:
426–31.
71. Kastrati A, Mehilli J, Dirschinger J, et al., for the Stent versus Throm-
bolysis for Occluded Coronary Arteries in Patients with Acute Myo-
cardial Infarction (STOPAMI-2) Study. Myocardial salvage after coro-
nary stenting plus abciximab versus fibrinolysis plus abciximab in
patients with acute myocardial infarction: a randomised trial. Lancet
2002;359:920–5.
72. Andersen HR, Nielsen TT, Rasmussen K, et al., for the DANAMI-2
Investigators. Thrombolytic therapy vs primary percutaneous coronary
intervention for myocardial infarction in patients presenting to hospitals
without on-site cardiac surgery: a randomized controlled trial. JAMA
2002;287:1943–51.
73. Kastrati A, Mehilli J, Dirschinger J, et al., for the Stent versus Throm-
bolysis for Occluded Coronary Arteries in Patients With Acute Myo-
cardial Infarction (STOPAMI-2) Study. A randomized trial of transfer
for primary angioplasty versus on-site thrombolysis in patients with
high-risk myocardial infarction: the Air Primary Angioplasty in Myo-
cardial Infarction study. J Am Coll Cardiol 2002;39:1713–9.
74. Andersen HR, Nielsen TT, Rasmussen K, et al., for the DANAMI-2
Investigators. A comparison of coronary angioplasty with fibrinolytic
therapy in acute myocardial infarction. N Engl J Med 2003;349:733–42.
75. Hochman JS, Sleeper LA, Webb JG, et al., for the Should We Emer-
gently Revascularize Occluded Coronaries for Cardiogenic Shock
(SHOCK) Investigators. Early revascularization in acute myocardial
infarction complicated by cardiogenic shock. N Engl J Med 1999;341:
625–34.
76. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intrave-
nous thrombolytic therapy for acute myocardial infarction: a quantitative
review of 23 randomised trials. Lancet 2003;361:13–20.
76a. Melandri G. The obsession with primary angioplasty. Circulation 2003;
108:e1620.
77. Rogers WJ, Dean LS, Moore PB, et al., for the Alabama Registry of
Myocardial Ischemia Investigators. Comparison of primary angioplasty
versus thrombolytic therapy for acute myocardial infarction. Am J
Cardiol 1994;74:111–8.
78. Every NR, Parsons LS, Hlatky M, et al., for the Myocardial Infarction
Triage and Intervention Investigators. A comparison of thrombolytic
therapy with primary coronary angioplasty for acute myocardial
infarction. N Engl J Med 1996;335:1253–60.
79. Tiefenbrunn AJ, Chandra NC, French WJ, et al. Clinical experience with
primary percutaneous transluminal coronary angioplasty compared with
alteplase (recombinant tissue-type plasminogen activator) in patients
with acute myocardial infarction: a report from the Second National
Registry of Myocardial Infarction (NRMI-2). J Am Coll Cardiol 1998;
31:1240–5.
80. Danchin N, Vaur L, Genès N, et al. Treatment of acute myocardial
infarction by primary coronary angioplasty or intravenous thrombolysis
in the “real world”: one-year results from a nationwide French survey.
Circulation 1999;99:2639–44.
81. Berger PB, Ellis SG, Holmes DR, et al. Relationship between delay in
performing direct coronary angioplasty and early clinical outcome in
patients with acute myocardial infarction: results from the Global Use of
Strategies To Open Occluded Arteries in Acute Coronary Syndromes
(GUSTO-IIb) trial. Circulation 1999;100:14–20.
82. Cannon CP, Gibson CM, Lambrew CT, et al. Relationship of symptom-
onset-to-balloon time and door-to-balloon time with mortality in patients
undergoing angioplasty for acute myocardial infarction. JAMA 2000;
283:2941–7.
83. Brodie BR, Stuckey TD, Hansen C, et al. Benefit of coronary reper-
fusion before intervention on outcomes after primary angioplasty for
acute myocardial infarction. Am J Cardiol 2000;85:13–8.
84. Stone GW, Cox D, Garcia E, et al. Normal flow (TIMI-3) before
mechanical reperfusion therapy is an independent determinant of
survival in acute myocardial infarction: analysis from the primary angio-
plasty in myocardial infarction trials. Circulation 2001;104:636–41.
85. Clements IP, Christian TF, Higano ST, et al. Residual flow to the infarct
zone as a determinant of infarct size after direct angioplasty. Circulation
1993;88:1527–33.
86. Juliard JM, Feldman LJ, Golmard JL, et al. Relation of mortality of
primary angioplasty during acute myocardial infarction to door-to-
Thrombolysis In Myocardial Infarction (TIMI) time. Am J Cardiol
2003;91:1401–5.
87. Cragg DR, Friedman HZ, Bonema JD, et al. Outcome of patients with
acute myocardial infarction who are ineligible for thrombolytic therapy.
Ann Intern Med 1991;115:173–7.
88. Brodie BR, Weintraub RA, Stuckey TD, et al. Outcomes of direct
coronary angioplasty for acute myocardial infarction in candidates and
non-candidates for thrombolytic therapy. Am J Cardiol 1991;67:7–12.
89. Himbert D, Juliard JM, Steg PG, et al. Primary coronary angioplasty for
acute myocardial infarction with contraindication to thrombolysis. Am J
Cardiol 1993;71:377–81.
90. Zahn R, Schuster S, Schiele R, et al., for the Maximal Individual
Therapy in Acute Myocardial Infarction (MITRA) Study Group. Com-
parison of primary angioplasty with conservative therapy in patients
with acute myocardial infarction and contraindications for thrombolytic
therapy. Cathet Cardiovasc Interv 1999;46:127–33.
91. Grzybowski M, Clements EA, Parsons L, et al. Mortality benefit of
immediate revascularization of acute ST-segment elevation myocardial
infarction in patients with contraindications to thrombolytic therapy: a
propensity analysis. JAMA 2003;290:1891–8.
92. Lotfi M, Mackie K, Dzavik V, et al. Impact of delays to cardiac surgery
after failed angioplasty and stenting. J Am Coll Cardiol 2004;43:
337–42.
93. Dehmer GJ, Gantt DS. Coronary intervention at hospitals without
on-site cardiac surgery: are we pushing the envelope too far? J Am Coll
Cardiol 2004;43:343–5.
94. Antoniucci D, Santoro GM, Bolognese L, et al. A clinical trial com-
paring primary stenting of the infarct-related artery with optimal primary
angioplasty for acute myocardial infarction: results from the Florence
Randomized Elective Stenting in Acute Coronary Occlusions
(FRESCO) trial. J Am Coll Cardiol 1998;31:1234–9.
95. Rodríguez A, Bernardi V, Fernández M, et al. In-hospital and late results
of coronary stents versus conventional balloon angioplasty in acute
myocardial infarction: Gianturco-Roubin in Acute Myocardial
Infarction (GRAMI trial). Am J Cardiol 1998;81:1286–91.
96. Suryapranata H, Ottervanger JP, Nibbering E, et al. Long term outcome
and cost-effectiveness of stenting versus balloon angioplasty for acute
myocardial infarction. Heart 2001;85:667–71.
97. Saito S, Hosokawa G, Tanaka S, et al., for the PASTA Trial Investi-
gators. Primary stent implantation is superior to balloon angioplasty in
acute myocardial infarction: final results of the primary angioplasty
versus stent implantation in acute myocardial infarction (PASTA) trial.
Cathet Cardiovasc Interv 1999;48:262–8.
98. Grines CL, Cox DA, Stone GW, et al., for the Stent Primary Angio-
plasty in Myocardial Infarction Study Group. Coronary angioplasty
with or without stent implantation for acute myocardial infarction.
N Engl J Med 1999;341:1949–56.
99. Kawashima A, Ueda K, Nishida Y, et al. Quantitative angiographic
analysis of restenosis of primary stenting using Wiktor stent for acute
myocardial infarction: results from a multicenter randomized PRISAM
study (abstr). Circulation 1999;100 Suppl I:I856.
100. Maillard L, Hamon M, Khalife K, et al., for the STENTIM-2 Investi-
gators. A comparison of systematic stenting and conventional balloon
angioplasty during primary percutaneous transluminal coronary angio-
716 Antman et al. JACC Vol. 44, No. 3, 2004
Management of Patients With STEMI: Executive Summary August 4, 2004:671–719
plasty for acute myocardial infarction. J Am Coll Cardiol 2000;35:
1729–36.
101. Scheller B, Hennen B, Severin-Kneib S, et al. Long-term follow-up of
a randomized study of primary stenting versus angioplasty in acute
myocardial infarction. Am J Med 2001;110:1–6.
102. Zhu MM, Feit A, Chadow H, et al. Primary stent implantation compared
with primary balloon angioplasty for acute myocardial infarction: a meta-
analysis of randomized clinical trials. Am J Cardiol 2001;88:297–301.
103. Stone GW, Grines CL, Cox DA, et al., for the Controlled Abciximab
and Device Investigation to Lower Late Angioplasty Complications
(CADILLAC) Investigators. Comparison of angioplasty with stenting,
with or without abciximab, in acute myocardial infarction. N Engl
J Med 2002;346:957–66.
104. Lemos PA, Saia F, Hofma SH, et al. Short- and long-term clinical
benefit of sirolimus-eluting stents compared to conventional bare stents
for patients with acute myocardial infarction. J Am Coll Cardiol 2004;
43:704–8.
104a. Ellis SG, Armstrong P, Betriu A, et al. Facilitated percutaneous coro-
nary intervention versus primary percutaneous coronary intervention:
design and rationale of the Facilitated Intervention with Enhanced
Reperfusion Speed to Stop Events (FINESSE) trial. Am Heart J 2004;
147:E16.
105. The TIMI Research Group. Immediate vs delayed catheterization and
angioplasty following thrombolytic therapy for acute myocardial
infarction: TIMI II A results. JAMA 1988;260:2849–58.
106. Topol EJ, Califf RM, George BS, et al. A randomized trial of immediate
versus delayed elective angioplasty after intravenous tissue plasminogen
activator in acute myocardial infarction. N Engl J Med 1987;317:581–8.
107. Sadanandan S, Buller C, Menon V, et al. The late open artery
hypothesis: a decade later. Am Heart J 2001;142:411–21.
108. Hochman JS, Sleeper LA, White HD, et al., for the SHOCK Investi-
gators: Should We Emergently Revascularize Occluded Coronaries for
Cardiogenic Shock: one-year survival following early revascularization
for cardiogenic shock. JAMA 2001;285:190–2.
109. Dzavik V, Sleeper LA, Cocke TP, et al., for the SHOCK Investigators.
Early revascularization is associated with improved survival in elderly
patients with acute myocardial infarction complicated by cardiogenic shock:
a report from the SHOCK Trial Registry. Eur Heart J 2003;24:828–37.
110. Dauerman HL, Goldberg RJ, Malinski M, et al. Outcomes and early
revascularization for patients greater than or equal to 65 years of age
with cardiogenic shock. Am J Cardiol 2001;87:844–8.
111. Dauerman HL, Ryan TJ, Piper WD, et al. Outcomes of percutaneous
coronary intervention among elderly patients in cardiogenic shock: a
multicenter, decade-long experience. J Invasive Cardiol 2003;15:380–4.
112. Simoons ML, Arnold AE, Betriu A, et al. Thrombolysis with tissue
plasminogen activator in acute myocardial infarction: no additional
benefit from immediate percutaneous coronary angioplasty. Lancet
1988;1:197–203.
113. Ross AM, Coyne KS, Reiner JS, et al., for the PACT (Plasminogen-
activator Angioplasty Compatibility Trial) Investigators: A randomized
trial comparing primary angioplasty with a strategy of short-acting
thrombolysis and immediate planned rescue angioplasty in acute myo-
cardial infarction: the PACT trial. J Am Coll Cardiol 1999;34:1954–62.
114. Montalescot G, Barragan P, Wittenberg O, et al., for the ADMIRAL
(Abciximab before Direct Angioplasty and Stenting in Myocardial
Infarction Regarding Acute and Long-Term Follow-up). Investigators.
Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute
myocardial infarction. N Engl J Med 2001;344:1895–903.
115. Zeymer U, Uebis R, Vogt A, et al., for the ALKK-Study Group. Ran-
domized comparison of percutaneous transluminal coronary angioplasty
and medical therapy in stable survivors of acute myocardial infarction with
single-vessel disease: a study of the Arbeitsgemeinschaft Leitende Kardi-
ologische Krankenhausärzte. Circulation 2003;108:1324–8.
116. Scheller B, Hennen B, Hammer B, et al., for the SIAM III Study
Group. Beneficial effects of immediate stenting after thrombolysis in
acute myocardial infarction. J Am Coll Cardiol 2003;42:634–41.
117. Braunwald E, Antman E, Beasley J, et al. ACC/AHA 2002 guideline
update for the management of patients with unstable angina and non–ST-
segment elevation myocardial infarction: summary article: a report of the
American College of Cardiology/American Heart Association Task Force
on Practice Guidelines (Committee on the Management of Patients With
Unstable Angina). J Am Coll Cardiol 2002;40:1366.
118. Stenestrand U, Wallentin L. Early revascularisation and 1-year survival
in 14-day survivors of acute myocardial infarction: a prospective
cohort study. Lancet 2002;359:1805–11.
119. Alter DA, Tu JV, Austin PC, et al. Waiting times, revascularization
modality, and outcomes after acute myocardial infarction at hospitals
with and without on-site revascularization facilities in Canada. J Am
Coll Cardiol 2003;42:410–9.
120. Gupta M, Chang WC, Van de Werf F, et al., for the ASSENT II
Investigators. International differences in in-hospital revascularization
and outcomes following acute myocardial infarction: a multilevel anal-
ysis of patients in ASSENT-2. Eur Heart J 2003;24:1640–50.
121. Gibson CM, Karha J, Murphy SA, et al., for the TIMI Study Group.
Early and long-term clinical outcomes associated with reinfarction
following fibrinolytic administration in the thrombolysis in myocardial
infarction trials. J Am Coll Cardiol 2003;42:7–16.
122. Lablanche JM, Gueret P, Blanchard D, et al. Beneficial effects of very
early PTCA in patients with intravenous thrombolysis for acute myo-
cardial infarction: data from a nation-wide registry in France (abstr).
Circulation 2002;106 Suppl II:II630.
123. Fernandez-Aviles F, Alonso JJ, Castro-Beiras A, et al. Prospective
randomized trial comparing a routine invasive strategy within 24 hours
to thrombolysis versus an ischemia-guided conservative approach to
acute myocardial infarction with ST-segment elevation: the Gracia-1
trial. Lancet 2004. In press.
124. ISIS-2 (Second International Study of Infarct Survival) Collaborative
Group. Randomised trial of intravenous streptokinase, oral aspirin,
both, or neither among 17,187 cases of suspected acute myocardial
infarction: ISIS-2. Lancet 1988;2:349–60.
125. Granger CB, Hirsch J, Califf RM, et al. Activated partial thromboplastin
time and outcome after thrombolytic therapy for acute myocardial
infarction: results from the GUSTO-I trial. Circulation 1996;93:870–8.
126. White HD, Yusuf S. Issues regarding the use of heparin following
streptokinase therapy. J Thromb Thrombolysis 1995;2:5–10.
127. Thrombin-specific anticoagulation with bivalirudin versus heparin in
patients receiving fibrinolytic therapy for acute myocardial infarction:
the HERO-2 randomised trial. Lancet 2001;358:1855–63.
128. Bertrand ME, Rupprecht HJ, Urban P, et al. Double-blind study of the
safety of clopidogrel with and without a loading dose in combination
with aspirin compared with ticlopidine in combination with aspirin
after coronary stenting: the Clopidogrel Aspirin Stent International
Cooperative Study (CLASSICS). Circulation 2000;102:624–9.
129. Mehta SR, Yusuf S, Peters RJ, et al., for the Clopidogrel in Unstable
angina to prevent Recurrent Events trial (CURE) Investigators. Effects
of pretreatment with clopidogrel and aspirin followed by long-term
therapy in patients undergoing percutaneous coronary intervention: the
PCI-CURE study. Lancet 2001;358:527–33.
130. Steinhubl SR, Berger PB, Mann JT III, et al., for the CREDO (Clopi-
dogrel for the Reduction of Events During Observation) Investigators.
Early and sustained dual oral antiplatelet therapy following percutane-
ous coronary intervention: a randomized controlled trial. JAMA 2002;
288:2411–20.
131. CYPHER™ sirolimus-eluting coronary stent on RAPTORTM over-
the-wire delivery system and CYPHER™ sirolimus-eluting coronary
stent on RAPTORRAIL rapid exchange delivery system [instructions
for use]. Miami, FL: Cordis, a Johnson & Johnson Company, April
2003.
132. TAXUS: paclitaxel-eluting coronary stent system Monorail and over
the wire coronary stent delivery system [directions for use]. Natick,
MA: Boston Scientific, March 2004.
133. Patrono C, Bachmann F, Baigent C, et al. Expert consensus document
on the use of antiplatelet agents: The Task Force on the Use of
Antiplatelet Agents in Patients With Atherosclerotic Cardiovascular
Disease of the European Society of Cardiology. Eur Heart J 2004;25:
166–81.
134. Levine GN, Kern MJ, Berger PB, et al., for the American Heart Asso-
ciation Diagnostic and Interventional Catheterization Committee and
Council on Clinical Cardiology. Management of patients undergoing per-
cutaneous coronary revascularization. Ann Intern Med 2003;139:123–36.
135. Lee DP, Herity NA, Hiatt BL, et al., for the TIrofiban Given in the
Emergency Room before Primary Angioplasty. Adjunctive platelet
glycoprotein IIb/IIIa receptor inhibition with tirofiban before primary
angioplasty improves angiographic outcomes: results of the TIrofiban
Given in the Emergency Room before Primary Angioplasty
(TIGER-PA) pilot trial. Circulation 2003;107:1497–501.
136. Finney SJ, Zekveld C, Elia A, et al. Glucose control and mortality in
critically ill patients. JAMA 2003;290:2041–7.
136a. Clement S, Braithwaite SS, Magee MF, et al. Management of diabetes
and hyperglycemia in hospitals. Diabetes Care 2004;27:553–97.
717JACC Vol. 44, No. 3, 2004 Antman et al.
August 4, 2004:671–719 Management of Patients With STEMI: Executive Summary
137. Third Report of the National Cholesterol Education Program (NCEP)
Expert Panel on Detection, Evaluation, and Treatment of High Blood
Cholesterol in Adults (Adult Treatment Panel III) final report. Circu-
lation 2002;106:3143–421.
138. Malan SS. Psychosocial adjustment following MI: current views and
nursing implications. J Cardiovasc Nurs 1992;6:57–70.
139. Havik OE, Maeland JG. Patterns of emotional reactions after a myo-
cardial infarction. J Psychosom Res 1990;34:271–85.
140. Moser DK, Dracup K. Is anxiety early after myocardial infarction
associated with subsequent ischemic and arrhythmic events? Psy-
chosom Med 1996;58:395–401.
141. Frasure-Smith N, Lespérance F, Talajic M. The impact of negative
emotions on prognosis following myocardial infarction: is it more than
depression? Health Psychol 1995;14:388–98.
142. Chae Cu, Hennekens CH. Beta blockers. In: Hennekens CH, ed.
Clinical Trials in Cardiovascular Disease: A Companion to Braun-
wald’s Heart Disease. Philadelphia, PA: WB Saunders, 1999;79–94.
143. Latini R, Maggioni AP, Flather M, et al. ACE inhibitor use in patients
with myocardial infarction: summary of evidence from clinical trials.
Circulation 1995;92:3132–7.
144. ACE Inhibitor Myocardial Infarction Collaborative Group. Indications
for ACE inhibitors in the early treatment of acute myocardial
infarction: systematic overview of individual data from 100,000
patients in randomized trials. Circulation 1998;97:2202–12.
145. Flather MD, Yusuf S, Køber L, et al., for the ACE-Inhibitor Myo-
cardial Infarction Collaborative Group. Long-term ACE-inhibitor
therapy in patients with heart failure or left-ventricular dysfunction:
a systematic overview of data from individual patients. Lancet
2000;355:1575– 81.
146. Pitt B, Zannad F, Remme WJ, et al., for the Randomized Aldactone
Evaluation Study Investigators. The effect of spironolactone on mor-
bidity and mortality in patients with severe heart failure. N Engl J Med
1999;341:709–17.
147. Pitt B, Remme W, Zannad F, et al., for the Eplerenone Post-Acute
Myocardial Infarction Heart Failure Efficacy and Survival Study Inves-
tigators. Eplerenone, a selective aldosterone blocker, in patients with
left ventricular dysfunction after myocardial infarction. N Engl J Med.
2003;348:1309–21.
148. Dickstein K, Kjekshus J, for the OPTIMAAL Steering Committee of
the Optimal Trial in Myocardial Infarction with Angiotensin II
Antagonist Losartan (OPTIMAAL) Study Group. Effects of losartan
and captopril on mortality and morbidity in high-risk patients after
acute myocardial infarction: the OPTIMAAL randomised trial:
Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist
Losartan. Lancet 2002;360:752–60.
149. Pfeffer MA, McMurray JJ, Velazquez EJ, et al., for the Valsartan in
Acute Myocardial Infarction Trial Investigators. Valsartan, captopril,
or both in myocardial infarction complicated by heart failure, left
ventricular dysfunction, or both. N Engl J Med 2003;349:1893–906.
150. Mann DL, Deswal A. Angiotensin-receptor blockade in acute myo-
cardial infarction: a matter of dose. N Engl J Med 2003;349:1963–5.
151. Gibbons RJ, Miller TD, Christian TF. Infarct size measured by single
photon emission computed tomographic imaging with (99m) Tc-
sestamibi: a measure of the efficacy of therapy in acute myocardial
infarction. Circulation 2000;101:101–8.
152. Klocke FJ, Baird MG, Bateman TM, et al. ACC/AHA/ASNC
guidelines for the clinical use of cardiac radionuclide imaging: a report
of the American College of Cardiology/American Heart Association Task
Force on Practice Guidelines (ACC/AHA/ASNC Committee to Revise the
1995 Guidelines for the Clinical Use of Radionuclide Imaging). Available
at: http://www.acc.org/clinical/guidelines/radio/rni_fulltext.pdf, 2003.
Accessed January 15, 2004.
153. Cheitlin MD, Armstrong WF, Aurigemma GP, et al. ACC/AHA/ASE
2003 guideline update for the clinical application of echocardiography:
a report of the American College of Cardiology/American Heart Asso-
ciation Task Force on Practice Guidelines (ACC/AHA/ASE Com-
mittee to Update the 1997 Guidelines for the Clinical Application of
Echocardiography). Available at: www.acc.org/clinical/guidelines/
echo/index.pdf, 2003. Accessed January 15, 2004.
154. Mahrholdt H, Wagner A, Holly TA, et al. Reproducibility of chronic
infarct size measurement by contrast-enhanced magnetic resonance
imaging. Circulation 2002;106:2322–7.
155. Menon V, Slater JN, White HD, et al. Acute myocardial infarction
complicated by systemic hypoperfusion without hypotension: report of
the SHOCK trial registry. Am J Med 2000;108:374–80.
156. Hochman JS, Boland J, Sleeper LA, et al., for the SHOCK Registry
Investigators. Current spectrum of cardiogenic shock and effect of
early revascularization on mortality: results of an International
Registry. Circulation 1995;91:873–81.
157. Hunt SA, Baker DW, Chin MH, et al. ACC/AHA guidelines for the eval-
uation and management of chronic heart failure in the adult: a report of the
American College of Cardiology/American Heart Association Task Force
on Practice Guidelines (Committee to Revise the 1995 Guidelines for the
Evaluation and Management of Heart Failure). Available at: http://
www.acc.org/clinical/guidelines/failure/hf_index.htm, 2001. Accessed
June 5, 2004.
158. Kinch JW, Ryan TJ. Right ventricular infarction. N Engl J Med 1994;
330:1211–7.
159. Núñez L, de la Llana R, López Sendón J, et al. Diagnosis and treatment
of subacute free wall ventricular rupture after infarction. Ann Thorac
Surg 1983;35:525–9.
160. Guidelines for cardiopulmonary resuscitation and emergency cardiac
care: Emergency Cardiac Care Committee and Subcommittees,
American Heart Association: Part III: adult advanced cardiac life
support. JAMA 1992;268:2199–241.
161. Campbell RWF. Arrhythmias. In: Julian DG. Braunwald E, eds. Man-
agement of Acute Myocardial Infarction. London, England: WB
Saunders, 1994;223–40.
162. Kontoyannis DA, Anastasiou-Nana MI, Kontoyannis SA, et al. Intrave-
nous amiodarone decreases the duration of atrial fibrillation associated
with acute myocardial infarction. Cardiovasc Drugs Ther 2001;15:
155–60.
163. Ryan TJ, Antman EM, Brooks NH, et al. ACC/AHA guidelines for the
management of patients with acute myocardial infarction: 1999
guideline update: a report of the American College of Cardiology/
American Heart Association Task Force on Practice Guidelines (Com-
mittee on Management of Acute Myocardial Infarction). J Am Coll
Cardiol 1999;34:890–911.
164. Gregoratos G, Abrams J, Epstein AE, et al. ACC/AHA/NASPE 2002
guideline update for implantation of cardiac pacemakers and antiar-
rhythmia devices: summary article: a report of the American College of
Cardiology/American Heart Association Task Force on Practice
Guidelines (ACC/AHA/NASPE Committee to Update the 1998
Pacemaker Guidelines). J Am Coll Cardiol 2002;40:1703–19.
165. Lamas GA, Ellenbogen KA. Evidence base for pacemaker mode
selection: from physiology to randomized trials. Circulation 2004;109:
443–51.
166. Eagle KA, Guyton RA, Davidoff R, et al. ACC/AHA guidelines for
coronary artery bypass graft surgery: a report of the American
College of Cardiology/American Heart Association Task Force on
Practice Guidelines (Committee to Revise the 1991 Guidelines for
Coronary Artery Bypass Graft Surgery). American College of Car-
diology/American Heart Association. J Am Coll Cardiol 1999;34:
1262–347.
167. Dyke C, Bhatia D. Inhibitors of the platelet receptor glycoprotein
IIb-IIIa and complications during percutaneous coronary revascular-
ization: management strategies for the cardiac surgeon. J Cardiovasc
Surg (Torino). 1999;40:505–16.
168. Yusuf S, Zhao F, Mehta SR, et al., for the Clopidogrel in Unstable
Angina to Prevent Recurrent Events Trial Investigators. Effects of
clopidogrel in addition to aspirin in patients with acute coronary syn-
dromes without ST-segment elevation. N Engl J Med 2001;345:
494–502.
169. Physician’s Desk Reference. Clopidogrel package insert. Montvale,
NJ: Medical Economics Co; 2756.
170. Gibbons RJ, Balady GJ, Bricker JT, et al. ACC/AHA 2002 guideline
update for exercise testing: a report of the American College of Car-
diology/American Heart Association Task Force on Practice
Guidelines (Committee on Exercise Testing). Available at: http://
www.acc.org/clinical/guidelines/exercise/exercise_clean.pdf, 2002.
Accessed February 12, 2004.
171. Théroux P, Waters DD, Halphen C, et al. Prognostic value of exercise
testing soon after myocardial infarction. N Engl J Med 1979;301:
341–5.
172. DeBusk RF, Kraemer HC, Nash E, et al. Stepwise risk stratification
soon after acute myocardial infarction. Am J Cardiol 1983;52:1161–6.
173. Krone RJ, Gillespie JA, Weld FM, et al. Low-level exercise testing
after myocardial infarction: usefulness in enhancing clinical risk strat-
ification. Circulation 1985;71:80–9.
718 Antman et al. JACC Vol. 44, No. 3, 2004
Management of Patients With STEMI: Executive Summary August 4, 2004:671–719
174. Valentine PA, Frew JL, Mashford ML, et al. Lidocaine in the pre-
vention of sudden death in the pre-hospital phase of acute infarction: a
double-blind study. N Engl J Med 1974;291:1327–31.
175. Ross J, Gilpin EA, Madsen EB, et al. A decision scheme for coronary
angiography after acute myocardial infarction. Circulation 1989;79:
292–303.
176. Risk stratification and survival after myocardial infarction. N Engl
J Med 1983;309:331–6.
177. Zaret BL, Wackers TH, Terrin M, et al. Does left ventricular ejection
fraction following thrombolytic therapy have the same prognostic
impact described in the prethrombolytic era? Results of the TIMI II
Trial (abstr). J Am Coll Cardiol 1991;17:214A.
178. Roig E, Magriñá J, Garcia A, et al. Prognostic value of exercise
radionuclide angiography in low-risk acute myocardial infarction sur-
vivors. Eur Heart J 1993;14:213–8.
179. Gibbons RJ, Abrams J, Chatterjee K, et al. ACC/AHA 2002 guideline
update for the management of patients with chronic stable angina: a
report of the American College of Cardiology/American Heart Asso-
ciation Task Force on Practice Guidelines (Committee to Update the
1999 Guidelines for the Management of Patients with Chronic Stable
Angina). Available at: www.acc.org/clinical/guidelines/stable/
stable.pdf 2002. Accessed March 18, 2004.
180. O’Neill WW. “Watchful waiting” after thrombolysis: it’s time for a
re-evaluation. J Am Coll Cardiol 2003;42:17–9.
181. Smith SC, Blair SN, Bonow RO, et al. AHA/ACC scientific
statement: AHA/ACC guidelines for preventing heart attack and
death in patients with atherosclerotic cardiovascular disease: 2001
update: a statement for healthcare professionals from the American
Heart Association and the American College of Cardiology. Circu-
lation 2001;104:1577–9.
182. Mosca L, Appel LJ, Benjamin EJ, et al. Evidence-based guidelines for
cardiovascular disease prevention in women. Circulation 2004;109:
672–93.
183. Dalal H, Evans PH, Campbell JL. Recent developments in secondary
prevention and cardiac rehabilitation after acute myocardial infarction.
BMJ 2004;328:693–7.
184. Gutstein DE, Fuster V. Pathophysiologic bases for adjunctive therapies
in the treatment and secondary prevention of acute myocardial
infarction. Clin Cardiol 1998;21:161–8.
185. CAPRIE Steering Committee. A randomised, blinded, trial of clopi-
dogrel versus aspirin in patients at risk of ischaemic events (CAPRIE).
Lancet 1996;348:1329–39.
186. Hurlen M, Smith P, Arnesen H. Effects of warfarin, aspirin and the two
combined, on mortality and thromboembolic morbidity after myo-
cardial infarction: the WARIS-II (Warfarin-Aspirin Reinfarction
Study) design. Scand Cardiovasc J 2000;34:168–71.
187. van Es RF, Jonker JJ, Verheugt FW, et al., for the Antithrombotics in
the Secondary Prevention of Events in Coronary Thrombosis-2
(ASPECT-2) Research Group. Aspirin and coumadin after acute cor-
onary syndromes (the ASPECT-2 study): a randomised controlled trial.
Lancet 2002;360:109–13.
188. Brouwer MA, van den Bergh PJ, Aengevaeren WR, et al. Aspirin plus
coumarin versus aspirin alone in the prevention of reocclusion after
fibrinolysis for acute myocardial infarction: results of the Antithrom-
botics in the Prevention of Reocclusion In Coronary Thrombolysis
(APRICOT)-2 Trial. Circulation 2002;106:659–65.
189. Yusuf S, Sleight P, Pogue J, et al., for the Heart Outcomes Prevention
Evaluation Study Investigators. Effects of an angiotensin-converting-
enzyme inhibitor, ramipril, on cardiovascular events in high-risk
patients. N Engl J Med 2000;342:145–53.
190. Fox KM, for the EURopean trial On reduction of cardiac events with
Perindopril in stable coronary Artery disease Investigators. Efficacy of
perindopril in reduction of cardiovascular events among patients with
stable coronary artery disease: randomised, double-blind, placebo-
controlled, multicentre trial (the EUROPA study). Lancet 2003;362:
782–8.
191. Granger CB, McMurray JJ, Yusuf S, et al., for the CHARM Investi-
gators and Committees. Effects of candesartan in patients with chronic
heart failure and reduced left-ventricular systolic function intolerant to
angiotensin-converting-enzyme inhibitors: the CHARM-Alternative
trial. Lancet 2003;362:772–6.
192. McMurray JJ, Ostergren J, Swedberg K, et al., for the CHARM Inves-
tigators and Committees. Effects of candesartan in patients with
chronic heart failure and reduced left-ventricular systolic function
taking angiotensin-converting-enzyme inhibitors: the CHARM-Added
trial. Lancet 2003;362:767–71.
193. Yusuf S, Pfeffer MA, Swedberg K, et al., for the CHARM Investigators
and Committees. Effects of candesartan in patients with chronic heart
failure and preserved left-ventricular ejection fraction: the CHARM-
Preserved trial. Lancet 2003;362:777–81.
194. Executive Council of the Heart Failure Society of America. Impli-
cations of recent clinical trials for heart failure performance measures.
J Card Fail 2004;10:4–5.
195. Deleted in press.
196. Antman E, Braunwald E. Acute myocardial infarction. In: Braunwald
E, Zipes DP, Libby P, eds. Heart Disease: A Textbook of Cardiovas-
cular Medicine. 6th ed. Philadelphia, PA: WB Saunders, 2001:
1114–251. Chapter 5.
197. Gheorghiade M, Colucci WS, Swedberg K. Beta-blockers in chronic
heart failure. Circulation 2003;107:1570–5.
198. Chen J, Radford MJ, Wang Y, et al. Are beta-blockers effective in
elderly patients who undergo coronary revascularization after acute
myocardial infarction? Arch Intern Med 2000;160:947–52.
199. Seventh report of the Joint National Committee on the Prevention,
Detection, Evaluation, and Treatment of High Blood Pressure (JNC
7): resetting the hypertension sails. Hypertension 2003;41:1178 –9.
200. Hulley S, Grady D, Bush T, et al., for the Heart and Estrogen/progestin
Replacement Study (HERS) Research Group. Randomized trial of
estrogen plus progestin for secondary prevention of coronary heart
disease in postmenopausal women. JAMA 1998;280:605–13.
201. Grady D, Herrington D, Bittner V, et al., for the HERS Research
Group. Cardiovascular disease outcomes during 6.8 years of hormone
therapy: Heart and Estrogen/progestin Replacement Study follow-up
(HERS II). JAMA 2002;288:49–57.
202. Rossouw JE, Anderson GL, Prentice RL, et al., for the Writing Group
for the Women’s Health Initiative Investigators. Risks and benefits of
estrogen plus progestin in healthy postmenopausal women: principal
results from the Women’s Health Initiative randomized controlled trial.
JAMA 2002;288:321–33.
203. Cairns JA, Markham BA. Economics and efficacy in choosing oral anti-
coagulants or aspirin after myocardial infarction. JAMA 1995;273:965–7.
203a. Kris-Etherton PM, Lichtenstein AH, Howard BV, Steinberg D,
Witzman JL. Antioxidant vitamin supplements and cardiovascular
disease. Circulation. In press.
204. Glassman AH, O’Connor CM, Califf RM, et al., for the Sertraline
Antidepressant Heart Attack Randomized Trial (SADHEART) Group.
Sertraline treatment of major depression in patients with acute MI or
unstable angina. JAMA 2002;288:701–9.
205. Swenson JR, O’Connor CM, Barton D, et al., for the Sertraline Anti-
depressant Heart Attack Randomized Trial (SADHART) Group.
Influence of depression and effect of treatment with sertraline on
quality of life after hospitalization for acute coronary syndrome. Am J
Cardiol 2003;92:1271–6.
206. Berkman LF, Blumenthal J, Burg M, et al., for the Enhancing Recovery
in Coronary Heart Disease Patients Investigators (ENRICHD). Effects
of treating depression and low perceived social support on clinical
events after myocardial infarction: the Enhancing Recovery in Coro-
nary Heart Disease Patients (ENRICHD) Randomized Trial. JAMA
2003;289:3106–16.
207. Alonzo AA. Acute myocardial infarction and posttraumatic stress dis-
order: the consequences of cumulative adversity. J Cardiovasc Nurs
1999;13:33–45.3
719JACC Vol. 44, No. 3, 2004 Antman et al.
August 4, 2004:671–719 Management of Patients With STEMI: Executive Summary
